The mechanobiology of the T-Cell Receptor: Structurally connecting catch bonds with ligand binding and triggering by Cardenas Lizana, Paul Antonio
THE MECHANOBIOLOGY OF THE T-CELL RECEPTOR:






Paul Antonio Cárdenas Lizana
In Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy in the
Wallace H. Coulter Department of Biomedical Engineering
Georgia Institute of Technology & Emory University
December 2017
Copyright© 2017 by Paul Antonio Cárdenas Lizana
THE MECHANOBIOLOGY OF THE T-CELL RECEPTOR:




Paul Antonio Cárdenas Lizana
THE MECHANOBIOLOGY OF THE T-CELL RECEPTOR:
STRUCTURALLY CONNECTING CATCH BONDS WITH LIGAND
BINDING AND TRIGGERING
Approved by:
Andrés J. García, Committee Chair
School of Mechanical Engineering
Georgia Institute of Technology
James Gumbart
School of Physics
Georgia Institute of Technology
Cheng Zhu, Advisor
Wallace H. Coulter Department of
Biomedical Engineering
Georgia Institute of Technology
Jizhong Lou
Institute of Biophysics
Chinese Academy of Sciences
Arash Grakoui
Department of Medicine, Division of
Infectious Diseases
Emory University
Date Approved: August 17, 2017
Dedicado a Carmen y Alejandro ...
iii
ACKNOWLEDGEMENTS
This thesis owes its existence and quality to a large number of people, I met during my
Ph.D. studies, and I am writing this acknowledgment to adequately honor these extraordi-
nary people.
I wish to express my warmest gratitude to my advisor and friend, Professor Dr. Cheng
Zhu, who originally introduced me to the field of immuno-engineering and the mechanics
of cells. His advice, guidance, and support were fundamental to this thesis. He suggested
me to study “the role of catch bonds in immunology”. His expertise and the excellent
facilities of his laboratory created the basis of this project. I believe that without his help
and the many discussions we held at the group meeting and his office, my apprehension
of many concepts and techniques about this project would have been much poorer and it
would not have turned out.
For the past few years, I am intellectually indebted and grateful to the former and cur-
rent Zhu lab members for much scientific advice on the group meetings and their friendly
attitude. I thank former lab members including Dr. Veronika Zarnistyna, Dr. Sergey
Pryshchep, Dr. Fang Kong, Dr. Wei Chen, Dr. Jack Wei Chen, Dr. Jin Qian, Dr. Zhenhai
Li, Dr. Ke Bai, Dr. Hyun-jung Lee, Dr. Lining Ju, Dr. Yunfeng Chen, Dr. Loice Chin-
gozha, Dr. Baoyu Liu, and Dr. Prithiviraj Jothikumar for their encouragement and helpful
discussions inside and outside the lab meeting. I cannot also express in words how thankful
I am to the current lab members including Dr. Kaitao Li, Dr. Chenghao Ge, William Rit-
tase, Fangyuan Zhou, Zhou Yuan, and Muaz Rushdi, and Aaron Rosado. I especially want
to thank Ms. Larissa Doudy–I am told she is coming back – for making a wonderful lab
environment for the students to do science. I want to thank Dr. Baoyu Liu for mentoring me
and helping me to figure out many fundamental aspects of T-cell biology. I wish to thank
iv
Dr. Jothikumar, my collaborator on the CMV study for his suggestions and for performing
the experiments for this part.
I wish to thank the official Committee of my thesis defense. I am grateful to Profes-
sor Dr. Andrés García for his help and constructive critics in my thesis and for reading
carefully this manuscript. I am grateful to Dr. Jizhong Lou for taking the time to meet
me multiple times through video conference and to discuss each aim in detail and his final
inputs for the defense. I would like to thank Dr. Arash Grakoui for his ideas in this project
and the opportunity he has provided me to understand the field of immunology. He was
always very supportive and willing to discuss my thesis in details. I am thankful to Dr. JC
Gumbart for allowing me to attend his group meeting and be a part of his lab; for the many
interesting discussions we had, and for his advice and depth knowledge of molecular dy-
namics simulation and biophysics of proteins. Finally, I am very grateful to Professor Dr.
Steve Harvey for initially advising me and helping me with molecular modeling until he
officially retired from Tech. I feel honored and grateful that these great and talented people
participated in my examination committee and co-advises me despite their busy schedules.
And last but not least by any means, I wish to express my deepest thanks to my family,
my mother Florencia for her advice, help and never-ending optimism during all this time,
my father Alejandro for his support and understanding in all fields of my life, and my sister
and at the same time my best friend Evelyn who has brought an enormous amount of joy
and energy to my life with her little son. Without their tireless support and unconditional
friendship and love, I would not have had the courage and the strength to finish this thesis.
They kept my feet on the ground during the busy and hard days and their cheerfulness
created an optimistic atmosphere for this work. I also want to thank the people and friends
I met during the past few years in Homepark and Atlanta; they helped me and made my
stay pleasant.
v
I want to thank the Fulbright Science & Technology Fellowship for financially support-
ing me during three years of my Ph.D. studies. This thesis was also supported by the Na-
tional Science Foundation grant ACI-1548562 through extensive used of the Extreme Sci-
ence and Engineering Discovery Environment (XSEDE), allocation N0 MCA08X014. Sim-
ulations were run on “Stampede” and “Comet” supercomputers located at the Texas Ad-
vanced Computing Center and at the San Diego Supercomputer Center, respectively. An-
ton 2 computer time was provided by the Pittsburgh Supercomputing Center (PSC) through
Grant R01GM116961 from the National Institutes of Health, allocation N0 BIO110001P. I
want to express my sincere gratitude to the members and staffs of the XSEDE and the cen-
ters for their valuable help and assistance. The Anton 2 machine at PSC was generously
made available by D.E. Shaw Research.
Paul Cárdenas Lizana.
Georgia Institute of Technology.




DEDICATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iv
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii
SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .xviii
LIST OF SYMBOLS OR ABBREVIATIONS . . . . . . . . . . . . . . . . . . .xviii
GLOSSARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .xviii
I SPECIFIC AIMS AND HYPOTHESES . . . . . . . . . . . . . . . . . . . . 1
1.1 Objetive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2.1 Aim 1: Describe the molecular mechanism of how TCRs recog-
nize featureless viral pMHC landscapes and how peptide muta-
tions decrease immune recognition in the context of human infec-
tion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2.2 Aim 2: Identify the molecular pathway of how peptide ligand
recognition by TCRs is propagated to the CD3 signaling domains
to induce T-cell activation . . . . . . . . . . . . . . . . . . . . . . 2
II BACKGROUND AND SIGNIFICANCE . . . . . . . . . . . . . . . . . . . . 4
2.1 General Structure of the αβ T cell receptor . . . . . . . . . . . . . . . . . 5
2.2 Structure of pMHC molecules . . . . . . . . . . . . . . . . . . . . . . . . 7
2.3 CD3 Signaling domains . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.4 TCR Cβ FG Loop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.5 The role of CD4/CD8 co-receptors . . . . . . . . . . . . . . . . . . . . . 12
2.6 The current models of interactions between the TCR and CD3 signaling
subunits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.7 Immune response against viruses and their mutant variations . . . . . . . 16
vii
2.8 Cytomegalovirus-specific T cell response . . . . . . . . . . . . . . . . . . 17
2.8.1 Private vs public T cell responses . . . . . . . . . . . . . . . . . . 20
2.9 T-Cell-Mediated Autoimmunity of Diabetes . . . . . . . . . . . . . . . . 20
2.10 Specficity vs Sensitivity . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.11 Receptor-ligand signatures: Catch, slip, and ideal bonds . . . . . . . . . . 22
2.12 Significance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
III METHODS: THE COMPUTATIONAL MICROSCOPE FROM STATIC STRUC-
TURES TO LIVING PROTEINS . . . . . . . . . . . . . . . . . . . . . . . . 26
3.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.2 Molecular dynamics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.3 Force fields . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.3.1 Nonbonded interactions . . . . . . . . . . . . . . . . . . . . . . . 31
3.3.2 Bonded interactions . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.3.3 Integration algorithm . . . . . . . . . . . . . . . . . . . . . . . . 34
3.3.4 Steered molecular dynamics simulation . . . . . . . . . . . . . . 35
3.3.5 Targeted molecular dynamics simulation . . . . . . . . . . . . . . 36
3.4 Nanoscale Molecular Dynamics (NAMD) . . . . . . . . . . . . . . . . . 36
3.5 NAMD Code Performance and Scaling . . . . . . . . . . . . . . . . . . . 38
3.6 Anton 2 supercomputer increases speed and size of micro molecular dy-
namics simulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.7 Visual Molecular Dynamics . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.8 Limitations of molecular dynamics simulations . . . . . . . . . . . . . . . 42
IV THE MOLECULAR BASIS OF MUTANT EPITOPES DECREASING THE
ACTIVITY OF CYTOTOXIC T CELL . . . . . . . . . . . . . . . . . . . . 45
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.2 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
4.3 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.3.1 RA14 TCR forms an “in silico” catch bond with agonist NLV-
HLA2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.3.2 The total number of contacts displays a catch-bond behavior . . . 60
viii
4.3.3 The buried SASA is not a good predictor of catch bonds when
using constant velocity pulling, it becomes constant at the catch
phase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.3.4 The RA14 changes its binding orientation on the pMHC to form
a catch bond. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.3.5 NLV peptide has a second conformation associated with the catch
bond . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.3.6 Mutants reduce the conformational states of the peptide . . . . . . 76
4.3.7 The principal component analysis isolates the two conformations . 79
4.3.8 The molecular basis of “in silico” catch bonds in RA14 interact-
ing with the NLV peptide ligand . . . . . . . . . . . . . . . . . . 80
4.3.9 The forced-induced H-bonds formed at the catch-bond phase . . . 82
4.3.10 The RA14-NLV-HLA2 exhibits a second state at catch bond phase 83
4.3.11 The RA14 uses a molecular to lever read out a featureless viral
peptide ligand . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
4.3.12 Understanding the evolution of viral escape mutants . . . . . . . . 88
4.3.13 Structural differences of NLV-specific TCRs from different donors
forming “in silico” catch bonds when ligated to NLV-MHC . . . . 92
V THE PRINCIPLES FOR MOLECULAR RECOGNITION OF ANTIGENS
AND ACTIVATION OF CD3 SIGNALING DOMAINS BY THE T-CELL
RECEPTOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.2 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
5.3 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
5.3.1 C7, C25, 2C, and 1E6 TCRs are capable of forming “in silico”
catch bonds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
5.3.2 Inside the catch-bond phase, TCRs start rotating with a polarity
around the binding axes defined by the right-hand rule. . . . . . . 105
5.3.3 TCRs rotating around the binding axis induce functional confor-
mational states in the peptide . . . . . . . . . . . . . . . . . . . . 108
5.3.4 TCRs forming catch bonds experience the opening and closing of
their Cβ FG loop . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
5.3.5 The forced-induced states of the Cβ FG loop at the catch phase . . 111
ix
5.3.6 Quantification of the states of the Cβ FG loop of C7, C25, 2C, and
1E6 TCRs forming “in silico” catch bonds . . . . . . . . . . . . . 112
5.3.7 Quantification of the states of RA14 Cβ FG loop forming an “in
silico” catch bond . . . . . . . . . . . . . . . . . . . . . . . . . . 115
5.3.8 Rotating around the binding axis and waving the FG loop is an
intrinsic property of TCRs . . . . . . . . . . . . . . . . . . . . . 120
5.3.9 The deformation of the FG loop is proportional to the peptide
potency. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
5.3.10 The mechanism of opening and closing of the Cβ FG loop . . . . . 125
5.3.11 The moment of inertia of the TCR shows that linear force is trans-
lated into rotational torque that twists the TCR domains . . . . . . 127
5.3.12 Stretching the TCR rotates the inter-domain hinge and induces
conformational changes of the Cβ FG loop . . . . . . . . . . . . . 129
5.3.13 The role of the 310 helix in changing the states of the Cβ FG loop . 131
5.3.14 Hinge rotation and the open state occur simultaneously when lin-
ear force is translated into rotational torque that twists the TCR
domains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
5.3.15 The unfolding of the 310-helix connector allows the closing of the
Cβ FG loop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
5.3.16 The hinge rotation brings together the 310 helix and Cβ FG loop
and creates a huge electrostatic repulsion . . . . . . . . . . . . . . 135
5.3.17 Performing single or double mutations on the Cβ FG loop abol-
ishes the open state . . . . . . . . . . . . . . . . . . . . . . . . . 136
5.3.18 Deleting the Cβ FG loop allows the hinge angle to rotate and un-
folds the 310 helix . . . . . . . . . . . . . . . . . . . . . . . . . . 138
5.3.19 Deformations that eventually open the Cβ FG loop can be ob-
served in long-time MD simulations. . . . . . . . . . . . . . . . . 140
5.3.20 The mechanism of how the opening and closing of the Cβ FG loop
induce T-cell activation by connecting with the CD3 signaling do-
mains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
5.3.21 What are the resting and activated states of the TCR? . . . . . . . 144
VI CONCLUSIONS AND FUTURE DIRECTIONS . . . . . . . . . . . . . . . 147
VII LIST OF EXPECTED PUBLICATIONS . . . . . . . . . . . . . . . . . . . . 151
7.1 Aim 1: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
x
7.2 Aim 2: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
7.3 Other: Simulations of the PD-1 complexed with PD-1 ligands . . . . . . . 151
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
xi
LIST OF TABLES
1 Summary of TCRs used in this chapter. . . . . . . . . . . . . . . . . . . . 100
2 List of unique species identified using the searching database HMMER for
sequence homologs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
xii
LIST OF FIGURES
1 Ribbon diagram of the structure of human RA14 TCR and NLV-MHC . . . 8
2 The Assembly of the TCR-CD3 complex. . . . . . . . . . . . . . . . . . . 10
3 The TCR safety model . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
4 The structure and sequence TCR Cβ FG loop. . . . . . . . . . . . . . . . . 13
5 TCR-pMHC-CD4 and TCR-pMHC-CD8 ternary complexes. . . . . . . . . 14
6 The endogenous pathway. . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
7 Catch, slip, and ideal bonds . . . . . . . . . . . . . . . . . . . . . . . . . . 23
8 An Illustration of the performing molecular dynamics simulation and anal-
ysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
9 NAMD Benchmarks on TACC Stampede. . . . . . . . . . . . . . . . . . . 39
10 NAMD Benchmarks on SDSC Comet. . . . . . . . . . . . . . . . . . . . . 39
11 NAMD Benchmarks on SDSC Comet and TACC Stampede for bigger sys-
tems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
12 The topology of peptide-MHC class I complexes can influence TCR reper-
toire diversity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
13 The native crystal structure of TCR-pMHC shows the peptide residue Pro4P,
Met5P, and Thr8P are interacting with the TCR. . . . . . . . . . . . . . . . 48
14 Free MD simulation of TCR-pMHC intractions. Time evolution of the
number of H-bonds between TCR and pMHC for wild type NLV, and mu-
tants T8V, and M5I in the absence of force . . . . . . . . . . . . . . . . . . 54
15 “In silico” catch bond in the presence of force using constant-velocity pulling’ 55
16 Illustration of the time evolution of the number of H-bonds between the
TCR and the peptide ligand for wild type in the presence of force . . . . . . 56
17 Steered MD simulation of RA14 interacting with different pMHCs . . . . . 57
18 Examination of statistical significance for the number of H-bonds, contacts,
and buried SASA for RA14 interacting with NLV, T8V, and M5I peptide
ligands in free MD and SMD simulation using constant-velocity pulling. . . 59
19 “In silico” catch bond using constant-force pulling. . . . . . . . . . . . . . 60
xiii
20 The time evolution of the total number of contacts between the TCR and
the peptide ligands for NLV, T8V, and M5I, at different ICs and ramping
rates. At the catch phase, NLV and T8V display catch-bond profiles are,
with T8V having a small one. M5I mostly display a slip profile . . . . . . . 62
21 The total number of vdW contacts over time for the TCR-NLV-HLA2 at
varying constant forces of 0, 25, 50, 90, 100, and 150 pN. . . . . . . . . . . 62
22 “In silico” catch bond in the number of contacts for the NLV complex using
constant-force pulling. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
23 Buried SASA using constant-force pulling. . . . . . . . . . . . . . . . . . 63
24 Examination of statistical significance using box and whisker plot of the
number of H-bonds, contacts and, buried SASA for RA14 interacting with
NLV peptide ligand in the presence of force using constant-force pulling. . 63
25 Buried Solvent Accessible Surface Area (SASA). the time evolution of the
buried SASA between the TCR and the peptide ligands for NLV, T8V, and
M5I, at different IC and ramping rates. . . . . . . . . . . . . . . . . . . . . 64
26 The dependence of buried SASA over time for the TCR-NLV-HLA2 at
varying constant forces of 0, 25, 50, 90, 100, and 150 pN. . . . . . . . . . . 65
27 The docking orientation between the RA14 interacting with NLV, T8V, and
M5I in the absence of force. . . . . . . . . . . . . . . . . . . . . . . . . . 68
28 The docking orientation between the RA14 interacting with NLV, T8V, and
M5I in the presence of force. . . . . . . . . . . . . . . . . . . . . . . . . . 68
29 General view of change of RA14 TCR binding orientation on the pMHC to
form a catch bond. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
30 The docking orientation over time for NLV, T8V, and M5I complexes at
two different IC and two ramping rate in the presence of force. . . . . . . . 70
31 The dependence of docking orientation over time for the RA14-NLV-HLA2
at varying constant forces of 25, 50, 90, 100, 150, and 200 pN. . . . . . . . 72
32 The RMSD of each peptide for NLV, T8V and M5I peptides in the absence
of force. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
33 The RMSD of each peptide for NLV, T8V and M5I peptides in the presence
of force. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
34 The RSMD for NLV, T8V, and M5I complexes at two different IC and two
ramping rate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
35 The RMSD for the NLV epitope pulled at constant forces of 25, 50, 90,
100, 150, and 200 pN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
xiv
36 Examination of statistical significance using box and whisker plot of the
docking angle and RMSD of the peptide for RA14 interacting with NLV,
T8V, and M5I peptide ligands in the absence and presence of force using
constant-velocity pulling. . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
37 Histograms comparing the peptide conformation in the absence and pres-
ence of force . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
38 Local mobility of the NLV peptide, T8V, and M5I mutants measured by the
RMSF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
39 dPCA and k-means clustering for NLV, T8V and M5I epitopes . . . . . . . 80
40 Catch-phase exhibiting a second state of RA14-NLV-HLA2 interaction . . . 81
41 Stability of H-bonds between TCR and MHC from crystal structure. . . . . 82
42 Stability of H-bonds between TCR and peptide from crystal structure. . . . 82
43 Stability of forced induced H-bonds between TCR and MHC at the second
conformation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
44 Stability of forced induced H-bonds between MHC and the epitope at the
second conformation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
45 The “in silico” catch bond exhibits a second state of RA14-NLV-HLA2
interaction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
46 Illustratiuon of the TCR using a molecular lever to form an “in silico”
catch bond . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
47 Quantification of the sequential events of the molecular lever . . . . . . . . 89
48 2D Diagram plot of the first state . . . . . . . . . . . . . . . . . . . . . . . 91
49 2D Diagram plot of the second state . . . . . . . . . . . . . . . . . . . . . 91
50 Free MD simulation:The average number of H-bonds at the binding inter-
face between the TCR and NLV-HLA2 for different donors . . . . . . . . . 92
51 TCR genes are shown in the table according to IMGT nomenclature . . . . 92
52 “In silico” catch bond for different donors . . . . . . . . . . . . . . . . . . 92
53 Structural interaction of immunodominant CMV-TCR to NLV peptide in
the absence of force for different donors. . . . . . . . . . . . . . . . . . . . 93
54 Structural interaction of immunodominant CMV-TCR to NLV peptide in
the presence of force for different donors. . . . . . . . . . . . . . . . . . . 94
55 C7, C25, 2C “In silico” catch bonds . . . . . . . . . . . . . . . . . . . . . 104
56 1E6 TCR “In silico” catch bond . . . . . . . . . . . . . . . . . . . . . . . 105
xv
57 The docking orientation around the binding site for the C7, C25, and 2C
TCRs interacting with their agonist pMHC . . . . . . . . . . . . . . . . . . 107
58 The docking orientation around the binding site for 1E6 TCR interacting
with a panel of ligands. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
59 The RMSD of each peptide for C7, C25, and 2C TCR interacting with their
agonist pMHC in the presence of force. . . . . . . . . . . . . . . . . . . . 109
60 The RMSD of 1E6 interacting with a panel of peptides in the presence of
force. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
61 Representation of the Cβ FG loop conformer . . . . . . . . . . . . . . . . . 112
62 Correlation between the opening of the Cβ FG Loop and the occurrence of
the catch-bond at constant-velocity pulling. . . . . . . . . . . . . . . . . . 113
63 Correlation between the opening of the Cβ FG Loop and the occurrence of
the catch-bond at constant-force pulling. . . . . . . . . . . . . . . . . . . . 113
64 Time evolution of the RMSD of the Cβ FG loop of C7, C25, 2C, and 1E6
TCRs interacting with their epitopes . . . . . . . . . . . . . . . . . . . . . 115
65 Forced-induced H-bonds between the Cβ FG loop and the Vβ domain for
the 2C TCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
66 Time evolution of the RMSD of the Cβ FG loop of RA14 TCR interacting
with peptides in the presence of force. . . . . . . . . . . . . . . . . . . . . 117
67 Time evolution of the RMSD of the Cβ FG loop of RA14 TCR interacting
with agonist NLV peptide ligand using six constant forces of 25, 50, 90,
100, 150, 200 pN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
68 Representation of the reversible states of the Cβ FG loop at different simu-
lation times in the presence of force. . . . . . . . . . . . . . . . . . . . . . 120
69 Summary of protein query produced by the HMMER and BLAST search . 122
70 PLS-based functional mode analysis for RA14-NLV-HLA2 forming a “in
silico” catch-bond. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
71 The percentage increase in the area of the Cβ FG loop of RA14 and 1E6
interacting with a panel of ligands in the presence of force as compared to
force-free simulation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
72 Time evolution of the number of H-bonds between 1E6 TCR interacting
with a panel of peptide ligands at slow pulling. . . . . . . . . . . . . . . . 127
73 The moment of inertia of the RA14 TCR . . . . . . . . . . . . . . . . . . . 128
74 The TCR inter-domain rotational hinge . . . . . . . . . . . . . . . . . . . 130
xvi
75 Molecular details of the 310 helix and Cβ FG loop . . . . . . . . . . . . . . 132
76 Characterization of the Opening and Closing states of the Cβ FG loop for
the RA14 and 1E6 TCRS. . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
77 Salt-bridges formed by charged residues located in the Cβ FG loop. . . . . . 136
78 States of the Cβ FG loop at high constant-velocity and constant-force pulling
for RA14 TCR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
79 Single and double in silico mutations on 1E6 TCR . . . . . . . . . . . . . . 139
80 Characterization of conformational changes of Cβ FG-loop deleted TCR
for the RA14. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
81 Characterization of the opening and closing states of the Cβ FG loop at the
microsecond scale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
82 Conformational changes of TCRs upon recognition of peptide ligands . . . 142
83 Salt-bridges formed by charged residues located in the Cβ FG loop at the
microsecond scale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
84 Molecular assembly of the TCR interacting with the CD3 signaling sub-
units at the resting state. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
85 Molecular assembly of the TCR interacting with the CD3 signalling sub-
units at the activated state . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
86 A visual summary of the results from Aim 1 and Aim 2. . . . . . . . . . . . 150
xvii
SUMMARY
There are continually strong demands in understanding the principles for molecular
recognition of antigens and activation of T cells because of their broad implications in im-
munology and the benefits in cancer immunotherapy. Antigen processing and presentation
was extensively studied; however, how TCR recognizes pMHC and then activates the sig-
naling machinery is not understood. This question has puzzled immunologist for decades
and understanding if there exists a mechanism genetically encoded to propagate informa-
tion read from the TCR distal-membrane binding site to inside the cell is considered the
“holy grail of molecular immunology”. It is believed that TCRs mediate T cell activation
by connecting their dimeric αβ chains with CD3εγ, CD3εδ, and CD3ζζ subunits using an
“unknown mechanism” and the Cβ FG loop in TCRs is regarded as very important since
its removal severely affects T cell activation and development.
The first part of this thesis studies the force response of a TCR reading out a pMHC
in the context of viral infection and explained how information encoded in the peptide is
decoded by the TCR. For the first time, it is demonstrated that TCRs are capable of forming
“in silico” catch bonds as they do in experiments. It is explained the characteristics and
requirements of catch bonds in antigen recognition and how mutant epitopes abolish it. It
is shown that TCR modulates the peptide conformation by using highly conserved residues
in MHCs. Finally, it is proposed the molecular mechanism of how the TCR reads a viral
featureless pMHCs: “RA14 uses a molecular lever to form an in silico catch bond and
recognize antigenic peptides”.
The second part established the principles for molecular recognition of antigens and
the mechanical activation of signaling domains by the TCR. It is proposed that the decod-
ing process and early intracellular signaling are connected by conformational changes in
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the TCR. The TCR interaction with either the pMHC and CD3 domains are hardwired on
its structural dynamics. TCRs are not rigid entities, as currently thought, but they are de-
formable proteins and mechanical forces modulate their conformations. The ability of the
TCR to deform without releasing the pMHC and to transform linear force into rotational
torque is the key to understand this molecular mechanism. Lastly, it is described the molec-
ular mechanism of how TCRs use the Cβ FG loop in contacting and potentially activating
the CD3 signaling domains.
xix
CHAPTER I
SPECIFIC AIMS AND HYPOTHESES
1.1 Objetive
we proposed to study at the molecular level the mechanobiology of the T-cell receptor
(TCRs) by using “in silico” biology. The TCR is an integral part of the immune sys-
tem and is a complex protein that has multiple domains. The TCR extracellular domain
or ectodomain binds multiple peptide ligands in the context of major histocompatibility
complex (MHC) molecules. Free molecular dynamics (MD), targeted (TMD), and steered
(SMD) simulations are employed to investigate the TCR conformational changes and its
ligand dissociation in the presence of mechanical forces. The simulation is driven and
motivated by the need to understand the intricate experimental studies.
TCR interacts with peptide-MHC (pMHC) to discriminate pathogens from self-antigens
and trigger adaptive immune responses. The sustained interest in TCR-pMHC interaction
stems from a fundamental hypothesis that their interaction parameters have a central role in
determining the subsequent T-cell response. Using computer simulations, the TCR-pMHC
interaction is modeled and the role of catch bond and epitope recognition are investigated
in the context of viral infection and autoimmune disease.
1.2 Aims
1.2.1 Aim 1: Describe the molecular mechanism of how TCRs recognize featureless
viral pMHC landscapes and how peptide mutations decrease immune recogni-
tion in the context of human infection.
The scientific question is how TCRs decode information in featureless pMHC landscape
presenting viral epitopes and produce a functional binding. The first hypothesis is that
“Force induces exposure of the buried residues in the MHC to enable contact with the TCR
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and generate new long-lived hydrogen bonds”. The goal is to understand how the TCR
exposes these residues and modifies/modulates the conformational states of the epitope.
Is force necessary during TCR scanning in the context of viral infection? We will also
study how force modulates the peptide flexibility and conformational states, which could
potentially regulate the binding affinity of TCR and pMHC. Viral persistence is linked in
part to the rise of “viral mutations” that have decreased functional effects compared to those
of the wild type (WT), thereby decreasing recognition by the immune system.
The second hypothesis is that viral persistence is characterized by converting “catch-
slip” into “slip-only” bond by mutant epitopes of antigen specific TCR-pMHC interactions.
We will investigate atomistically the role of converting catch into slip-only bonds and its
role in peptide recognition for the escaping mutations in the context of viral infection. We
will describe the molecular mechanisms for this change in bond type and correlate the
catch-slip conversion to the loss of function of epitopes previously recognized by the TCR.
This Aim explains how persistent viral infection employ mechanically-regulated pathways
to escape immune recognition.
1.2.2 Aim 2: Identify the molecular pathway of how peptide ligand recognition by
TCRs is propagated to the CD3 signaling domains to induce T-cell activation
The question that has puzzled immunologist for decades is that if there exists a precon-
ceived traveling pathway genetically encoded in the TCR genes to propagate information
read from its distal-membrane binding site to activate the CD3 signaling domains. First,
the general rules for molecular recognition of antigens and activation of CD3 signaling
domains by the TCR are investigated. Different TCRs are used to study how catch bonds
relate to TCR specificity and sensitivity and how TCRs employ catch bonds for molecu-
lar recognition of antigens and activation. The first hypothesis is that the weak interaction
between the TCR and pMHC becomes strong in the presence of force to produce an “in
silico” catch bond and activate the T cells.
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Second, we will study how the decoding process and intra-cellular signaling are con-
nected and if they involve conformational changes in the TCR domains. The second hy-
pothesis is that “in the presence of force, a cognate peptide presented to TCR induces
conformational changes in the TCR domains that are away from its membrane-distal bind-
ing site, and includes the opening/closing of the FG loop and the extension (or unfolding)
of connecting peptides (CP) –the membrane-proximal stalks. The rationale is that an open
Cβ FG loop contacts the upper surface of CD3εγ and push it down; then it is pull up the
CD3 domains that in turns expose its ITAMs for phosphorylation and the activation of sub-
sequent signaling cascade. In addition, the extension of the CPs expose a highly conserved
sequence of residues located on the α-chain stalk, that is importantly functional.
Currently, the rules for recognition and activation are not well understood; there are
many parameters when defining a successful engagement of TCR-pMHC, i.,e.; specificity,
sensitivity, etc. The question is what TCR property governs them. Is the TCR dynami-
cal structure? Sensitivity and specificity refer to the TCR’s ability to correctly detect an




The immune system is composed of innate and adaptive responses and their fundamental
role is to protect the body and fight against infectious organisms and tumor cells. The first
line of defense is mediated by the innate immune system between hours while the adaptive
response develops over a longer period of time, usually days [1]. The adaptive response
is divided into antibody-mediated (also called humoral) and cell-mediated immunity with
the major players being the lymphocytes. Lymphocytes originate in the bone marrow from
lymphoid progenitor [2] and either remain there and mature into B cells, or migrate to the
thymus, where they undergo development to become T lymphocytes.
Lymphocytes residing in the thymus are called thymocytes and they undertake multiple
stages to fully develop a T-cell antigen receptor (TCR), bind weakly self-antigens to be
positively selected, and finally commit their lineage to either be CD4+ or CD8+ naïve T
cells [3, 4]. Thus, T-cell recognition of antigens is the central event of the adaptive im-
mune response [5, 6], where each mature T cell expresses a unique TCR, which is the only
molecule on the T-cell surface that senses micro-organism-derived peptides conjugated
with the major histocompatibility (MHC) molecules expressed on the antigen presenting
cells (APC) [7].
T cells are distinguished from other lymphocytes by the presence of TCR on their mem-
brane surface and they can be broadly divided into Helper, Cytotoxic, Memory, Regulatory,
γδ, and Natural Killer T cells. Fully maturated, naïve T cells circulate in the lymph nodes or
spleen to patrol for antigens expressed on APCs, survival signals (i.e., immunological toler-
ance), and activation cues. When T cells encounter a foreign antigen, they become effector
T cells and undergo clonal expansion. The effector T cells will function as either releasing
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cytotoxic granule (CD8+ T cells) to kill the specific cells directly or release cytokines to
trigger other immune cells like B cells for help (CD4+ T cells). After their activity, some T
cells acquire memory, they migrate and reside in the body, and they are able to remember
and respond strongly if they meet the same invader. TCRs have exquisite sensitivity and
specificity and their recognition capabilities are very important in both thymic development
and T cell activation [8, 2].
Cytotoxic T Lymphocytes (CTLs, CD8+ T cells) are an important type of T cells that
express on their surface the CD8+ coreceptor, are capable of killing infected cells, and inter-
act with a peptide bound in major histocompatibility (pMHC) molecule at the cell surface
on APCs. Similarly, T helper cells also play a fundamental role in the adaptive responses
as they help to activate other immune cells by releasing cytokines [8, 2]. They express on
their surface the CD4 coreceptor and thus are commonly called CD4+ T cells. CD4+ T
cells assist in suppressing or down regulating immune responses. They are essential in B
cell antibody class switching, in the activation and growth of cytotoxic T cells, and in max-
imizing the bactericidal activity of phagocytes such as macrophages [8, 2]. In general, the
T cell activation and effector functions rely mainly on the recognition of a pMHC molecule
at the cell surface by TCR and the engagements of its coreceptors.
Understanding how the TCR in the immune system accomplishes its biological func-
tion is very critical for organ transplants and treatment of immunodeficiency, autoimmune
diseases, persistent viral infection, and cancer since it is shown that they are the result of
malfunctioning and misunderstanding of T cell immunity [9, 10, 11].
2.1 General Structure of the αβ T cell receptor
Although the αβ TCR is the most widely studied and commonly referred in the literature
as the TCR, there is a very small set of T cells expressing a similar TCR formed by γ
and δ chains, termed as the γδ T cells with their biological relevance still highly debatable
and not established yet [12, 13]. Most T cells have αβ TCRs (95%); however, 5% of
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them express only the γδ TCR [2]. T cells recognize peptides derived from cell-associated
pathogens of viral, bacterial or fungal origin, as well as tumor antigens bound in major
histocompatibility (MHC) molecule at the cell surface on antigen presenting cells (APC)
through the T cell antigen receptor (TCR) [8, 2]. The antigen-binding TCR is similar in
topology and size (height and width) to an Ig Fab fragment. The TCR is a disulfide-linked,
membrane-anchored heterodimer consisting of α and β chain [14, 15, 16, 17].
Each α and β chain are composed of one Ig-like variable (V) domain, one Ig-like con-
stant (C) domain, a short connecting peptide just proximal to the membrane, a hydrophobic
transmembrane region, and a short cytoplasmic region as shown in Fig 1 (B). The V do-
mains provide clonotypic antigen specificity and vary from one to another T cell, while
the C domains are constant or invariant. Ig-like domains consist of two β-sheets formed
by antiparallel β-strands each containing an average of 6 to 8 amino acids. The two β-
sheets are arranged in a sandwich-like fold to form a hydrophobic core. The β-sheets are
further stabilized by a conserved disulfide bond between two cysteines, and an “invariant”
hydrophobic residue (W). The Ig fold for Vα and Vβ domains have each 115 amino acid
residues in average that form four anti-parallel β-strands per β-sheet plus a short β-strand
segment across the top of the domain.
The Ig fold for Cβ domains is smaller and has about 105 residues, yielding sheets with 4
and 3 β-strands. The Vα and Vβ fold consists of A, B, C, C’, C”, D, E, F, G β-strands, while
Cβ domain is composed of A, B, C, C’, D, E, F, G. The A, B, E strands are on one sheet
and G, F, C in the other [15, 18, 14]. The Cα domain diverges from typical Ig C domains
sequences [14], having only about 15% sequence identities plus missing many conserved
residues; e.g., an “invariant” hydrophobic residue (W) that occurs in the C strand is not
present. The Cα domain shows that the A, B, E, and D strands from the back a sheet and are
highly similar to the corresponding back sheet of the standard Ig-fold. However, the C, F,
and G strands do not form the top β-sheet; they are far from each other and loosely packed
against the bottom sheet since the hydrophobic residue (W) used to attach the C strand to
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the bottom sheet is missing. The C’ strand is removed from the classical C-like Ig domain.
These differences complicate the classification of the Cα domain into typical Ig-like folds.
The flexible loops in the membrane-distal area of the Vα and Vβ domains form the
antigen-binding site and are termed the complementary-determining regions (CDRs). They
are analogous to the loops used by antibodies to capture antigens; however, as opposed
to the concave antigen-binding surface of antibodies, they form a relatively flat binding
surface to interact with the pMHC molecule on the APC. There are three CDRs in each
Vα and Vβ domain. CDR1 and CDR2 are germ line-encoded while CDR3 is somatically
rearranged. The CDR3s is the most diverse portion of the TCR and usually contact directly
the peptide presented by the MHC. On the other hand, the CDR1 and CDR2 loops mostly
recognize parts of MHC that form the peptide-binding groove [12].
2.2 Structure of pMHC molecules
Antigenic peptides are presented to T cells via the heterodimers MHC class I or class II
molecules and remarkably they share common structural features. MHC class I molecules
are expressed on almost all kinds of cells, while MHC class II molecules are restricted to
professional APCs, such as dendritic cells, macrophages or B cells. Class I MHC forms it
peptide-binding site from folding the α1, α2, α3 domains, while the β2 µicroglobulin pro-
vides stability to the α domains by forming tight dining with the α3 domain. The overall
architecture is shown in Fig 1 (B). Polymorphic residues are located around the binding
site and they provide sequence variation for the peptide specificity of individual MHC al-
leles. MHC class I molecules present endogenous peptides produced by protease-degraded
proteins, while MHC class II molecules present exogenous peptides derived from the envi-
ronment. The peptide length ranges from 8 to 10 and from 13 to 25 residues for MHC class
I and MHC class II, respectively [19]. In MHC class II, the peptide is located deep inside
the binding groove compared to MHC class I. The MHC binding groove is closed at both
ends so longer peptides have to adopt bulged conformations, providing specific hot spots.
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In MHC class II, the binding groove is open so longer peptides can be outside the ends of
MHC binding site. Humans carry one set of HLA-A, HLA-B, and HLA-C as HLA class
I molecules, and HLA-DP, HLA-DR, and HLA-DQ as HLA class II molecules. Human
leukocyte antigens are abbreviated as HLA. Each individual HLA alleles from the same
person can differ up to 20 amino acids. This polymorphic nature permits HLA proteins to
express and present any kind of epitope in their binding groove to be easily scanned by the
TCR [20].
(A) (B)
Figure 1: Ribbon diagram of the structure of human RA14 TCR and the MHC displaying
an NLV peptide using the PDB code: 3GSN [21]. (A) Crystal structure of the human T-cell
receptor, (TCR). TCR is an immunoreceptor found on the surface of every T lymphocytes
and it is responsible for molecular recognition of antigenic peptides, also called epitopes.
The TCR α and β chains are represented in ribbon diagram and are colored blue and red,
respectively. The constant and variable domains are labeled. The membrane-distal binding
site is about 80Å away from the membrane. Importantly TCRs do not have intrinsic sig-
naling properties. (B) The structure of HLA-A2 bound to a viral NLV peptide colored in
green. The major histocompatibility complex, also called MHC, is a cell surface molecule
and its principal function is to bind to antigenic determinants derived from pathogens, dis-
play them on the cell surface, and present them to T-cells for recognition. The heavy and
light chain of HLA-A2 are shown and they are labeled. β2 microglobulin is colored in
orange. The bound TCR or pMHC are not shown in both structures for clarity.
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2.3 CD3 Signaling domains
TCRs do not have intrinsic signaling properties since it has a short cytoplasmic tail that
lack signaling motif, and as a consequence they are required to transduce signals through
the associated CD3 subdomains [22]; thus the αβ TCR associates noncovalently with the
CD3 εγ, εδ, and ζζ dimers to form a multisubunit complex across the membrane [7, 23].
TCR/CD3 complex plays an important role in differentiation, survival, and function of T
cells by engaging with pMHC. In the TCR complex, the TCR αβ chains are responsible for
antigen recognition whereas the invariant CD3 chains are responsible for the signal trans-
duction. The CD3 contains a total of 10 immunoreceptor tyrosine-based activation motifs
(ITAMs). Binding of the extracellular domains of TCR to pMHC results in changes in the
cytoplasmic region of the CD3 complex become phosphorylated and it triggers downstream
signaling cascades leading to eventual responses.
The association is stabilized by polar interactions between CD3 molecules and TCR that
have negatively charged and positively charged transmembrane region, respectively. For
instance, sequence analysis in the transmembrane domains indicates that for each chain of
the TCR complex, at least one charged residue is located within this transmembrane region
and published studies indicate that these charged residues are responsible for the assembly
of the transmembrane domains of the TCR complex [25, 26, 27, 24]. As shown in Fig. 1,
each of the three basic residues on TCR αβ chain interacts with a pair of acidic residues of
the CD3 signaling dimers (CD3εδ, CD3εγ and ζζ). Structural studies provide insight on
the arrangement of the TCR transmembrane domains [25], which reveal the basic residue
motif that interacts with two acidic residues.
Even though the structure of the transmembrane domain of ζζ chain [26] are solved,
it is still a mystery how recognition of peptide by the TCR is propagated to CD3 domains
and to initiate activation since the detail molecular assembly between αβ TCR with CD3
signaling machinery is not available. Once propagated, the immunoreceptor tyrosine-based
activation motif (ITAMs) of the CD3 signaling dimers are exposed and phosphorylated [28,
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Figure 2: Assembly of the TCR-pMHC with the CD3 complex. (A) The TCR-pMHC as-
sociates noncovalently with the CD3 εγ, εδ, and ζζ dimers to form a multisubunit complex
across the membrane. The TCR-CD3 complex plays an important role in differentiation,
survival, and function of T cells by engaging with pMHC. In the TCR complex, the TCR αβ
chains are responsible for antigen recognition whereas the invariant CD3 chains are respon-
sible for the signal transduction. The CD3 has a total of 10 immunoreceptor tyrosine-based
activation motifs (ITAMs). (B) Each of the three basic residues in the TCR Transmem-
brane(TM) regions serves as a critical contact for one of the three signaling dimers that
associate with TCR. TCR-CD3 polypeptides are shown in a representation of the lipid bi-
layer. (C) Simplified helical wheel projection depicting interactions among TM domains in
the same relative positions as above. Images adapted from references [2, 24].
29], which are required for activation of the downstream process. Several models, including
a “safety” model [30], have been proposed to explain how engagement of the TCR by
agonist pMHC may lead to the phosphorylation of the ITAMs in the associated CD3 dimers.
The “safety” model hypothesizes that the cytoplasmic domains of the CD3 ζ and ε chains
are associated with the plasma membrane, which buries the tyrosine residues inside the
membrane; thus preventing them from being phosphorylated. TCR-pMHC engagement
destabilizes their associations and releases those tyrosines from protection and allows their
phosphorylation. NMR structures of the CD3ε domain [27] supports this model.
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Figure 3: The TCR safety model: The TCR subunits including its extracellular portion
are depicted and colored as TCR α (gray), TCR β (purple), CD3γ (dark green), CD3δ
(light green), and CD3ε (orange), the cytoplasmic domains, including CD3 ζ (yellow). The
phenyl-rings indicate the critical tyrosines located inside the ITAM motifs of CD3ζ cy-
toplasmic domains while the blue dots represent the basic residues that interact with the
acidic residues located in the inner leaf of the membrane. (A) Prior to activation, basic
residues in the cytoplasmic domain of the CD3 subunits associate with the plasma mem-
brane such that the key signaling tyrosines are sequestered in the plasma membrane; thus
the TCR safety is “on” and the ITAMs are embedded. (B) The safety is “off” due to pMHC
binding. The critical tyrosine residues in the ITAMs are accessible to cytoplasmic Src ki-
nases and become phosphorylated in the “off” state. However, this model does not answer
what dislodges the ITAM motifs from the membrane and allow phosphorylation?. The
Figure is taken form ref [30].
2.4 TCR Cβ FG Loop
Currently, it is widely accepted that TCRs mediate T cell activation by connecting their
dimeric αβ chains with CD3εγ, CD3εδ, and CD3ζζ subunits using an “unknown mech-
anism”. The TCR β chain contains the Cβ FG loop insertion that protrudes between Vβ
and Cβ domains. The 14-residue Cβ FG loop is a mammalian adaptation and it is highly
conserved. Contemporaneous with this insertion event was molecular speciation of a CD3
precursor into CD3γ, CD3δ genes. The FG loop is critical in the mechanosensing operation
of the TCR since it greatly increases the sensitivity of T cell-based recognition. A number
of features point to its potential role in mechanosensing. First, the positioning of the Cβ FG
loop between the Cβ and VCβ domains physically rigidifies and stabilizes these structures.
Second, the FG loop contains several residues that are conserved across mammals. Third,
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the FG loop region is adapted to CD3εγ but not CD3εδ to promote interaction. Last, sensi-
tivity measurements suggest that the FG loop is significantly influential in TCR triggering.
T cells expressing TCR mutants that lack the FG loop require 100 to 1,000 fold higher mo-
lar concentrations of antigenic peptides for stimulation than T cells expressing wild-type
TCR counterparts. Thus, the TCR Cβ FG loop is regarded as very important in this process
since its removal also affects T cell activation and development [31]. For instance, FG-loop
deleted T cells: induce less tyrosine phosphorylation; manifest reduced proliferation and
cytokine production abilities upon T cell stimulation; and impair negative selection [32].
The FG loop is internally well-structured and is composed of 12 to 14 amino acid long
chain that protrudes out of Cβ domain [33, 34], as shown in the inset of Fig 4. The FG loop
has a conserved W223 that forms hydrogen bonds with the backbone of Q225 and R227;
W223 also makes extensive hydrophobic contacts with residues L217 and P230. W223
is held fixed in space by those interactions that in turn lend rigidity to the FG loop. This
closely packs the FG loop to the β chain and integrates the Cβ and Vβ domains by forming
a rigid structural entity. It has been long asked how recognition of peptide by TCR evokes
activity on T cells since TCR antigen-specific binding site is located distant from the FG
loop and CD3 subunits. Therefore understanding how recognition of epitopes presented by
MHC is transmitted to the CD3 domains to induce T-cell activation is still regarded as the
“holy grail” of molecular immunology.
2.5 The role of CD4/CD8 co-receptors
Along with TCR/CD3 complex, the role of coreceptors is still controversial in T cell recog-
nition and activation. T cells have two co-receptors, CD4 and CD8– that play important
roles in the binding of TCR-pMHC. Co-receptors bind the MHC molecule mainly to bring
Src family tyrosine kinase p56 Lck or Lck to the TCR/CD3 complex and trigger the signal-
ing cascades [35, 36].
CD4 is composed of 4 immunoglobulin domains (D1, D2, D3, and D4) that are linearly
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Figure 4: The structure and sequence TCR Cβ FG loop. (A) Crystal structure of the αβ
TCR coloring in yellow the FG loop. (B) Molecular detail of the FG loop, highlighting
key residues. (C)Sequence comparison among various species. The FG loop insertion
contains well-conserved key residues. The F strand cysteine contributing to the Cβ intra-
chain disulfide bond is indicated by a dot. Overall mammals have elongated Cβ FG loops
and correspondingly distinct CD3γ and CD3ε subunits. The TCR Cβ FG loop is very
important since its removal affects T cell activation and development. FG-loop deleted
T cells: 1) induce less tyrosine phosphorylation; 2) manifest reduced proliferation and
cytokine production abilities upon T cell stimulation, and 3) impair negative selection. The
PDB code: 3GSN [21] is employed to depict the TCR.
joint as a glycoprotein chain. The D domain is flexible to change conformation and interact
with the MHC. D1 interacts with the β2 domain of an MHC II molecule [37, 38] while
cytoplasmic C-terminal end interacts recruits Lck molecules. CD8 is a αβ heterodimer
transmembrane glycoprotein formed by two IgV-like domain located away from and con-
nected to the plasma membrane by a thin stalk. The extracellular IgV α chain interacts
with the α3 portions of a Class I MHC molecule and the cytoplasmic tail also recruits
Lck molecules to the TCR/CD3 complex. CD4 and CD8 are expressed on different sub-
populations of T cells that have different functions. CD4 is restricted to an MHC class II
expressed on T helper cells, and CD8 is restricted to an MHC class I expressed on cytotoxic
T lymphocytes (CTL) [39]. CD8 and CD4 interacting with the TCR-pMHC complexes are
shown in Fig 5.
13
Currently how the TCR and its (CD8/CD4) co-receptors interact to initiate signals with
defined cellular responses is not entirely understood. The TCR α-chain connecting peptide
contains an conserved motif called α-CPM. Mutations α-CPM promote unresponsiveness
to antigenic stimuli and defects in positive selection; interestingly, negative selection with
an agonist ligand was unaffected [40].
Figure 5: (A) The Crystal structure of the ternary complex of TCR-pMHC-CD4 (MS2-
3C8-MBP-DR4-CD4) using the PDB code 3T0E [41]. (B) Model of the ternary complex
of TCR-pMHC-CD8. It is constructed by superposing the H2Dd-CD8αβ complex using
PDB code 3DMM [42] onto a TCR-H2Db complex using the MHC class I molecule as a
reference, (3PQY) [43]. The CD8αβ stalk regions are drawn manually and they are in-
serted in the cell membrane. All domains are labeled. Mature T cells express CD4 or CD8
molecules and function as important co-receptors by binding to invariant portions of the
MHC I (CD8) or MHC II (CD4) and increasing the interaction of the pMHC. CD4 and
CD8 play important roles is to bring the Src family tyrosine kinase p56 Lck or Lck to the
TCR/CD3 complex and trigger the signaling cascades. CD4 is composed of 4 immunoglob-
ulin domains that are linearly joint as a glycoprotein chain. CD8 is a αβ heterodimer trans-
membrane glycoprotein formed by two IgV-like domain located away from and connected
to the plasma membrane by two thin stalks. The plasma membrane is created using VMD.
2.6 The current models of interactions between the TCR and CD3 sig-
naling subunits
The contacting interactions between the TCR and CD3 signaling subunits and how they
are docked one respect to others are still highly debatable and controversial in the scientific
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community. It is shown that the FG loop in TCR Cβ interacts with CD3εγ while the DE
loop in TCR Cα interacts with CD3εδ; and the CC’ loop in TCR Cβ was found to interact
with both CD3εγ and CD3εδ [44, 45, 46]. It is suggested that CD3ε domain lies in close
proximity to the Cβ FG loop and it is potentially accommodated in a small cavity formed
below the Cβ FG loop and the Cα CD and EF loops [47] and the Cβ FG loop facilitates sig-
nal initiation [44]. It is suggested that AB loop located on the TCR Cα domain experiences
conformational changes when interacting with the CD3ε [48, 49].
More sophisticated NMR studies have independently reported that the helix-3 and helix
4-F strand on the TCR β interacts with the CD3εγ [50, 51] while F and C strands on the
TCR α chain interacts with CD3εδ [51]. It is proposed that CD3εδ is placed below rather
than alongside the TCR α-chain [52]. A previous study also supports this model of the
TCR binding to CD3 signaling subunits [40]. TCRs with a substituted α-chain connect-
ing peptide motif exhibit a reduced association with the CD3δ subunit and this correlates
with the finding that CD3δ-deficient thymocytes are defective in undergoing positive selec-
tion [53]. This implies a role for CD3δ being placed below the TCR and interacting with
the connecting peptides.
Based on these experiments, many competing models of how the CD3 signalling sub-
units re-arrange around the TCR have been proposed. Importantly, these models are con-
structed by using indirect experiments such as mutagenesis, MNR, small-angle x-ray scat-
tering, electron microscopy images, and T-cell functional assays since it is very compli-
cated to crystallize the TCR bound to CD3 signaling subunits. The molecular models can
be broadly classified into 3 categories: the one-sided model [50, 54, 55, 56], the two-sided
model [57, 33], and the sitting-underneath model [52, 51, 40].
It is reported recently that the buried residues of TCR α/β-interface undergo significant
conformational transitions upon cognate ligand binding, with most of these residues located
at the Cα/Cβ interface [48, 58, 59, 60]. This proposed a systematic reorganization of the
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TCR α/β interface. In addition, upon binding, a residue (V116β) located at end of the 310-
helix connector is indicated to become mobile based on the broadening of the NMR spectra
line [60]. These new conformational changes are not included in the previous models.
Importantly, the structural basis of the TCR conformational changes, their impact on
interactions with the CD3 signaling subunits, and how they can be related to the models are
not investigated. The proposed models are not mutually exclusive if the TCR is thought to
be a dynamic structure.
2.7 Immune response against viruses and their mutant variations
In human, CTLs play a critical in controlling infections as humans are constantly fighting
persistent viral infections. CTLs recognize viral determinants in the context of HLA class
I molecules. Once the CTLs are activated, they eliminate infected cell by secreting per-
forin/granzyme lytic granule or antiviral cytokines [61, 62]. The Epstein Barr Virus (EBV)
and the cytomegalovirus (CMV) infect asymptomatically humans with more than 70% and
80% of adult populations, respectively [63, 64]. Hepatitis C (HCV; infecting globally about
∼175 million people) and Human Immunodeficiency Virus (HIV; infecting globally about
∼36.7 million people) are also viral infection; however, they are very severe to the body
and they pose challenge to the immune system with inhibitor molecules to impair the TCR
activation [65, 66, 67].
Another alternative used by viruses to escape immune recognition is via mutations that
increase the viral fitness [68]. The killing capability of the immune response is severely
disrupt by chronic and persistent infections [69, 70] bearing epitope mutations. In such
case, if some viral variants survive the attack of the immune response, they are select based
on their viral fitness to allows the virus to rebounds displaying persistent viral infection. At
this stage, if the system is incapable of adapting and killing the variants a chronic infection
is established and it will persist in the host.
The cause of persistent infections can be attributed to the viral mutations. A single
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amino acid substitution can take place at anchoring residues and this results in the com-
plete loss of an exposed residue at the MHC groove that initially interacts with the TCR;
hence, the infected cell escapes the immune response. If the single amino acid substitution
takes place at non-anchoring residues, it could potentially lead to the TCR forming a loose
binding with the pMHC; thus this interaction produces an improper immune response to
the infected cell [71, 72, 73]. In addition, viruses utilize the machinery of the infected
cell to express components of viral proteins that disrupt the presentation of the epitope and
dramatically impacting TCR recognition.
However, T cells are expected to adapt to the mutant variations as it is shown in the
case of the influenza viral infection (NP418-426 the epitope of HLA-B*3501) [71], where
the TCR shows signs of antigenic drift and emphasizes its adaptability. TCRs adapting
to variations have the ability to recognize viral mutations and induce a proper CTL re-
sponse [74, 75]. The TCR variants are shown to be compatible inducing cross-reactivity
against multiple viral strains [76].
2.8 Cytomegalovirus-specific T cell response
Antigens produce an immune response by the host since they are considered foreign ma-
terials by the body and they are usually recognized by the immune system. Antigens are
made of multiple linear antigenic determinants, known as epitopes, and the epitopes bind to
a specific TCR in the context of MHC or antibody. Although Viruses could infect the host
by multiple means, they usually enter into the cell’s body by two pathways. The virions
predominantly bind to the cell surface by forming an interaction between its glycoproteins–
located at the surface– and the respective proteins found on the host cell surface. Alterna-
tively, virions break into the cell by receptor-mediated endocytosis. The result of these
pathways primarily guarantees that the viral genome enters the cytoplasm and fuses to the
native genome. After entering the host, the proteasome degrades the virus-associated pro-
teins and other unneeded or damaged proteins by proteolysis into small and linear peptides.
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The peptides are usually smaller than 10 to 13 amino acids and they are easily shuttled into
the endoplasmic reticulum (ER). The complex pMHC is formed and is delivered to the
cell surface in this process. The peptide is very important in forming and stabilizing the
complex pMHC where antigen specific CD8+ T cells recognize and act upon after recogni-
tion [77, 78]. This process is depicted in Fig 6.
Figure 6: Proteins from intracellular pathogens, such as viruses, are degraded by the pro-
teasome into small peptides that are shuttled into the ER by the transporter associated with
antigen processing proteins (Endogenous pathway). These peptides are loaded onto MHC
class I molecules and the complexes are presented to cytotoxic T cells that recognize vi-
ral peptides and kill the infected cells. In the exogenous pathway, extracellular pathogens
are engulfed by phagosomes where the pathogen-derived peptides are loaded directly onto
MHC class II molecules. This pathway usually activates helper T cells that stimulate the
production of antibodies. But some peptides from extracellular antigens can also be “pre-
sented” on MHC class I molecules. The figure is adapted from Ref [78].
Cytomegalovirus (CMV) is classified as a member of the Betaherpesvirinae subfamily
of Herpesviridae; although the infection is persistent, it is asymptomatic. It infects 50-
85% of adults by the age of 40 and the virus has evolved to live in equilibrium with some
cells and is typically in a latent state of infection [79]. However, immunocompromised
individuals with CMV infection can lead to morbidity and mortality[7]. Hepatitis C virus
(HCV) belongs to the Hepacivirus. Unlike CMV, HCV poses various features to evade the
immune detection causing even an immunocompetent host the possibility of developing
cirrhosis or hepatocellular carcinoma following HCV infection. CMV does not pose a
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threat to an immune competent subject in terms of developing a life-threatening disease;
however infected subject with HCV evolves to a chronic state during the course of infection.
The development of a chronic condition is linked in part to the rise of “viral mutations” that
have decreased functional effects as those of the wild type thereby escaping recognition
from the immune system. Nevertheless, the true extent of TCR-pMHC interaction, its
role in the molecular mechanism of antigen recognition, and the tolerance of leukocytes
to viral epitopes upon infection, still remain a speculative issue, largely due to the lack of
experimental approaches that could definitively address this question [80, 81].
Even though CD8+ T cells specific for 55 kDa immediate-early protein 1 (IE1) are
found at higher frequencies in some populations, the immune response is mounted against
a CMV peptide derived 65kDa viral tegument protein (pp65) also called phosphoprotein
65. The epitope, NLVPMVATV, is extracted from the linear sequence of residues from
495-503 of pp65, and it is refer referred as NLV for its 3 first letter sequence. Humans
expressing the HLA class I molecules HLA-A2 (*0201) and HLA-B7 reacts against the
epitope, NLVPMVATV (495-503), from the pp65, referred to as for its first 3 letter. The
pp65 is responsible for modulating the host cell immune response during CMV infection
and it also serves as the immunodominant antigen for CD8+ T cells [82, 83].
The virus has a double DNA inside an icosahedral capsid. Between the capsid and
the outer lipid envelope contains tegument protein. The virus infects epithelial cells, B
cells, and monocytes. The virus binds to the cell surface by forming an interaction between
glycoproteins on the virion envelope and the heparin sulfate proteoglycans found on the cell
surface. Followed by the fusion that takes place involving the envelope of the virion and
the plasma membrane of the cell, the capsid, and associated tegument proteins are released
into the cytoplasm. The dynein inside the cytoplasm mediates the movement of these viral
proteins to the nucleus allowing the viral DNA enters the nucleus through the nuclear pore.
The viral genomic DNA is encapsulated inside an icosahedral protein capsid and between
this capsid and the outer lipid envelope contains proteinaceous tegument. Some of these
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tegument proteins are responsible for modulating the infected cell that disrupts the immune
response during a viral immune response of the host [84].
2.8.1 Private vs public T cell responses
Multiple crystal structural of NLV-specific TCRs in complex with NLV-HLA-A2 are gen-
erated [21, 85] to study private vs public T cell response and understand the rise of a
high clonal diversity. Private T cell response is when the TCR repertoires elicited by a
particular antigenic epitope are distinct between individuals and public T cell response
is when the repertoires contain TCRs that are frequently observed in multiple unrelated
people. Public TCRs have been described in immune responses to a variety of human
viruses, including human CMV, human immunodeficiency virus (HIV), and Epstein-Barr
virus (EBV) [86, 87].
2.9 T-Cell-Mediated Autoimmunity of Diabetes
Autoimmunity occurs when the body’s immune system attacks and destroys its own healthy
cells and tissues. It is estimated that there are >80 types of autoimmune disease. Promi-
nent examples include diabetes mellitus type1, multiple sclerosis, celiac disease, rheuma-
toid arthritis, dermatomyositis, sarcoidosis, systemic lupus erythematosus, Hashimoto’s
thyroiditis, and Graves’ disease. Autoreactive T lymphocytes are key players in these
autoimmune diseases by mistakenly recognizing self-pMHC as foreign antigen via their
TCRs [88]. Many studies of autoimmune TCRs have demonstrated that their interaction
with autoantigen pMHC is very important to T cell activity [89, 90, 91, 92]. However,
the structural database for human autoantigen-reactive TCRs in complex with their self-
pMHC is very limited. Indeed, there exist only 5 complexes: Four are restricted to MHC
class II and specific for multiple sclerosis [93, 94, 95, 96], while only one is restricted to
MHC class I and specific for Diabetes mellitus type 1–a human, preproinsulin reactive,
CD8+ T cell clone [97]. The latter is also shown that it is capable of recognizing over 1
million different peptides. High-resolution structures of the TCR bound to 7 altered peptide
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ligands shows that binding was stabilized through a conserved lock-and-key-like minimal
binding footprint; this enables 1E6 TCR to tolerate vast numbers of substitutions outside
of this so-called hotspot [98].
Diabetes mellitus type 1 is commonly known as type 1 diabetes (T1D). It affects >1.25
million Americans and the incidence is increasing at an alarming rate of 4% per year [99].
The precise cause of T1D is unknown but may be attributed to genetic factors, environ-
mental triggers, and exposure to viruses and drugs. T1D results from the autoimmune de-
struction of the insulin-producing β-cells in the pancreas [97] that leads to lifelong insulin
dependence. T1D is currently not preventable and involve the expansion of autoreactive
CD4+ T helper cells and CD8+ T cells, autoantibody-producing B cells, and activation of
the innate immune system [100, 101]. Recently, the crystal structure has been solved for
an autoreactive TCR (1E6) on CD8+ T-cells liganded with its cognate autoantigen peptide
from the major β-cell preproinsulin (PPI) protein complexed with HLA-A2 MHC [97]. The
study suggests that the TCR-pMHC interaction is very important in determining the fate of
T cell. “Autoreactive T cells could evade negative selection due to a light-touch MHC con-
tact footprint and weak TCR binding”. However, it is still unclear what molecular nature
of TCR-pMHC interaction leads to T cells escape thymic selection.
2.10 Specficity vs Sensitivity
The TCR differs from other cell-surface receptors by its unusual features of antigen recog-
nition. Firstly, each unique TCR recognizes only a subset of pMHC molecules. Since the
high-affinity agonist pMHC molecules on APCs are of very low abundance, TCR recog-
nition must be very sensitive. Indeed, it has been shown that a single antigenic pMHC
can trigger TCR activation [102, 103, 104]. Secondly, generally MHC molecules on APCs
are conjugated with self-peptides, so the TCR has to be able to recognize a tiny subpopu-
lation of agonist from a huge background of self-pMHCs. During the maturation process,
21
however, T cells are positively selected for survival by the ability of their TCRs to bind self-
pMHCs [105]. So the TCR has to be able to bind self-pMHC but this binding cannot trigger
TCR activation; otherwise, it would cause autoimmunity. Interestingly, the concurrent pres-
ence of self-pMHCs can increase the sensitivity of TCR to agonist pMHC [106, 107, 108].
Thirdly, the same TCR can recognize multiple ligands with different binding affinities, re-
sulting in different immune responses [89]. Lastly, TCRs can recognize foreign peptide
ligands that they have never encountered before, exemplifying the diverse nature of TCR-
pMHC interactions. T-cells also expresses coreceptors CD8 or CD4, which enhances TCR
signaling for binding with MHC class I or class II molecules respectively [6]. The precise
roles of the coreceptors are not fully understood.
The triggering mechanism of TCR and the effect of CD8 or CD4 coreceptors are major
focuses of current immunological studies. Various TCR triggering models have been sug-
gested. It has been reported that the application of mechanical forces to the TCR induces
or enhances TCR triggering [44, 109]. It has also been proposed that pMHC binding could
push or twist the TCR [110, 33]. A piece of circumstantial evidence is that agents that
disrupt the actin cytoskeleton abrogate TCR triggering [111], presumably by inhibiting the
force transmission.
2.11 Receptor-ligand signatures: Catch, slip, and ideal bonds
Force spectroscopy experiments manipulate single molecules and are capable of producing
forces in the range of pico Newton that are necessary to dissociate a receptor from its ligand.
At the same time, these experiments sensitively measure the dissociation time with a high
precision. If the effects of mechanical forces on single receptor-ligand bonds is measured
under different forces, it would produce a specific molecular signature shown in a bond
lifetime vs force profile. Experimentally, the force between a single bond interaction is
kept at a constant level until the bond dissociates.
A bond behavior is called “slip” bond (Fig 7 A) if the average bond lifetime decreases as
22
the force increases; thus this bond becomes shorter lived in the presence of force. “Catch”-
bond (Fig 7 B) behavior exhibits a unique phenomenon where under a certain regime of
force, the lifetime increases as the force increases. Then the catch bond would transition
to slip bond behavior as this is due to the forces overpowering the bonds formed. It is
said that the interacting proteins catch and their bond becomes longer lived when they
are mechanically pulled. Catch bonds are nonlinear responses that prolong the protein-
protein interactions in the presence of mechanical stress and it provides a way for proteins
to grip tightly and stabilize their attachments. “Ideal” bonds (Fig 7 C) are independent
or insensitive to mechanical forces. Slip bonds have basically a constant bond lifetime
under different forces. Slip bonds are commonly observed in nature while catch bonds
have been observed with motor proteins, with adhesive proteins like selectins, integrins,
and cadherins, and with immune receptors like TCRs interacting with pMHCs. Ideal bonds
are currently observed only for cadherins [112, 113].
Figure 7: Catch, slip, and ideal bonds: When a mechanical force is applied to a receptor-
ligand interaction, it responds as: (A) Slip bonds when the interacting molecules slip apart
and the bond becomes shorter lived in the presence of tensile force, (B) Catch bonds when
they catch and the bond becomes longer lived when they are mechanically pulled or (C)
Ideal bonds when they are insensitive to mechanical stress and the bond is basically con-
stant under different forces.
2.12 Significance
T cell activation is an important feature of the immune response of the host to effectively
clear viral pathogen and cancerous cells. It is also important in establishing self-tolerance
and avoid autoimmunity. The TCR is a mechanosensor and there is a huge effort from the
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scientific community in understanding how peptide ligand recognition is translated to TCR
activation and how it is influenced by peptide potency and force. It has been more than
3 decades of extensive study and the rules of TCR recognition and activation of T cell is
still not understood. This thesis studies how the structural dynamics of the TCR are relate
to the recognition of pMHC, and triggering of the CD3 signaling domains and it provides
insight in how to structurally manipulating the interaction of the TCR ligated to pMHC. It
is described 1) how the information encoded in the peptide is decoded mechanically by the
TCR and what is the structural role of catch bonds; 2) how information read from the TCR
binding site is propagated to the CD3 signaling domains. This can be exploited to develop
and engineering proteins for a medical and biotechnological application. For instance, the
ImmTAC technology for cancer immunotherapy combines old primitive structural knowl-
edge of TCR and CD3 for producing vaccines.
This study is also relevant because it employs human TCRs. All previous models are
performed in mice TCR that have been shown previously to map poorly when used to un-
derstand human infections, immune disease, and cancer. This study elucidates the molecu-
lar mechanism driving the human TCR-pMHC interaction and how it leads to activation in
the context of viral persistent infections and autoimmune diseases. Viral persistent infec-
tions pose problems to the host by making viral mutations, which occurs to increase viral
fitness by evading immune responses. Autoimmunity is a condition where the TCR rec-
ognizes its self-peptide ligand and induces the body’s immune system attacks the healthy
cells. This study also aims to investigate the molecular details of such interactions by char-
acterizing their molecular footprint in the presence of force and correlating the findings
with a functional assay. More importantly, it describes how the contribution of force in-
creases the number of H-bonds (bond-lifetime) at the atomic level in the context of viral
and autoimmune peptide ligands with the capability to lower cytolytic responses of CTLs.
This study will contribute to understand how altered peptide ligands impact on recog-
nition to activate or induce tolerance in T cells by using computer simulations. This study
24
is also significant because it provides evidence that TCRs are capable to experience large
deformations without releasing the peptide ligands and be still functional and describes the
molecular mechanism of how TCRs uses their Cβ FG loop to propagate information to CD3
signaling domains. This approach is also innovative since it allow to study the mechanical
regulation of TCR-pMHC interactions at the atomic level and provides a unique perspec-
tive to the field of Immuno-engineering. Overall, the resulting insights of this study provide
evidence to understand how to manipulate and optimize the interactions between TCR and
pMHC to effectively trigger cytolytic function and improve emerging technologies, such
as, chimeric antigen receptors, ImmTAC, etc.
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CHAPTER III
METHODS: THE COMPUTATIONAL MICROSCOPE FROM
STATIC STRUCTURES TO LIVING PROTEINS
3.1 Background
Optical microscope has played a fundamental role in understanding and capturing biolog-
ical samples using the single and compound lens. The first microscopes were developed
to see the inner working of biological materials beyond the limit of a naked eye and ex-
plore their biophysical properties. Since the seventeenth century, science and technological
developments have led to a manufacturing breakthroughs of microscopes that significantly
advanced their designs improving dramatically the image quality. However, despite the
manufacturing breakthroughs, optical microscopes are still hampered by an optical limit
that is imposed by the diffraction of visible light. For instance, to see the atomic world, the
wavelength of radiation normally needs to be similar to the dimensions of the atoms to be
observed ( 0.05 nm). This wavelength of light ( 500 nm) is unable to accomplish it since
it is several orders of magnitude bigger. To achieve atomic resolution and overcome the
diffraction barrier, nowadays structural biologists commonly use three main experimental
techniques to determine and observe the 3D structure of macromolecules. These experi-
mental techniques have been developed and complement each other since they have their
own limitations [114].
“X-ray crystallography” is used to determine the positions of atoms in biomolecules.
The goal of X-ray experiments is to calculate an “electron-density” map of a molecule
from its diffraction pattern. The obstacles are that X-rays cannot be focused as it is done in
conventional microscopes, where lenses are used to focus and magnify light. In an X-ray
diffraction film, spots convey only information about amplitudes of the waves that caused
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them but not their phases; thus important information is lost. This “phase” problem was
solved and determined by introducing heavy atoms into protein crystals and comparing the
diffraction patterns obtained from different “isomorphous” crystals [115].
“Electron microscopy” (EM) has higher magnifications and greater resolving power as
it uses a beam of electrons rather than light to produce an image of the sample, allowing
smaller objects to be observed in finer detail. There are two main types of EMs: Trans-
mission Electron Microscope (TEM) and Scanning Electron Microscope (SEM). TEM is a
high-resolution tool based on transmitted electrons while SEM is based on scattered elec-
trons. SEM focuses on the surface of the sample and its composition whereas TEM pro-
vides great details about internal composition. SEM is used to characterize the surface
morphology, micro particle size, cross-sections of coatings deposit, and thickness. TEM is
capable of measuring nano particles size, crystallite size, atomic arrangement in materials
at nano resolution. Thus, TEM is used to obtain 3D structure of proteins at low resolution
(3.5 to 7.0 Å) [116, 117, 118].
“Nuclear magnetic resonance” (MNR) is a physical phenomenon in which nuclei are
made to resonate in an applied magnetic field such as the spin polarization is transferred
from one population of nuclear spins to another. Nuclear spin that is coupled through space
due to spatial proximity give rise to nuclear Overhauser effect (NOE). NOE is the change in
intensity of one NMR resonance that occurs when another is saturated. To determine pro-
tein structures, observed resonances have to be assigned to a particular chemical group. The
distance information that is provided by the observed NOEs is the main basis for structure
determination. NMR experiments are constrained by protein size since the width of reso-
nances increases with the protein size. The advantage of NMR is that the macromolecule
is studied in aqueous solution where no crystals are required or heavy atom derivatives are
introduced [119].
X-ray crystallography is the most powerful and efficient structural method, however,
it requires the production of good crystals. NMR only deal with macromolecules that are
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smaller than about 50 kDa. However, it works in aqueous solution and is able to capture
multiple modes of flexible regions of proteins. Although TEM experiments are performed
in harsh conditions, they are a good fit for obtaining the overall structure of large systems
and their multiple conformational states at relatively low-resolution. About 89% of solved
protein (129,367 entries) in the Protein Data Bank (PDB) were obtained using X-ray crys-
tallography, while 1% and 9% are coming from EM and MNR, respectively.
Unfortunately, those techniques only provide static pictures without any information
about the dynamic nature of macromolecules. In biological processes, protein-protein
interactions are likely to involve structure fluctuations and small-to-large conformational
changes. For instance, kinetic properties of molecular interactions, such as catch or slip
bonds, are modified by applying a force; thus its structural mechanism may include forced-
induced conformational changes between states not observed in the static structures in
which the crystal is formed in the absence of force. To overcome those challenges and un-
derstand the inner working of proteins, single-molecule force spectroscopy has been largely
developed. Although these experiments are somehow successful sensing their properties
and describing their molecular feature, they do not provide a clear representation of their
dynamic process. Proteins are not static structure having a single unique conformation, but
rather they are most likely undergoing multiple conformational changes locally (tenths of
Å) or globally (tenths of nm). These conformational changes are functionally relevant and
span a variety of time scales (from ns to s). It is known that such conformational changes
are involved in ligand-receptor recognition, signaling, and many other biological processes.
A microscope with an atomic resolution is required to capture the dynamic molecular detail
of proteins and how their changing structure relates to their function. The development of
high-performance computing in capacity and speed has opened new avenues of research.
A well-established approach is molecular dynamics simulations that have elucidated the
microscopic interactions between macromolecules that play an important roles in folding,
binding, ligand recognition, and catalytic mechanisms.
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Molecular dynamics simulation is a powerful technique and has become indispensable
for understanding the structure and function relationship of biomolecules. Nowadays com-
puter is just as important a tool for scientist, if not more, as the test tubes since simulations
are becoming so realistic that they predict the outcome of traditional experiments. The
scientific community has recognized it by awarding the 2013 Nobel Prize in Chemistry
to Martin Karplus, Michael Levitt, and Arieh Warshel for “the development of multiscale
models for complex chemical systems”. These scientist have dramatically advanced the
field of structural biology by developing sophisticated computer algorithms to build mod-
els of complex biological molecules. This Nobel Prize is the first given to work in com-
putational biology, indicating that the field has matured and is on a par with experimental
biology.
3.2 Molecular dynamics
Molecular dynamics (MD) simulation is a computational technique used to study the physi-
cal movements of atoms from small molecules to relatively large proteins. MD was initially
developed in 1955 within the field of theoretical physics [120, 121, 122] but now it is virtu-
ally applied to most fields. In biology, it is widely employed since it provides fundamental
tools for understanding the molecular relationship between structure and function of pro-
teins. Proteins are not viewed as rigid entities anymore, they are dynamic structures that
constantly modify their internal motions. These motions not only change the conforma-
tional state of proteins but also plays an essential role in determining their function. MD
simulation creates a way to do “statistical mechanics by numbers” [123] and it magically
implements the Laplace’s demon–a deterministic vision of predicting the future by using
Newtonian mechanics [124]. If a demon determines at a specific time the position and mo-
mentum of every particle in the universe, the past and future of all particles for any time
can be calculated from the laws of classical mechanics. The demon not only tracks the se-
quence of events of all atoms but also provides insight into molecular motion on an atomic
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scale by animating nature’s forces.
In a protein, the atoms are allowed to interact for a period of time and their trajecto-
ries are determined by solving numerically Newton’s second law of motion, where forces
between atoms and their potential energies are calculated using interatomic potentials or







Utotal(~r1,~r2, ...,~rN), i = 1, 2, ...,N (1)
Where the mi is the mass of atom i and Utotal is the total potential energy. The trajectory
of an MD simulation is employed to determine macroscopic thermodynamic properties of
macromolecules, only if, the systems comply with the “ergodic hypothesis” in which the
time averages of the system corresponds to microcanonical ensemble averages; 〈Aensemble〉 =
〈Atime〉.
Molecular dynamics simulation is usually performed by controlling the temperature,
T [125, 126]. The velocity Langevin thermostat is used for this purpose and it generates
the Boltzmann distribution for canonical (NVT) ensemble simulations. Molecular dynam-
ics with the Langevin thermostat becomes a stochastic differential equation in which two
additional force terms are being added to the equation of motion. The effects of solvent
molecules are approximated by these two terms. The first term represents a frictional force
which takes into account the frictional drag on the solute and the second one corresponds to
random kicks associated with the thermal motions of the solvent molecules. It is assumed
that friction force is proportional to the particle’s velocity and opposite to the direction of
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where ζ is the damping constant, Utotal is the total potential energy, and ~ηi is the vectorial





~ηi · ~η j
〉
= 6kBTζδi jδ(t − t′) (3)
30
where δi j and δ(t − t′) are the Kronecker delta and Dirac delta function, respectively. For
constant pressure simulations (NPT ensembles), the “Langevin-Hoover” method is used
and it is shown to generate the correct ensemble distribution [125, 126, 127, 128, 129]. The
“Langevin-Hoover” equations are demostrated and found in Ref [126].
The total energy of the system is the summation of the following terms
Utotal = UvdW + UCoulomb + Ubond + Uangle + Udihedral (4)
where UvdW is the Lennard-Jones potential, UCoulomb is the Coulomb potential, Ubond is the
harmonic potential, Uangle is the bond-angle potential, and Udihedral is the dihedral angle
potential. These potentials are explained in the following sections.
3.3 Force fields
The force fields refer to the interactions that one particle exerts on another particle or a
collection of other particles. Generally speaking, the force field can be divided into two
categories, a bonded and nonbonded interaction. In this study, bonded interactions act
between particles which have a common bond or bond-angle, and they are divided into
bond potential and bond-angle potential. They are calculated on the basis of a fixed list.
Nonbonded interactions act between atoms in the same molecule and those outside the
molecule. In this study, nonbonded interactions are separated into Coulomb interaction
and excluded-volume interaction. They are computed on the basis of a neighbor list.
3.3.1 Nonbonded interactions
3.3.1.1 Excluded-volume potential
The excluded volumes of particles, including the monomers and the counterions, are de-
scribed by Lennard-Jones (LJ) potential, which is represented by an attractive and a re-
pulsive term. The attractive term represents the van der Waals interaction due to induced
dipole-dipole interaction. The repulsive term arises from the nonbonded overlap between
electron clouds and has an arbitrary form. The LJ potential repels at close range, then
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attracts, and at long range vanishes. It is defined by








where ri j is the separation distance between particle i and j, εvdW is the strength of LJ
interaction, which describes the hardness of explicit particles, and σvdW is the collision di-
ameter. The Lorentz- Berthelot mixing rule is applied for the interaction between different
kinds of particle, σi j = (σii + σ j j)/2.
3.3.1.2 Coulomb potential
The particles also interact with each other via electrostatic interaction. The electrostatic
interaction is defined by the Coulomb’s law, which states that the magnitude of the electro-
static force between two point charges is directly proportional to the magnitudes of each
charge and inversely proportional to the square of the distance between the charges. The
Coulomb potential is thus written as






Here zi , z j are the valances of particles i and j, respectively. The Bjerrum length, λB,
can be defined as the distance at which the Coulomb potential of two unit charges “e”
is equal to the thermal energy kBT . kB is the Boltzmann constant. λB is expressed as
e2/(4πεoε)kBT where ε is the dielectric constant of the continuum and εo is the vacuum per-
mittivity. Particle-particle particle-mesh (PPPM) algorithm is used to calculate the long-
range Coulomb interaction, in which interactions with periodic images are taken into ac-
count. The PPPM method, which is an alternative approach to the Ewald sum and was
proposed by Hockney and Eastwood [130], is an accurate and com- putationally efficient
method for calculating interactions in molecular simulations. The PPPM method is based
on separating the long-range inter-particle force into the sum of rapidly-varying short-range
interactions and slowly-varying long-range interactions. The PPPM method is computed
by two steps, first, by a PP method, and then by a PM method. The PP method is used to
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find the total short-range contribution to the force on each particle and is only computed
by direct particle- particle summation within some cutoff radius. Then, the PM method is
used to compute the total slowly-varying, long-range interaction contributions which are
calculated in the reciprocal space, approximated on a grid.
3.3.2 Bonded interactions
3.3.2.1 Harmonic potential
Neighboring atoms on the protein are connected by a spring, described by a harmonic po-
tential. The harmonic potential, associated with small bond stretches about the equilibrium
bond length, can be approximated by a parabolic equation, and it is defined by
U i jbond(ri j) = k(ri j − bo)
2 (7)
where k is the spring constant that gives the stiffness of the bond and bo is the equilibrium
distance.
3.3.2.2 Bond-angle potential
The bond-angle potential provides an intrinsic stiffness to the protein backbone. It is mod-
eled by a three-body potential acting among adjacent atoms triplets on the protein chain,
and it is defined by
U i jangle(θi jk) = kθ(θi jk − θo)
2 (8)
where θi jk is the bond angle between three consecutive atoms, (i, j, k = i − 1, i, i + 1),
and θo is the equilibrium angle, whose value is π rad. kθ is the spring constant.
3.3.2.3 Dihedral-angle potential
The dihedral angle potential is also known as torsion potentials and they describe the inter-
action arising from torsional forces. A dihedral angle is formed between two intersecting
planes through two sets of three atoms, having two atoms in a specific plane. The dihe-
dral describes atom pairs separated by exactly three covalent bonds with the central bond
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subject to the torsion angle φ
U i jkldihedral(φi jkl) = K
φ
i (1 + cos(niφi jkl − γi jkl)) (9)
where θi jk is the dihedral angle between four consecutive atoms, (i, j, k, l = i − 1, i, i +
1, i + 2), and γi jkl is the equilibrium angle. k
φ
i is the spring constant. (Fig. 2). An “im-
proper” dihedral term governing the geometry of four planar covalently bonded atoms is
also included.
Nowadays, multiple force fields for MD simulations are available. Basically, there are
three major force fields dominating most MD simulations. They are CHARMM, AMBER,
OPLS-AA, etc, they also have different versions. Those force fields have similar functional
forms for the potential energy as it was proposed in the study of “Consistent Force Field
for Calculations of Conformations, Vibrational Spectra, and Enthalpies of Cycloalkane and
n-Alkane Molecules” by Lifson [131].
3.3.3 Integration algorithm
The velocity-Verlet algorithm is used to integrate the equation of motion. There are various
versions of Verlet algorithm and even new numerical integration schemes. However, the
velocity-Verlet algorithm is, at the same time, simple, accurate and stable. The velocity-
Verlet algorithm generates a phase-space trajectory which is a sequence of “snapshots” for
the particle coordinates and velocities at time t, by the following procedure







~v(t + dτ) = ~v(t) +
~f (t + dτ) + ~f (t)
2m
dτ (11)
where dτ is a small time increment and ~f (t) is the total force acting on a particle at time
t. If the initial conditions ~r(0) and ~v(0) are given, it is possible to compute ~r(t) and ~v(t),
sequentially by applying Equations (10) and (11).
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3.3.4 Steered molecular dynamics simulation
It was proposed in MD simulations [132] that a group of atoms is constrained and another
is chosen as pulling atoms. The proteins are pulled apart by external forces following a
specific direction and it can be applied to one or more atoms in the proteins. This protocol
is termed steered molecular dynamics (SMD) simulations. The application of an external
force was initially used to study the unfolding process of proteins. Here it is used to induce
small-to-large conformational changes the protein since MD simulations do not effectively
access or sample all possible configurations of the protein during nanoscale simulations.
SMD simulations closely represent the manipulation of proteins through a force probe.
The addition of an external force is a computational technique used to reduce the energy
barriers and move across different conformations. The equilibrium state is usually an en-
semble of structures as it is observed in the crystal structure. The other states are either rare
events or steady conformers. SMD simulations usually include the proteins without the cy-
toplasmic tail and plasma membrane; however, in SMD it is assumed that the ectodomains
are attached to an imaginary cell membrane and the proteins are constrained at their C-
terminus.
The external force can be constant or variable over time, and this is accomplished by
using constant-force or constant-velocity pulling, respectively. In the former, the SMD
atoms are undergoing a constant force. In the latter, the center of mass (COM) of the SMD
atoms is connected to a dummy atom via a spring with a force constant, k and the COM
of SMD atoms is then moved at a constant velocity, v. The force is measured following a
harmonic potential, US MD, defined as




k[vt − (~r − ~r0) · ~n]2 (13)
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~r and~r0 are the current and initial positions of the COM of the SMD atoms, respectively.
~n is the direction of pulling.
3.3.5 Targeted molecular dynamics simulation
Targeted molecular dynamics (TMD) is a computational technique to produce conforma-
tional change that leads to a known target structure at ordinary temperature by using purely
a time-dependent geometrical constraint while the dynamics of the molecule is only min-
imally influenced by the applied constraint. TMD simulations enforce the transition inde-
pendently of the height of barriers. Generally speaking, TMD simulations move initially
a subset of atoms toward to a final target reference by using steering forces. Similarly to
SMD, a harmonic potential is added to the total potential energy and the force on the target







RMS (t) − RMS Target(t)
]2
(14)
The spring constant k is scaled down by the number of selected atoms,N. The RMS
distance between the current coordinates and the target structure is computed after first
aligning the target to the current structure at each timestep. RMS (t) is the instantaneous
best-fit RMS distance of the current from the target coordinates. RMS Target(t) is changing
linearly from the initial RMSD to the final RMSD.
3.4 Nanoscale Molecular Dynamics (NAMD)
NAMD– also formerly known as Not Another Molecular Dynamics Program– is a parallel
molecular dynamics code designed for high-performance simulation of large biomolecu-
lar systems, written using the Charm++ programming model– an object-oriented portable
parallel language built on top of C++ [133]. NAMD is famous for its parallel efficiency
and is often used to simulate systems containing millions of atoms. It scales well to 10s
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and 100s of CPUs on small commodity clusters and high-end parallel supercomputers, re-
spectively. NAMD is capable of using multiple force fields such as AMBER, CHARMM,
and GROMACS. NAMD has been developed by the joint collaboration of the Theoretical
and Computational Biophysics Group (TCB) directed by Prof Schulten, and the Paral-
lel Programming Laboratory (PPL) directed by Prof Kale, at the University of Illinois at
Urbana-Champaign. It was first introduced by Nelson et al. in 1995 as a parallel molecular
dynamics code enabling interactive simulation by linking to the visualization code Visual
Molecular Dynamics (VMD). NAMD has since matured, adding many features and scaling
beyond ∼ 0.5 millions of CPUs.
Figure 8: An Illustration of the performing molecular dynamics simulation and analysis.
Molecular dynamics is a method that uses Newton’s equations of motion to simulate the
time evolution of a set of interacting particles. MD simulations are dependent on a descrip-
tion of how the particles interact using a force field and are popular in materials chemistry,
biochemistry and biophysics.
Multiple molecular dynamics software packages are also available, for instance, CHARMM,
AMBER, NAMD, GROMACS, Desmond, and OpenMM. They have a similar functionality
to NAMD.
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3.5 NAMD Code Performance and Scaling
In this thesis, the simulations are run on “Stampede” and “Comet” located at the Texas Ad-
vanced Computing Center (TACC) and at the San Diego Supercomputer Center (SDSC),
respectively. NAMD is employed and it is benchmarked on these high-performance su-
percomputer using systems with sizes varying from 0.05 to 1.16 million of atoms under a
different number of CPU cores. The CHARMM36 force field is used and it is observed
that systems in that range can be linearly scaled up to ≈ 2000 cores. For this scaling, the
systems can be roughly categorized into 3 sizes: 0.1, 0.2 and 2 millions of atoms.
Figure 9 (a) and 10 (a) show that Performance scales linearly with the number of nodes
when they are smaller than 60 nodes for the two smaller systems. Performance is reported
as simulation time in ns/day. The average simulation time is 100 ns. In Stampede, 60 nodes
are able to complete such simulation in 1 and 1.5 days for 0.1 and 0.2 M, respectively. In
Comet, 50 nodes are capable to finish it in 2 and 2.5 days for the two smaller systems.
Figure 9 (b) and 10 (b) report that Speedup is at an optimal point around 50 and 60 nodes for
Comet and Stampede, respectively. Figure 9 (c) and 10 (c) similarly show that Efficiency
is optimal around that range. The requested SUs are estimated according to equation
S Us = (walltime)(# node)(# cores) (15)
The wall time is set to 24 hours. Stampede and Comet have 16 and 24 cores per node,
respectively. For the smaller systems,Figure 9 (d) (Stampede) and Figure 10 (d) (Comet)
shows that the SUs per nanosecond of simulation per millions of atoms are economically
optimal when 50 and 60 nodes are employed, respectively, because those use less SUs and
yet they require less time for completing the simulation. For bigger systems, Figure 11
(b) shows that Performance for Stampede is invariant for systems ranging from 0.5 to 1.3
million of atoms under different of nodes, while it decreases for Comet in Figure 11 (a).
Figure 11 (d) (Stampede) shows that the SUs per nanosecond of simulation per millions
of atoms are best at 120 nodes in term of performance. Similarly, Figure 11 (c) (Comet)
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Figure 9: NAMD Benchmarks on TACC Stampede. (a) Performance, (b) Speedup, (c)
Efficiency, and (d) SUs/(ns x millions of atoms) vs Number of nodes for 0.1 and 0.2 M
atoms. Figure (d) is used to estimate the SUs usage in the present study. The optimal SU is
about 2600 and is located at 60 nodes.
Figure 10: NAMD Benchmarks on SDSC Comet. (a) Performance, (b) Speedup, (c)
Efficiency, and (d) SUs/(ns x millions of atoms) vs Number of nodes for 0.1 and 0.2 M
atoms. Figure (d) is used to estimate the SUs usage in the present study. The average is
about 3600 in the range of 30 to 50 nodes for 0.1 and 0.2 M atoms.
shows that it is roughly constant for 50 nodes but inefficient and expensive. These suggest
that the output rate on Stampede is significantly better than Comet; thus our bigger system
will be best run at Stampede. NAMD 2.10 were employed for this benchmark. The canon-
ical ensemble (NVT) with periodic boundary conditions are used and the temperature is
kept constant at 310 K using Langevin dynamics. The CHARMM36 force field was used
with SETTLE (non-iterative) and SHAKE (iterative) algorithms to constrain the lengths
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Figure 11: NAMD Benchmarks on SDSC Comet and TACC Stampede for bigger systems.
Performance vs Number of atoms for Comet (a) and Stampede (b) at two number of nodes.
SUs/(ns x millions of atoms) vs Number of atoms for Comet (c) and Stampede (d) at two
number of nodes. Figure (d) shows Stampede provides an optimal SUs usage for bigger
systems and the average is about 2600.
of bonds of water and other hydrogens, respectively. Water is represented by the stan-
dard TIP3P models. Electrostatic interactions are treated using Particle Mesh Ewald with
a grid spacing of 1.0 Å. 2 fs is the timestep employed in all simulation with long-range
non-bounded interactions evaluated every two steps.
3.6 Anton 2 supercomputer increases speed and size of micro molecular
dynamics simulations
Anton 2 machine located at the Pittsburgh Supercomputing Center (PSC) is used in Aim 2
of this thesis. Anton 2 machine is a second-generation, special-purpose, massively-parallel
supercomputer built by D. E. Shaw Research [134] for performing Microsecond MD sim-
ulations of proteins. Anton 2 machine is ten times faster than its predecessor, Anton 1,
and it greatly expands the reach of molecular simulations. Anton 2 is the first platform to
achieve MD simulation of multiple microseconds of physical time per day for systems with
millions of atoms. For instance, Anton 2 easily simulates a 24K particle system at a rate of
85 µs/day. This is 200 times faster than any other general-purpose supercomputer.
For this thesis, a total of 128 cores are available on Anton 2 machine and used to
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perform the simulations of Aim 2. Based on the benchmarks provided by Anton 2, it is
estimated that the TCR-pMHC complex requires 4.53 machine-day to complete the simu-
lations; 24us ∗ 1/5.3(machine-day/us). This makes a total of 230000 MD simulation units
on Anton 2 machine. The simulations are performed using NPT ensemble with position
restrains and SHAKE constrains. The CHARMM36 force field is used and the system
is composed of protein, ions, and water. Water is modeled with standard TIP3P models.
When fully solvated and counterion balanced, the system has systems have about 210,000
atoms. 2.5 femtosecond time step is used in the simulations with long-range non-bonded
interactions evaluated every two steps and with thermostat applied every 100 steps and save
the coordinate files each 250 ps.
3.7 Visual Molecular Dynamics
Visual Molecular Dynamics (VMD) [135] is developed at the Theoretical and Computa-
tional Biophysics Group at the University of Illinois and it is a program for modeling,
visualization, and analyzing MD simulations of biomolecules. VMD is capable of display-
ing the structure of standard Protein Data Bank (PDB) files, it does not have limits on the
number of particles or number of simulation frames, and it offers support for multicore
processors and GPU accelerated computers. VMD provides a wide variety of methods for
rendering and coloring a protein such as the space-filling spheres (CPK model), licorice
bonds, ribbons, (new-) cartoon drawings, and many others. VMD also produce quality im-
age and movies by using a number of popular ray tracing and image rendering packages,
including POV-Ray and Tachyon. It usually acts as a graphical front end for an external MD
program by animating a molecule through the simulation and it also offers stereo display
capabilities. VMD supports multiple sequence alignment and it has a unified bioinformat-
ics analysis environment that integrates and interact well with many MD package.
The images and movies on this thesis are produced using VMD [135] with its tachyon
parallel ray tracing system [136] and the secondary structures in the proteins are computed
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from the atomic coordinates using the STRIDE program incorporated into VMD [137]
3.8 Limitations of molecular dynamics simulations
The timescale is one of the limitations of MD simulations; structural changes in proteins
span easily from nanoseconds to milliseconds or even seconds. MD is computationally
constrained to the range of ns-to-micro seconds since it requires a time step of 2 fs for nu-
merical stability and this time step cannot achieve milliseconds yet using current computing
power. Million-to-quadrillion operations are needed to reach longer simulation time and
this requires a substantial amount of computer power not available currently. Non-bonded
interactions are very expensive and they influence most of the calculation since they act
between every single pair of atoms. For instance, in a system consisting of N atoms, the
number of non-bonded calculations is proportional to N2. Atoms separated by more than
a cutoff distance could be only ignored for van der Waals interactions since these forces
fall off quickly with distance. However, for electrostatics interactions, the forces fall off
very slowly with distance and they require a special treatment since they are longer-range
interactions. MD simulation timescales still remain a big challenge even though recent ad-
vances in computer power is enabling microsecond MD simulations. The ultimate goal is
going from microsecond to longer timescale simulations (seconds) and this is still an active
research area that must involve a collaborative effort in algorithmic improvements, parallel
computing, and specialized hardware.
It is almost impossible to solve the equation (1) analytically for proteins since they are
large systems that typically have a vast number of atoms. MD simulations use numerical
integration to solve Newton’s second law of motion; however using the numerical tech-
niques produce problems if they are employed over a long period of timesteps. The results
become mathematically ill-conditioned since the numerical integration schemes generate
cumulative errors. The error can be minimized if a proper algorithm and parameters are
selected but they can not be eliminated entirely.
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Force field accuracy is another limitation since molecular mechanics force fields are
inherently created by many approximations. Although they have been improved substan-
tially over time, they still have limitations and no all force fields are experimentally tested
and validated. In addition, during standard MD simulations, the force fields cannot de-
scribe critical events such as the formation or breakage of covalent bonds; proteins, in
MD simulations, have all their covalent bonds well-defined form using a typical function.
This is different from proteins that some of their covalent bonds do form and break more
frequently during the cell life, for instance, disulfide bonds between cysteines are usually
formed. Electron transfer events cannot be described with the MD force fields such as
acidic or basic amino acid residues experience the loss or gain of protons.
MD simulations are improving and reducing the amount of computation per timestep
by using faster algorithms. PPPM, for instance, is a fast approximate method to compute
electrostatic interactions and other methods allow to evaluate some force field terms every
other time step. Reducing the number of time steps would require freezing some very fast
motions of atoms such as certain bond lengths. Another important research area to reduce
the simulation time is making events of interest to occur rapidly or making the simulation
reach all conformational states more quickly. For example, one might apply steered forces
to pull a protein from its ligand or push the simulation away from states it has already
sampled.
In SMD simulation, the main drawback is that the pulling velocity is still several orders
of magnitude from experiments (102 to 103). Thus, a direct comparison between simula-
tions and single-molecule experiments was not possible because of the large difference in
pulling velocity exerted on the protein. However, the gap between experiments and com-
puter simulation was recently closed using high-speed force spectroscopy [138]. It was
demonstrated that manipulating proteins experimentally using similar speed as in simula-
tions provides a dissociation and unfolding pathway consistent with the prediction of SMD
simulations, hence allowing a direct comparison.
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Parallelizing the simulation across multiple computers is still the main technique to
reduce simulation time. The computation is divided among CPU nodes and each node is
associated with atoms in one spatial region. Multiple CPUs also require efficient commu-
nication protocol and improving the message passing library and the algorithms can reduce
the communication requirements. Another more expensive and time-consuming route is
to redesign and create computer chips to make this computation run faster. Graphics pro-
cessor units are now used for MD simulations. They pack more arithmetic logic units on
a chip than CPUs, and give a substantial speedup, although parallelizing across multiple
GPUs is still a challenge. Several projects, such as Anton machine, have designed chips,
especially for MD simulation.
Another limitation of MD simulation of biological molecules is that it requires a crystal
or NMR structure as the initial configuration for the simulation. This external limitation
does not arise from the method itself but it depends on having the structure of the protein
or complex of interest. This is an important limitation if the structure is not available
since the folding of large proteins from their linear sequence will be almost impossible
to be accomplished by using MD simulation. Although there is some success generating
initial structures of proteins using homology models, they are unreliable in predicting the
new conformational changes a protein would undergo if a sequence of residues that do
not align with the template is inserted or deleted. In addition, Homology model or docking
techniques are not very useful in predicting the structure of a protein binding its ligand even
though both receptor and ligand structures are available. Thus, a crystal or NMR structure
is initially required for performing the MD simulation of biomolecules.
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CHAPTER IV
THE MOLECULAR BASIS OF MUTANT EPITOPES
DECREASING THE ACTIVITY OF CYTOTOXIC T CELL
4.1 Abstract
The main goal of this chapter is to understand how mutations modulate the TCR-pMHC
interaction that leads to a decrease in the cytolytic activity of T cells. Thus it is proposed
to study atomistically the force-induced dissociation of TCR-pMHC interaction by means
of computer simulations. Adaptive immune receptors binding and recognizing their ligand
remains as one of the most interesting mechanisms and hot topics in immunology and at the
same time, they are still highly debatable and controversial. This chapter studies the force
response of a TCR reading out a pMHC in the context of molecular-antigen recognition of
viral epitopes. It is demonstrated for the first time that catch bonds formed experimentally
between a TCR and a pMHC can be predicted a priori by using “in silico” biology. The
best predictor of catch bonds for the TCR-pMHC interaction is shown to be the total num-
ber of H-bonds at the binding interface and this is in good agreement with the experimental
studies. It is described the molecular characteristics and requirements for a TCR to form
catch bonds in the context of antigen recognition and how mutant peptides abolish it. It
is then explained the mechanism of how the TCR changing its initial docking orientation
modulates the peptide conformation inside the MHC binding groove. Finally, it is proposed
a molecular mechanism of how TCRs read featureless pMHCs in the context of viral infec-
tion: RA14 uses a molecular lever to form an “in silico” catch bond to uncover the peptide
from the featureless pMHC and then the RA14 is able to read and recognize the antigenic
peptide.
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The following abbreviations are used in this chapter: HCMV, human CMV; HLA2,
HLA-A*0201 allele; NLV, NLVPMVATV; RA14-NLV-A2, RA14 TCR-NLV-A2 complex;
Hydrogen bonds, H-bonds; Protein-protein interactions, PPI.
4.2 Background
The topology of pMHC class I complex not only influences TCR repertoire diversity but
also play a pivotal role in TCR recognition. The structural accessibility of the pMHC
class I complexes presenting peptides can be classified as “featureless”, “featured” or
“bulged” [86]. Fig. 12 shows a simplified cartoon of the structural accessibility and reports
the types of specific TCR repertoire that is selected after infection. Featureless peptides
are 8-10 residues but have little to no solvent-exposed amino acids with prominent side-
chains; thus the peptides tend to look more similar to self and the T cells that are capable of
recognizing these self-looking peptides are deleted from the repertoire by thymic negative
selection [86, 139, 140, 141]. Featured peptides are also 8-10 amino-acid long but with 1
to 3 prominent side-chains residues being exposed for recognition by specific TCRs. The
positive and negative selection in the thymus results in a diverse array of T cells in the
naive repertoire that can recognize such pMHC complexes. Bulged peptides, on the other
hand, are longer peptides (>11 residues) and due to structural constraints, the peptides are
bent in the center to allow binding to the MHC class I. This leads to a prominent bulge
that is protruding out of the MHC and limits TCR ligation as the TCR contacts with the
MHC α-helices are geometrically constrained and impaired. Few T cells are capable of
overcoming these structural constraints, resulting in a T-cell repertoire of limited diversity
in the periphery.
Antigen recognition by T cell is a crucial feature for adaptive immunity and clearance
of viruses. Since the TCR is the only T-cell surface molecule that senses antigens, a TCR is
required to ligate a free pMHC displayed on the APC to initiate a cascade of T-cell signaling
events that lead to activation. The TCR-pMHC interaction not only plays a pivotal role in
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Figure 12: The topology of peptide-MHC class I complexes can influence TCR repertoire
diversity. A schematic of pMHC class I complexes that are “featureless”, “featured” or
“bulged”, and the types of specific TCR repertoire that are selected after infection. Fea-
tureless peptides are 8-10 residues but have few or no solvent-exposed amino acids with
prominent side-chains; thus the peptides tend to look more similar to self and T cells that
are capable of recognizing these peptides are deleted from the repertoire. Featured peptides
are also 8-10 amino-acid long but with few prominent side-chains residues being exposed
for recognition by specific TCRs. The selection process in the thymus results in a diverse
array of T cells. Bulged peptides are longer peptides (>11 amino acids) and the peptides
are bent in the center to allow binding to the MHC class I. This results in a prominent bulge
that protrudes out of the MHC and limits TCR ligation. There are few T cells that can
overcome both the structural constraints and this results in an immune T-cell repertoire of
limited diversity. Image is taken from ref [86].
activation but also in T-cell selection, development, differentiation, fate, and function. The
question of what governs the TCR interacting with different pMHC to trigger intracellular
signals is still unanswered. It has long been hypothesized that the TCR-pMHC binding
parameters determine the subsequent T cell response [90] and mechanical force plays a
critical role in T-cell activation [92]. Experimentally, a force, applied across the T cell lig-
ated to an APC, triggers intracellular calcium signaling–a known hallmark of early T-cell
activation– only if a cognate pMHC is detected but not for irrelevant pMHCs. Force spec-
troscopy experiments such as a Biomembrane force probe (BFP) permit the manipulation
of single molecules under physiological conditions. The BFP is capable of producing pico
Newton forces necessary to dissociate the ligand from its receptor and sensitively measure
its bond lifetime with a high precision. This produces a specific molecular signature for the
interaction between a receptor and its ligand called the bond lifetime vs force profile. By
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measuring the lifetimes under different forces, the profile determines the effects of mechan-
ical forces on single receptor-ligand bonds. The force exerted on a single bond interaction
is kept at constant until the bond dissociates. A bond is called “slip” if the average bond
lifetime decreases as the force increases. A bond is called “catch” if the lifetime increases
as the force increases under a certain regime of force. The catch bond would then transition
to slip bond behavior as this could be due to forces overpowering the formed bond. Catch
bonds are unique phenomena as they exhibit nonlinear responses that prolong the duration
of the receptor-ligand interaction.
Figure 13: The native crystal structure of TCR-pMHC [21] reveals that peptide residue
Pro4P, Met5P, and Thr8P (A, B, C) are interacting with the TCR. Residues Met5P and
Thr8P are important since their side chains are longer, reactive, and flexible for adopting
any changes. The structural analysis (B, C) reveals that Met5P side chain is solvent-exposed
while Thr8P is barely exposed for interacting with the TCR; the functional study (Table I)
also suggest that those two residues are hot spots.
Using the powerful BFP, it is demonstrated currently that the best predictor of T cell
response is the bond lifetime of TCR-pMHC interactions [92]. The catch bond is clearly
observed for potent pMHCs compared to the weak peptides. Indeed, the TCR-pMHC catch
bonds are less pronounced for weaker ligands and are converted into slip-only bonds for
antagonist pMHCs. Note this behavior is different from the shorter bond lifetimes mea-
sured in the absence of force (or so-called zero force) for the potent pMHCs compare to the
bond lifetimes of weaker ligands. The idea of force regulation the TCR-pMHC interaction
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is consistent with the fact that cells are constantly not only experiencing forces from the
environment but also from the cellular components that made the membrane along with
the intracellular components of the cytoskeleton. Thus, a role of mechanical force in TCR
triggering has long been suspected and it is proposed that catch bonds may serve as a mech-
anism for the force to regulate TCR-pMHC interactions. This plethora of information was
collected via a pMHC engaged to a TCR on a naive transgenic T cell. Here it is proposed
to study persistent viral infections involving human TCRs; this is a more physiologically
relevant system.
Persistent viral infection uses latent strategies to escape the immune response. The
virus epitope is usually expressed in low-to-moderate levels when it is presented by the
APC, and its pMHC landscape tends to look more similar to self-peptides (“featureless”),
as observed in the crystal structures of (1) Epstein-Barr Virus (EBV) LC13 TCR bound
to an HLA-B*08:01-FLR [142]; (2) Influenza JM22 TCR bound to an HLA-A*02:01-
GIL [143]; (3) HIV TRAV17/TRBV7-3 TCR bound to an HLA-B51-TI8 [144]; (4) Hu-
man Cytomegalovirus (HCMV) R14, C7, and C25 TCRs bound to an HLA-A*02:01-
NLV [21, 85]. Thus, the virus survives for long-term due to corresponding low levels
of CTL activation. In addition, viruses such as HIV-1 and HCV adopt a more improved
mutation strategy. This is searching evolutionary the best mutation that provides the “sur-
vival of the fittest” that leads to a decreased response of the immune system. Viruses do
not have the luxury to modify their sequence as will since most mutations would render
them dysfunctional; thus the best mutation is most of the time a single-residue replacement
in the peptide sequence. This Aim employs human CMV to model persistent viral infec-
tion. CMV is an excellent human infection model since: 1) It is used to study “public” vs
“private” TCRs due to their diverse repertoire; 2) It is not only a life-threatening in com-
promised individuals, but also it has been shown recently that CMV infection may impact
and decreases host immune responses in healthy individuals over time; 3) CMV continues
to have a tremendous impact in organ transplantation as it affects allograft function and
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increase patient morbidity.
MD simulations are employed to understand how local conformational changes at the
interface of TCR-pMHC enable T-cell activity. When interactions are measured in ex-
periments, both TCR and pMHC are bound to the cell membrane or bead. Although the
simulations only include the TCR-pMHC without the cytoplasmic tail and membrane, it is
assumed that the ectodomains are attached to an imaginary cell membrane. α and β chain
of TCR and α3 domain of MHC are constrained at their C-terminal for this purpose. In
the experiment, MHC is of a mutant type (MT) and it is not able to bind the CD8; hence
the contribution of CD8 to the TCR-pMHC interaction is completely suppressed. There-
fore, the molecular model only includes the TCR and its pMHC without any co-receptor to
mimic the BFP experiments. CMV infection is employed to model persistent viral infection
using wild-type and altered peptides. The native crystal structures of CMV specific-TCR
bound to NLV-MHC [21, 85] reveal that the peptide residues Pro4P, Met5P, and Thr8P are
interacting with the TCR. Met5P is important since its side chain is longer, reactive, and
flexible for adopting different conformations. Thr8P is smaller but it is able to form mul-
tiple hydrogen bonds with the TCR. The structural analysis and the functional studies (see
Fig. 13 for details) suggest that those residues are indeed hot spots [21, 85].
The hypothesis is that peptides forming catch bonds are detected by the TCR, whereas
mutant peptides that present slip-only bond behavior easily decrease recognition (bind-
ing affinity) from the TCR. In other words, to escape detection, epitope mutations have to
convert their mechanical response from catch-slip to slip-only bond behavior. To test the
hypothesis, the in silico mutants, M5I and T8V, are proposed and used together with the
NLV peptide. Note that M5I is a naturally occurring infrequent mutation in human CMV-
seropositive patients[145]. This chapter focuses on performing steered MD simulations.
SMD simulations are used to apply an external force to proteins, and it closely represents
the manipulation of proteins through Biomembrane force probe, atomic force microscopy
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or optical tweezers. Note that the addition of external forces in MD simulations is a com-
putational technique used to reduce the energy barriers and access different conformations
and most importantly it mimics most force-spectroscopy experiments.
The equilibrium state is usually observed in the crystal structure, and the others are ei-
ther rare events or steady states. In conventional SMD simulations, the interacting proteins
are pulled apart by the external force following a specific direction and it can be applied to
one or more atoms in the proteins. In free MD simulations, on the other hand, the system
is simulated without any external force applied to the protein and here it is mostly used to
equilibrate the system since MD does not effectively access or sample all possible config-
urations of a protein during nanoscale simulations. SMD is also a standard methodology
to study the unfolding or dissociation pathway of proteins. The simulations are run with
the external force being constant and variable over time, and this is accomplished by us-
ing constant-force or constant-velocity pulling, respectively. Using computer simulations
provides a unique perspective to understand how viral peptides utilize mutation to modify
TCR recognition and manipulate molecularly the T-cell functional outcome.
4.3 Results and Discussion
4.3.1 RA14 TCR forms an “in silico” catch bond with agonist NLV-HLA2.
This Aim describes the mechanical behavior of an NLV-specific TCR (RA14) interacting
with wild type and altered pMHCs using a total of 8.7µs of simulations including all atoms
and explicit solvents. Thus far it was shown experimentally that TCRs are capable of
forming catch bonds when ligated to agonist pMHCs; however, it still remains elusive if
this counter-intuitive phenomenon could be captured using “in silico” biology experiments
and studied molecularly. For the first time, here it is reported that TCRs forming catch
bonds can be predicted by using computer simulation and that a single peptide mutation
can convert a catch into a slip bond as it happens in experiments.
Receptor-ligand interactions are highly dominated by hydrogen bonds (H-bonds), salt
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bridges, and hydrophobic contacts across their binding site [146, 147] as these interactions
densely pack and deeply bury the residues located at the binding hot spot and for the un-
binding of a receptor from its ligand, they need to be broken and desolvated. The hot spot
residues are energetically important since they tend to cluster into small regions with a low
solvent-accessible surface area (SASA) in order to favor the binding [147, 148]. The buried
SASA is commonly used as a predicting parameter of protein folding and misfolding and
hot spot prediction.
The buried SASA is used here to measure indirectly the contribution of the hydrophobic
effect since it buries non-polar surfaces in aqueous solution and provides a driving force
for receptor-ligand compaction and strength. The total number of contacts also include the
contribution of the H-bonds, the hydrophobic effect, and the salt bridge. It is shown here
that the total number of H-bonds is an excellent predictor of experimental catch bonds of
TCR-pMHC interactions and they play a seminal role in decreasing their dissociation time
as applied tensile forces are increased in the bonds.
It is defined an in silico catch bond when the total number of H-bonds and van der
Waals contacts at the binding interface of protein-protein interactions (PPI) increase as a
function of force. The underlying assumption is that by creating new forced-induced H-
bonds, the binding interface is strengthened, and this prolongs the bond lifetime. A tighter
binding between the TCR and the pMHC also promotes effectively killing of infected cells
and accelerates clonal expansion. Increasing the number of H-bonds at the interface and
as a result prolonging the bond lifetime is consistent with studies performed in a large data
set of PPI structures with documented binding affinities [149]. It is shown that there is a
high positive correlation between affinities and the total number of H-bonds at the binding
interface of PPI. It is also shown experimentally that only 2 H-bonds formed by two base-
pairs survive for more than 0.1s even at high forces (≈60 pN) [150]. Thus forming a few
forced-induced H-bonds couple with an increase of their total count at the binding interface
could prolong the bond lifetime.
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It was shown recently that force produces structural rearrangement of a PPI to induce
the formation of several de novo H-bonds [151] and it was assumed a priori that they
are responsible for producing experimentally catch bonds. However, it is unclear from
these computational experiments, whether the new H-bonds are formed at the expenses of
breaking the existing ones. Or they replace only a few but more H-bonds are produced
so that the total replacement is smaller compared to the created ones; thus the de novo
H-bonds could be responsible for the catch bond behavior. In other words, it is unknown
if the total number of H-bonds increases, decreases, or remains the same at the binding
interface in the presence of force. For example, consider that a PPI has eight H-bonds in
force-free conditions and formed 3 de novo H-bonds in the presence of force; however,
their formation disrupts and breaks five existing H-bonds. At the end, the total number (six
H-bonds) is smaller than the original state (eight H-bonds). In this case, if an experimental
catch-bond is confirmed, it may not be only the result of the de novo H-bonds or H-bonds
alone may not be a good predictor of catch bonds in this PPI.
The total number of H-bonds at the TCR-pMHC is used to predict catch bonds between
TCRs and pMHCs and they are determined based on cutoffs for angle (30o) and distance
(3.5Å) for donor-acceptor atoms. The angle is considered zero when the atoms are aligned
and extended. “OH” and “NH” groups are regarded as donors, while “O” and “N” are ac-
ceptors. Fig. 14 shows the total (A) and the average (B) number of H-bonds at the binding
interface between the TCR ligated with NLV-HLA2, T8V-HLA2, and M5I-HLA2 in free
MD simulations; here the complexes are considered in force-free conditions (zero force).
Experimentally NLV, T8V, M5I epitopes are considered agonist, very weak agonist, and
antagonist, respectively. In the absence of force, the number of H-bonds does not cor-
relate with the peptide potency. Apparently, weak agonist and antagonist form a similar
number of H-bonds when compared to the agonist peptide. The histogram plots are con-





































Figure 14: Free MD simulation of TCR-pMHC interactions. (A) Time evolution of the
number of H-bonds between TCR and pMHC for wild type NLV, and mutants T8V and
M5I in the absence of force. (B) The average number of H-bonds at the binding interface
between the TCR and NLV-, T8V-, and M5I-HLA2 in free MD simulations.
Fig. 15 (A) illustrates the time evolution of the total number of H-bonds between the
TCR and the pMHC for NLV (red) and mutants, T8V (green) and M5I (blue) peptides; the
curves are produced by “block averaging” the number of H-bonds every 10 ns. This post-
processing does not change the overall response as they are plotted together with the raw
data in Fig. 15 for each peptide ligand, NLV (B), T8V (C), and M5I (D). The complexes
are undergoing a “constant-velocity pulling” with a ramping rate of kv = 7pN/ns and this
is considered a normal ramping rate in the simulations. The constant-velocity pulling is
depicted in Fig. 15 (E). For TCR-NLV-HLA2, the total number of H-bonds increases at the
binding interface as force is applied at the protein’s C-terminal, and it is simultaneously
growing, building and propagating over time; thus, forming an in silico catch bond. The
overall increase is a result of the formation of new forced-induced H-bonds since its to-
tal count is higher. The catch bond, then, transitions to slip bond since the applied force
becomes big enough to overpower the new formed H-bonds at the binding interface. The
transition also corresponds to the rupture of H-bonds and the decrease in their total num-
ber. Fig. 16 visually illustrates the time evolution of the number of H-bonds between the
NLV-specific TCR (RA14) and the NLV-HLA2 using average structures at the different
time point in the simulation. Clearly, there are multiple new H-bonds when the TCR is
forming a catch bond (Fig. 16 D). The interacting residues are not labeled as they are ana-









































































Figure 15: “In silico” catch bond of TCR-pMHC interactions. (A) Time evolution of the
total number of H-bonds between TCR and peptide-MHC for wild type NLV, mutant T8V,
and M5I, in the presence of force. (B), (C), and (D) show the raw data for each peptide
ligand with its averaged curve. NLV shows clearly a catch-bond phase represented by an
increased in the total number of the H-bonds; there is a small increased for T8V; M5I does
not have any increase and apparently displays an ideal bond. The complexes are undergoing
a constant-velocity pulling. The number of independent points (or the bin size) of the block
averaging method are determined by using the autocorrelation time, τ f , of the number of
H-bonds in the simulation as Nsample ∼ ttotal/τ f . Nsample denotes the number of independent
samples in the trajectory and if Nsample  1 would suggest good sampling for any measured
variable.
complex initially increases the number of H-bonds at the binding interface; however, its
catch bond is weak and small. Thus it is unstable and unable to sustain the pulling force
and starts dissociating from the RA14 TCR early. T8V peptide does not allow the force
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to build and propagate over time. Initially, T8V and NLV peptides produce a similar catch
bond pathway. TCR-M5I-HLA2 complex does not increase the number of H-bonds at the
binding interface, its total count is independent of force, and it is considered an ideal bond.
The number of independent points or the bin size of the block averaging method are
determined by using the autocorrelation time, τ f , of the number of H-bonds in the simula-
tion. τ f measures the time required for the trajectory to lose memory of earlier values. τ f is
used for estimating the number of statistically independent values in a simulation of length
ttotal as Nsample ∼ ttotal/τ f . Nsample denotes the number of independent samples contained in
the trajectory and if Nsample 1 would suggest good sampling for any measured variable.
Figure 16: Illustration of the time evolution of the number of H-bonds between TCR and
peptide for wild type in the presence of force. There is clearly an increased in the number
of the H-bonds in the presence of force under the umbrella of catch bond, t = 100 to 160
ns. The H-bonds are colored in cyan at the catch phase.
Similar to experiments, the results may depend on several factors; for instance, in sim-
ulations differences could arise due to numerical computing errors defined by physical
nature of the machine compiler (hardware); due to numerical methods (software), e.g., the
integration step size, PME algorithm, etc; due to initial assignment of velocities (random
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number seed) affecting the kinetic energy of the system; as it was completely explained in
the previous chapter. Thus repeating the simulations is always performed to evaluate not
only the convergence and reproducibility of the results and avoid random events, but also
address concerns of whether or not the simulations are depended on any parameters (e.g.
pulling velocity, spring constant, etc). The main constraint is that multiple simulations are




































































































































Figure 17: Steered MD simulation of RA14 interacting with different pMHCs.(A-C) The
total number of hydrogen bonds of RA14 to NLV-HLA2 and altered peptide ligands(T8V-
and M5I-MHC) using three different initial configurations at normal constant velocity. (D-
E) Single simulation of RA14 interacting with NLV- and altered T8V- and M5I-HLA lig-
ands at medium and high ramping rates. (F) Histogram of the number of hydrogen bond
profile of free vs. steered MD simulation of RA14 to NLV and altered peptide ligands.
The results show that: 1) Changing the IC has no significant difference and the H-bond
curves are indistinguishable for each epitope. 2) The responses are also not dependent on
the pulling parameters as the NLV complex always forms a clear catch bond phase and
the T8V shows a very weak, small catch, while the M5I is unsuccessful forming any catch
bond. Note that increasing the ramping rate impacts the quality of the catch bond (height
and duration) and it is expected to eventually transition to a slip bond at a very high ramping
rate.
To evaluate reproducibility, two additional simulations starting with different initial
configuration (IC) are performed for NLV, T8V, M5I complexes using a normal constant-
velocity pulling; in total 3 simulations per peptide ligand. The three complexes are also
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pulled using two different ramping rates. Fig. 17 shows the time evolution of the number
of H-bonds between the TCR and the peptide ligand for NLV and mutants, T8V and M5I,
at different ramping rates and equilibrated ICs. First, steered MD (SMD) simulations are
performed with the three equilibrated ICs only at a normal ramping rate of kv = 7pN/ns for
the NLV (A), T8V (B), and M5I (C). The results show that there is no significant difference,
and the H-bond curves are indistinguishable for each peptide ligand. Second using another
random IC, the pulling parameters are varied as shown in Fig. 17 (D) and (E) where they are
increased to medium (KV = 35pN/ns) and high ramping rate (kv = 70pN/ns), respectively.
The responses are also not strongly dependent on the pulling parameters as the NLV peptide
always forms a clear catch bond phase, and the T8V shows a small catch, while the M5I
is unsuccessful forming any catch bond. It should be noted that as the ramping rate is
increased, the quality of the catch bond (height and duration) is decreased and at a very high
ramping rate all curves are expected to eventually transition to a slip bond, consistent with
the experiments. Fig. 17 (F) shows the probability density function (PDF) of the number
of H-bonds for each peptide ligand where all performed SMD simulations are included
in the calculation and compared to the free MD simulations. In free MD simulations, all
TCR-pMHC complexes form in average two H-bonds; however, in the presence of force,
only NLV and T8V complexes shift to five and three H-bonds in average, respectively.
The TCR-pMHC complex has a narrow PDF for the NLV, while the complex for M5I has a
wider one. M5I has a similar profile in the presence or absence of force. This shows that the
overall peptide-ligand responses are not rare or random events and they do not dependent
strongly on pulling parameter or initial configuration; thus the simulations are reproducible
in general. Fig. 18 (A) shows that there is statistical significance in the number of H-bonds
for the NLV and T8V complexes in the presence of force compared the absence of force.
There is no statistical significance for the M5I complex in the absence or presence of force.
Last, SMD simulation is performed using a constant-force pulling only for the NLV
complex. In this case, the Cα atom of the C-terminal residue of the MHC is kept fixed in
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Figure 18: Examination of statistical significance using box and whisker plot of the num-
ber of hydrogen bond of the number of H-bonds, contacts and, buried SASAs for RA14
interacting with NLV, T8V, and M5I peptide ligands in free MD vs. steered MD simulation
using constant-velocity pulling. A Welch two sample t-test is employed reporting p-value
< 10−16 with a 95% confidence interval for the sample with a statistical significance. No
statistical significance is shown in the figure and it is indicated as n.s.
space and the Cα atoms of the TCR’s C-terminus are subjected to a constant force in the
direction perpendicular to the binding interface. Fig. 19 (A) shows the time evolution of
the number of H-bonds between TCR and NLV-HLA2 at different constant-force pulling
of 25, 50, and 100 pN. Dissociation is not observed for the NLV complex experiencing
forces ≤ 100pN. Rising upward the force in the simulation increases the total number of H-
bonds at the binding interface after the force propagates and the duration of forced-induce
H-bonds decreases with an increasing force as shown in the Fig. 19 (A). Fig. 19 (B) shows
the evolution of the average number of H-bonds between the RA14 and the NLV-HLA2 at
different constant forces. The NLV complex forms an in silico catch bond (Fig. 19 B): The
total number of H-bonds increases at the binding interface while the applied constant force
is varied and increased in different independent simulations. There is a transition from a
small number of H-bonds (short-lived state) at zero force (Free MD) to a larger number of
H-bonds (long-lived state) at big force (around 50 to 100 pN). At the long-lived state, the
catch bond reaches a peak in the total number of H-bonds since larger force will eventually
break even the strongest H-bonds. For forces ≤ 100pN, each point represents the average
of H-bonds from a 200 ns MD simulation of the NLV complex subject to varying constant
forces. For forces ≥ 100pN, it is the average of H-bonds until the complex completely
dissociates. Although this is a closer representation of a BFP experimental dataset where
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the bond lifetime is measured at different constant forces, it is worth noticing that creating
such curve (Fig. 19 B) for the mutants is computationally expensive and demanding. For
instance using this protocol requires about 2000 ns of simulation for generating a single
H-bond profile (# H-bonds vs forces) while pulling at constant velocity requires about 200
ns of simulation per curve. This limitation constrains the simulations to be performed
using constant-velocity pulling. It is important to note that increasing the pulling velocity
introduces nonlinear effects to the system. Nevertheless, both computational protocols
provide consistent and comparable results. Furthermore, the critical force is around 50
to 100 pN for both protocols where the “in silico” catch-bond is increased the highest.
Fig. 24 (A) shows that there is statistical significance in the number of H-bonds for the
NLV complex in the presence of force and that in average it display a well-defined catch
bond in the number of H-bonds. Using both protocols, the total number of H-bonds at the




































Figure 19: “In silico” catch bond using constant-force pulling. (A) H-bonds profiles
pulling at a constant force of RA14 to NLV peptide over time for 25, 50, and 100 pN.
(B) NLV complex shows clearly a catch-bond phase represented by an increased in the
average number of the H-bonds at different constant forces.
4.3.2 The total number of contacts displays a catch-bond behavior
Since receptor-ligand interactions are mostly dominated by H-bonds, salt bridges, and hy-
drophobic contacts across their binding site, the number of contacts assess their total con-
tribution. Fig. 20 shows that the total number of contacts increases in a similar manner as
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the number of H-bonds.
Fig. 20 shows the time evolution of the number of contacts between the TCR and the
peptide ligands for NLV, T8V, and M5I, at different IC and ramping rates. The results show
that the NLV-HLA2 (A, D, G) increases the number of contacts and forms a catch bond
phase, T8V-HLA2 (B, E, H) has a subtle increase in the number of contacts and displays
a small catch, while the M5I (C, F, I) is unsuccessful increasing it and mostly display a
constant profile. Similarly, increasing the ramping rate impact negatively the quality of the
catch bond; however, only the RA14-NLV-HLA2 still displays a catch phase in the number
of contacts at medium and high ramping rate, Fig. 17 (J and K). The other peptide ligands
become very insensitive when the ramping rate is increased. In addition, the number of
contacts is slightly higher in the absence of force. Nevertheless, when force is applied, it
decreases and starts increasing when the complex is entering the catch-bond phase. Fig. 18
(B) shows that there is statistical significance in the number of contacts for all complexes
in the presence of force compared the absence of force. In average, NLV decreases the
number of contacts at the binding interface, while T8V and M5I increase it from the initial
value. Overall this quantity is in good agreement with the number of H-bonds; however,
it is not very sensitive to exhibit small changes in its value when it is calculated using
constant-velocity pulling.
Fig. 21 shows the time evolution of the number of H-bonds between TCR and NLV-
HLA2 when the NLV complex is pulled at different constant-force pulling of 25, 50, 90,
100, 150, and 200 pN and their average are plotted in Fig. 22. Increasing the force increases
the total number of contacts at the binding interface. The NLV complex forms an in silico
catch bond, Fig. 22: The total number of contacts increases at the binding interface while
the applied constant force is increased in different independent simulations. Fig. 24 (B)
shows that there is statistical significance in the number of contacts for NLV complexes at
different constant forces. In average, NLV increases the number of contacts from the initial
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Figure 20: The time evolution of the total number of contacts between the TCR and the
peptide ligands for NLV, T8V, and M5I, at different ICs and ramping rates. At the catch
phase, NLV and T8V display catch-bond profiles are, with T8V having a small one. M5I
mostly display a slip profile.
the number of H-bonds when it is calculated using constant-force pulling. In general, this







































































































Figure 21: The total number of vdW contacts over time for the TCR-NLV-HLA2 at vary-
ing constant forces of 0, 25, 50, 90, 100, and 150 pN.
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# of Contacts of NLV complex
NLV
Figure 22: “In silico” catch bond in the
number of contacts for the NLV complex
using constant-force pulling. NLV com-
plex shows clearly a catch-bond phase
represented by an increased in the total
number of contacts at different constant
forces.













Buried SASA of NLV complex
NLV
Figure 23: Buried SASA of RA14 in-
teracting with NLV peptide ligand us-
ing constant-force pulling. NLV com-
plex shows a subtle increase in the area;
however, they are basically constant for
≤ 200 pN. The buried SASA is not a
good predictor of catch bonds.
Figure 24: Examination of statistical significance using box and whisker plot of the num-
ber of H-bonds, contacts and, buried SASA for RA14 interacting with NLV peptide ligand
in the presence of force using constant-force pulling. A Welch two sample t-test is em-
ployed reporting p-value < 10−16 with a 95% confidence interval for the sample with a
statistical significance. No statistical significance is shown in the figure and it is indicated
as n.s.
4.3.3 The buried SASA is not a good predictor of catch bonds when using constant
velocity pulling, it becomes constant at the catch phase
Fig. 25 shows the time evolution of the buried SASA between the TCR and the peptide
ligands for NLV, T8V, and M5I, at different IC and ramping rates. The results show that
the buried SASA of NLV-HLA2 (A, D, G) at the catch phases is roughly constant, T8V-
HLA2 (B, E, H) has a subtle increase in the buried SASA and roughly stay constant at
catch phase, while the M5I (C, F, I) mostly display a slip profile. Increasing the ramping
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rate does not impact the buried SASA profile for the peptide ligands. The buried SASA is
very insensitive to changes in the ramping rate. The initial buried SASA is slightly higher
in the absence of force. However, when force is applied, it decreases before reaching the
catch phase and then it becomes constant until dissociation occurs. Fig. 18 (C) shows that
there is statistical significance in the buried SASA for all complexes in the presence of force
compared the absence of force. In average, NLV decreases the buried SASA, while T8V
and M5I increase it from the initial value. In summary, the buried SASA is not a parameter





 0  20  40  60  80  100 120 140 160 180














 0  20  40  60  80  100  120  140  160












 20  40  60  80  100  120  140













 0  20  40  60  80  100 120 140 160 180












 0  20  40  60  80  100  120  140  160













 20  40  60  80  100  120  140













 0  20  40  60  80  100 120 140 160 180














 0  20  40  60  80  100  120  140  160












 20  40  60  80  100  120  140























































































Buried SASA of M5I complex
M5I
Figure 25: Buried solvent accessible surface area (SASA). The time evolution of the
buried SASA between the TCR and the peptide ligands for NLV, T8V, and M5I, at dif-
ferent IC and ramping rates. At the catch phase, NLV and T8V are roughly constant, with
T8V having a subtle increase in the buried SASA. M5I mostly display a slip profile.
Fig. 21 show the buried SASA for different constant-force pulling of 25, 50, 90, 100,
150, and 200 pN and its average is plotted in Fig. 23. Although, it is believed that the
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hydrophobic effect is a major driving force for binding since it buries nonpolar surfaces
from aqueous solution, here it is shown that this parameter is not very sensitive to the
subtle changes in the binding interface for the TCR interacting with peptide ligands. For
forces ≤200, the buried SASA is roughly constant. This is because the binding interface
is small and its changes in the contacting interface are not very sensitive. Buried SASA
is not capable of distinguishing slightly buried residues, of which most are not hot spots;
the deeply buried ones are usually inside and are hot spots. Overall the buried SASA
is not a good parameter to predict catch bonds. Fig. 24 (C) shows that there is statistical
significance in the buried SASA for NLV complexes at different constant forces. In average,
it increases from the initial value (zero force) when force is increased. Overall this quantity















































































Buried SASA of NLV complex
F= 150pN
Figure 26: The dependence of buried SASA over time for the TCR-NLV-HLA2 at varying
constant forces of 0, 25, 50, 90, 100, and 150 pN.
In Summary, the total number of H-bonds is a good predictor of catch bonds when
the complex undergoes either constant-velocity or constant-force pulling. However, the
total number of contacts and the buried SASA display only catch-bond behaviors when
the complex undergoes constant-force pulling. This is because in a single simulation at
constant-velocity pulling, the complex visits all forced-induce states (starting from zero to
dissociation) and in average it provides a value that is smaller than the initial one (Fig. 18).
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4.3.4 The RA14 changes its binding orientation on the pMHC to form a catch bond.
One important parameter for characterizing TCR recognition of antigenic peptides is the
TCR binding (or docking) orientation on the pMHC and it is called the crossing angle. The
TCR-pMHC crossing angle is usually calculated between the MHC-bound peptide axis and
a line that connects the center of mass of the CDR loops of the TCR α and β chain. As a
general rule, TCR CDR1 and CDR2 recognize the MHC α-helices, whereas the hypervari-
able CDR3 regions interact mainly with the presented and diverse peptide as seen in most
TCR-pMHC crystal structures. This topological rearrangement generally produced in most
TCRs a diagonal docking angle. The binding orientation is always measured in force-free
conditions in experiments and it is believed that when a specific TCR binds to a cognate
pMHC, the complex obtains a defined crossing angle and its structural rearrangement does
not change after the initial binding as the docking orientation is unique and it provides one
specific TCR footprint.
The protein crystal structure shows that NLV-specific RA14 bounds to NLV-HLA2 in
diagonal docking mode with a crossing angle of about 35o. The association and dissociation
between a TCR and a pMHC is a dynamic and stochastic process where their engagement
is subjected to several pico Newtons of mechanical forces during immune surveillance
possible through cell movement and by cytoskeletal rearrangements at the immunological
synapse after cell migration stops. However, this important component has been omitted in
most structural studies of TCRs when characterizing recognition of antigens.
The Fig. 27 shows the docking (or crossing) angle in free MD simulations for all com-
plex. After reaching thermodynamic equilibrium (≈ 20ns), all complex oscillate around an
average angle that probably defines a particular footprint on the pMHC and it is constant
over simulation time after reaching equilibrium. The angle for the NLV complex slightly
decreases from its experimental value and becomes around 25o. A caveat is that T8V and
M5I peptide ligands are single in silico mutations performed on the wild type NLV com-
plex and they are expected not to change the docking topology significantly. T8V crossing
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angle changes considerably; however, it is assumed that this is the natural response of the
T8V complex and not a computational artifact. The angle of RA14-NLV-HLA2 initially
decreases from its experimental value of 35o to 20o; however, later it oscillates between
20o to 30o. In the absence of force, thus, the angle and interface are stable and this orien-
tation and molecular structure are similar to the one observed in the crystal structure. The
in silico mutants, T8V and M5I, show a different trend. RA14-T8V-HLA2 increases to
55o and oscillate around it, while the RA14-M5I-HLA2 does not change its original angle
and oscillates around 30o. For T8V complex, the crossing angle diverges from the NLV
trajectory as it initially increases and moves to a different value (55o) in free dynamics.
Fig. 28 shows the dependence of docking angles over time in the presence of force for
RA14 interacting with NLV, T8V, and M5I peptide ligands. In the presence of force, the
angle starts to linearly increase at 40ns to reach its experimental value (35o) at 60 ns and
then it suddenly jumps to 55o in a stepwise manner forming a new state. This second state
is very stable and the complex remains in this orientation until dissociation occurs. Fig. 29
(A) and (B) show visually the “force-free” and “forced-induced” orientation, respectively.
The complex is aligned according to the MHC to highlight the difference in docking angles
for RA14. The unbinding of RA14 from NLV-HLA2 requires that the orientation of the
complex returns to its initial force-free state (35o). The transitioning to the second orien-
tation is fast. Surprisingly the second state is very stable even though RA14-NLV-HLA2
is experiencing a huge load. Note that the initial angle is formed in a force-free condition
whereas the second is a forced-induced state.
Interestingly, the footprint of RA14 interacting with T8V peptide ligand in free dynam-
ics is similar in angle (50o) to the forced-induced state of NLV complex (55o). However,
in the presence of force, the angle decreases to 20o and forms an orientation similar to
NLV complex when it is in the force-free state. T8V complex remains here until 100ns.
The angle for T8V is reversed compared to the NLV complex. After it reaches 110 ns, the
complex moves again to the second state just before the α3-MHC starts unfolding, and as a
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consequence, the angle suddenly increases. This implies that the interface between RA14
and pMHC is unstable and weak for T8V peptide.
For M5I complex, the crossing angle does not change significantly over time in the ab-
sence or presence of force and the RA14 footprint is in a similar to the force-free state of
NLV complex and it stays until dissociation occurs. After it reaches 120 ns, the α3-MHC
also unfolds. The unfolding happens only with the “in silico” mutants. This could poten-
tially be an artifact arising from the fact that those structures are produced by performing
“in silico” mutations in the wild type NLV complex and they are not structures obtained
by protein crystallography. Importantly, the unfoldings are also consistent with two ex-
perimental studies describing viral immune escape strategies where mutant epitopes were
observed to affects T cell recognition by reducing pMHC-complex stability [152] and allow
peptides get out of the groove [153].
A striking result is that not only complexes transitioning to a forced-induced orientation
are able to form a catch-bond, but also their discrete shifting in angle coincides with the rise
of a catch bond. Although all measured angles in the simulation oscillate around a central
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Figure 27: The docking orientation be-
tween the RA14 interacting with NLV,
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Figure 28: The docking orientation be-
tween the RA14 interacting with NLV,
T8V, and M5I in the presence of force.
Fig. 30 shows the docking angle over time for NLV, T8V, and M5I complexes at two
different IC and two ramping rates. The two additional ICs are pulled at a normal ramping
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Figure 29: General view of the change of RA14 TCR binding orientation on the pMHC to
form a catch bond. (A) Initial state similar to the crystal structure. (B) The force-induced,
the TCR has rotated over the binding site. The complex is aligned according to the MHC
to highlight the difference in docking angles for the TCR. The unbinding of the TCR from
the pMHC requires that the orientation of the complex returns to its initial force-free state
(35o). The transitioning to the second orientation is short and fast. The second state is very
stable even though the complex is experiencing a huge load. Note that the initial angle is
formed in a force-free condition whereas the second is a forced-induced state.
rate. Fig. 30 shows the angle for NLV (A, D), T8V (B, E), and M5I (C, F) complexes.
Fig. 30 shows simulations pulled at medium (G, H, I) and high (J, K, L) ramping rate for
the three peptide ligands. The color coding is red, green, and blue for RA14 ligated with
NLV-, T8V-, and M5I-HLA2, respectively. As the ramping rate is increased for the NLV
complex, the docking angle is affected and starts decreasing; this is consistent with the
experimental observation that high ramping rates transform catch to slip bonds. A high
rate does not allow the complex to move to the second state; the protein dynamics becomes
very fast and it is mostly dominated by the rate that introduces nonlinear effects to the
system. A closer look to the atomic structure of T8V complex reveals that residue V8P
(mutated from Threonine) is unable to form any stable H-bond with the RA14 and thus it
loses this anchor point, originally seen in the wild type. RA14 is initially anchored to this
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residue and if removed, RA14 is able to rotate around the binding axis and it can either
increase or decreases its docking angle. Note that VAL (T8V) is unable to form H-bonds
so it is not anchor point. M5I complex does not change its docking and it is invariant
to the presence of force. The results are in general consistent and there is no significant
difference between different runs for the same complex. The NLV complex always shows
a stable forced-induced angle and the T8V shows an unstable second phase, while the M5I




























































































































































Figure 30: The docking orientation over time for NLV, T8V, and M5I complexes at two
different IC and two ramping rates in the presence of force. The color coding is red, green,
and blue for TCR ligated with NLV-, T8V-, and M5I-HLA2, respectively. As the ramping
rate is increased for the NLV complex, the docking angle decreases; this is consistent with
the experimental observation that a high ramping rate will transform a catch into slip bond.
A high rate also does not allow the complex to move to the second stable state as the
protein dynamics becomes very fast and be dominated by the high rate. In T8V, residue
V8P is unable to form any stable H-bond with the TCR and thus it loses this anchor point.
NLV is anchored at least in two residues, Met5P and Thr8P and Without them, it is free
to rotate around the binding. M5I complex does not change its docking. The results show
there is no significant difference between different simulations for the same epitopes. The
NLV peptide always shows a stable second angle and the T8V shows an unstable second
phase, while the M5I is unsuccessful forming any stable state.
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Fig. 31 shows the dependence of docking angles over time for the RA14-NLV-HLA2
pulled at constant forces of 25, 50, 90, 100, 150, and 200 pN. At lower ( ≤ 25 pN) or higher
forces ( >100), NLV complex has only one state and displays a relatively constant angle
before dissociation (Fig. 31 A, E, F). This angle is close and similar to the one measured
in the crystal structure. In the catch phase, (50 pN to 100 pN, Fig. 19), the complex shifts
to a second state by changing the docking angles. 50 pN is considered the peak or critical
force since it forms more H-bonds compared to other forces (Fig. 19). At the critical force
(Fig. 31 B), the complex initially has a sudden increased shown as a prominent peak (at
45 ns) and then set the docking angle to 40o; this is the second state and it remains at this
orientation for at least 60 ns. Importantly the complex not only transitions to the second
orientation discretely but also is able to increase in average the total number of H-bonds
simultaneously (Fig. 19). After this point (120 ns), the angle starts slowly decreasing;
however, the complex resists and opposes the change by returning to the forced-induced
state. This is clearly seen around 160 to 180ns where the angle basically moves back
to 40o. Passing this region the forces become large and start overpowering the H-bonds.
This level of force does not allow the complex to reach the optimal docking orientation
to form catch bonds. At 90 and 100 pN, the complex’s angle initially moves to 15o and
then increases and maintain a relatively constant value (30o) below the optimal orientation;
however the complex always remains moving in an upward direction trying exhaustively to
increase it as seen in Fig. 31 (C, D). Although the angles fluctuate, it is considered constant
since their amplitude is relatively small.
Important to note that measuring the angle is very sensitive to small variation in the
binding site and the problem with the docking orientation oscillating widely is character-
istic of the manner is defined initially by scientists in the field. Using the peptide’s end
terminus or defining a line going through the MHC α2 chain only works if the complex
is static and rigid structures. In MD simulations, they are flexible and fluctuate. A better
methodology is to use the axis parallel to the MHC binding groove defined by calculating
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Figure 31: The dependence of docking orientation over time for the RA14-NLV-HLA2 at
varying constant forces of 25, 50, 90, 100, 150, and 200 pN. At lower forces ( ≤ 25 pN)
or higher ( >100) forces, the complex has only one state and displays a relatively constant
angle before dissociation. In the catch region, (50 to 100 pN), the complex shifts to a second
state by changing its docking angles. At this orientation, the complex is able to increase in
average the total number of H-bonds. Passing this region the forces become large and start
overpowering easily the H-bonds and does not allow the formation of an optimal docking
orientation. At 90 and 100 pN, the complex’s angle initially moves to 15o and then increases
and maintain a relatively constant value (30o) below the optimal orientation; however, the
complex always remains moving in an upward direction to increase the angle.
4.3.5 NLV peptide has a second conformation associated with the catch bond
The problem of describing structurally catch bonds is tangled since the peptide is experi-
encing positional, orientational, and conformational changes at the TCR-MHC interface;
however these small changes are inconsistent with the enormous variation in functional
outcomes. Having multiple configurations may also modulate the affinity and the duration
of the bond lifetime. There is a question if the peptide configuration inside the MHC bind-
ing groove is modulated by force when the complex moves to the second state and forms a
catch bonds. Or the epitope conformation does not change or it is moving in a randomly.
The dynamic nature of the peptide, when is inside the MHC and it is interacting with the
TCR, has been never addressed adequately in experiments or simulation.
The root-mean-square deviation (RMSD) measures an average displacement of atoms
and it is routinely used to examine if the protein has equilibrated; it can also provide in-
formation if (parts of) proteins have experienced any conformational change. Using the
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RMSD, the protein behavior over time is compared to a starting point of the simulation.
The initial reference and the time-varying target are usually aligned before calculating the
RMSD to remove any translational and rotational diffusion (deviation) and explore mostly
local conformational changes of the protein.
Fig. 32 shows the RMSD of each peptide in the absence of force (Free MD). In free dy-
namics, the RMSD of NLV, T8V, and M5I peptides are initially expected to increase since
crystal structures are produced by artificially packing the protein inside a very dense crys-
tal; thus, proteins need to relax in order to achieve their native conformation as they are not
rigid entities. An increase of 0.5Å is reasonable and expected for native states; however,
if larger changes are observed in the RMSD, it implies that a conformational change has
occurred. The RMSD reaches a plateau value for the NLV and T8V peptides meaning that
they are progressing towards their equilibrium state, where all properties become time in-
dependent apart from small fluctuations; this is the thermodynamic equilibrium state. This
plateau is not observed immediately for the M5I epitope. M5I displays larger fluctuations
and changes in its RSMD from beginning to middle of the MD simulations. Basically, the
RMSD measures distance and changing its value means that the atoms are displaced from
its original position and they are potentially forming a different configuration. At the new
position, the RMSD for M5I epitope eventually displays a constant value (after 50 ns) indi-
cating that its structure has also converged. Finally, the NLV and “in silico” mutants, T8V
and M5I, are moving towards their equilibrium state in the absence of force.
Fig. 33 shows the RMSD of each peptide in the presence of force (SMD) using nor-
mal constant-velocity pulling. The NLV epitope transitions fast in a stepwise fashion to a
stable second state defined when the RMSD value reaches 2Å and it remains in this phase
inasmuch as the complex is inside the catch-bond region (Fig. 15). This forced-induced
conformation is optimal for producing new H-bonds at the binding interface and prolong-
ing the bond lifetime. The T8V epitope initially moves to the second state; however, it
is unstable and unable to sustain this conformation and returns back to its original state.
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The M5I epitope does not have any well-defined state and its conformation is independent
of force in the sense that it is always increasing and displaying large fluctuations. The
peptides, NLV and T8V, discretely transition to a forced-induced state when the docking
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Figure 32: The RMSD of each peptide
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Figure 33: The RMSD of each peptide
for NLV, T8V, and M5I peptides in the
presence of force.
Fig. 34 shows the RMSD of NLV, T8V, and M5I complexes at different IC and ramping
rate. The two independent ICs are pulled using constant-velocity pulling at a normal ramp-
ing rate and are shown for the NLV (A, D), T8V (B, E), and M5I (C, F). Fig. 34 shows the
simulations pulled at medium (G, H, I) and high (J, K, L) ramp rate for the three epitopes.
normal, medium and high ramping rate have been previously defined. The color coding is
red, green, and blue for NLV, T8V, and M5I peptides, respectively. As the ramping rate is
increased, their peptides are losing the ability to transition to the new state; nevertheless, all
NLV simulations display a well-defined, forced-induce state as the RMSD changes to 2Å,
excluding only the high rate pulling. Only one simulation for the T8V epitope is able to
access the second state. Although one simulation for the M5I epitope reaches a stable state,
it either dissociates faster or force unfolds the MHC α3 domain in the other runs, being is
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consistent with experimental studies [152, 153]. The second state formed by the NLV epi-
tope is longer-lived, while the mutants have their second state shorter-lived. Overall there
is no significant difference between runs for the epitopes. The NLV peptide always shows
a longer-lived, stable second state and the T8V shows an unstable second phase, while the










































































































































































Figure 34: The RSMD for NLV, T8V, and M5I complexes at two different IC and two
ramping rates. The color coding is red, green, and blue for NLV, T8V, and M5I peptides,
respectively. As the ramping rate is increased, the peptides are losing the ability to tran-
sition to the new state. All NLV simulations display a forced-induce state as the RMSD
changes to 2Å, excluding the high rate pulling. Only one simulation for the T8V epitope
is able to access the second state. Although one simulation for the M5I epitope reaches
a stable state, it either dissociates faster or unfolds the MHC α3 domain in the other runs.
The second state formed by the NLV epitope is longer-lived, while the mutants have their
second state shorter-lived.
Fig. 35 shows the RMSD for the NLV epitope pulled at constant forces. When force is
≤ 25 pN, the epitope is flexible and does not adopt a clear state and the changes observed
in the RMSD correspond to the free movement of its side chains. In the catch region, (50,
90, and 100 pN), the RMSDs increase roughly to a constant value of 2Å and it defines
the second conformer. At the critical force, 50 pN (Fig. 35 B), the epitope has a sudden
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increased and forms the second state; it remains at this conformation until dissociation and
it mostly happens a the end of the simulation. Importantly the NLV not only transitions to
the second conformation discretely but also is promoting the increase of the total number
of H-bonds at the same time (Fig. 27). At 90 and 100 pN, the peptide also changes its
conformation reaching 2Å at the end of the simulation Fig. 35 (C, D). For higher forces
(>100), the peptide does not change its RMSD and has only one state until dissociation.
This state is similar to the crystal structure, Fig. 35 (E, F).
Fig. 37 are probability density function (PDF) and show pattern distribution of the
RMSD values for NLV, T8V and M5I epitopes in free and steered MD simulations, re-
spectively. All simulation are included in the PDF calculation. NLV epitope has only one
state (population located at 1Å) in the absence of force (Fig. 37 A); however when force is
applied it obtained a second state at 2.5Å (Fig. 37 D). Both states are easily differentiated
since they lie within a closely packed interval. The second state has greater height and it
means this conformation is the most dominant. There is only one state for the T8V epitope
in free dynamics (Fig. 37 B); however, a second conformation appears in the presence of
force (Fig. 37 E). This conformer is not the most populated; the dominant is the force-free
state for the T8V epitope. Fig 37 (C) and (F) show that the M5I epitope displays only one
state in the absence or presence of force, respectively. The distribution of this state is wider
implying that the epitope is mostly moving randomly.
4.3.6 Mutants reduce the conformational states of the peptide
In order to understand how local conformational states and internal motion of the epitope
change in the absence and presence of force, the per-residue root mean square fluctua-
tion (RMSF) averaged over simulation time is calculated. It quantitatively compares the
flexibility and total displacement among peptides per residue. RMSF is also calculated
in the standard manner after rotational and translational alignment to the initial structure.



























































































Figure 35: The RMSD for the NLV epitope pulled at constant forces of 25, 50, 90, 100,
150, and 200 pN. When force ≤ 25 pN, the epitope is flexible and does not adopt a clear
state. In the catch region, (50, 90, and 100 pN), the RMSD increases. At the critical force,
50 pN, the epitope has a sudden increased forming a second state and remains at this con-
formation until dissociation. At 90 and 100 pN, the epitope also changes its conformation
reaching 2Å at the end of the simulation. For higher forces ( >100), the peptide does not
change its RMSD and has only one state before it dissociates.
Figure 36: Examination of statistical significance using box and whisker plot of the dock-
ing angle and RMSD of the peptide for RA14 interacting with NLV, T8V, and M5I peptide
ligands in the absence and presence of force using constant-velocity pulling. A Welch two
sample t-test is employed reporting p-value < 10−9 with a 95% confidence interval for the
sample with a statistical significance.
peptides in the absence and presence of force. NLV epitope (Fig. 38 A) has a higher dis-
placement compared to mutant T8V and M5I in the absence of force. The NLV epitope is
































































































































Figure 37: Histograms comparing the peptide conformation in the absence and presence
of force. All simulations are included in their calculation. NLV epitope has only one state
in the absence of force; however when force is applied it obtained a second state. Both
states are easily differentiated. The second conformation is the most dominant as shown by
the height of the histogram. There is only one state for the T8V epitope in free dynamics;
however, a second conformation appears in the presence of force but it is not the dominant.
M5I epitope displays only one state in the absence or presence of force.
more conformational states. However, NLV epitope (Fig. 38 B) experienced a large dis-
placement and is rigidified inside the binding groove in the presence of force. M5I and T8V
also experience a small displacement. Force promotes the formation of new H-bonds that
constrains the spatial motion and bias the epitope to a specific conformational state. Point
mutations disrupt the epitope flexibility, mobility, and dynamic footprint by abolishing the
formation of those interactions.
Perhaps a great mobility is observed in NLV because the epitope is switching confor-
mations across multiple states in the absence of force and allowing TCR scanning. Then,
if the interacting regions are highly mobile within the binding interface in the absence of
force; the probability of complementary matching the opposing interfaces can be favor-
ably enhanced. And once the match is found, force enhances their stability of what would
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be otherwise a weak TCR-pMHC interaction. Force modulates and induces a bias in the
energy landscape; for instance, at zero force (Free MD), peptide moves across multiple

































Figure 38: Local mobility of the NLV peptide, T8V, and M5I mutants measured by the
RMSF of their Cα atoms in the absence (MD) and the presence (SMD) of force. NLV
has comparable displacement to T8V and M5I in the absence of force. However, NLV
displaced to a new state and becomes rigid in the presence of force.
4.3.7 The principal component analysis isolates the two conformations
The dihedral angle principal component analysis (dPCA) are used to separate different
conformations of a protein occurring through an MD trajectory. The dPCA differentiates
conformational changes by using orthogonal eigenvectors (or principal components) that
describe the axes of a maximal variance in the distribution of structures in the simulation.
The distribution of structures are projected into the largest eigenvectors which provide a
reduced dimensional representation of the data set and their corresponding eigenvalues
represents the percentage of total variance of atom fluctuations obtained in each dimension.
This reduces the dimensional space while still retaining most of the dynamics of the original
protein.
Fig. 39 shows the dPCA plots with a k-means clustering for different conformers of
NLV, T8V, and M5I peptide ligands, respectively. The distribution of conformations along
the principal component plane is represented by dots. Dots with the same color indicates
that they belong to the same groups as they have a similar conformer throughout the MD
trajectory simulation. Fig 39 (A) shows that NLV complex has two well-defined population
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of conformer, while Fig 39 (B) shows that T8V epitope has also two conformers being the
second less populated. The transition between distinct structural clusters corresponds to
significant dynamical changes in conformation of the peptide sidechain. On the contrary,
M5I epitopes (Fig 39) shows a densely pack plot meaning that it has only one conformer.
Interestingly only 3 principal components are capable to capture more than 50% of the total
dynamics in the simulation. Fig 40 shows the force-free (A) and forced-induced states (B)
and it highlights the important interactions between residues.
(A)




















































































































































































































































































































































































Figure 39: dPCA and k-means clustering for NLV, T8V, and M5I epitopes, respectively.
The distribution of conformations along the principal component plane is represented with
dots. Dots with the same color indicates they belong to the same groups and they have a
similar conformer throughout the trajectory of the simulation.
4.3.8 The molecular basis of “in silico” catch bonds in RA14 interacting with the
NLV peptide ligand
The RA14– αβ TCR –is genetically encoded by rearranging TRAV24 and TRAJ49 gene
segments for the α-chain and TRBV6-5, TRBD1, and TRBJ1-2 gene segments for the
β-chain and these genes mandate the structural arrangement and interaction between the
RA14 and the peptide ligand (NLV-HLA2). The crystal structure of RA14-NLV-HLA2 [21]
shows special TCR germline-encoded residues interacting with HLA2. Residues Asn29α
and Tyr31α located at CDR1α are exclusively expressed in TRAV24 and TRAV21 genes
and they interact with the NLV-HLA2. TRBV6-5 gene features a hydrophobic sequence
core located at CDR2β and they form multiple van der Waals contacts with the ligand.
Residues Tyr48β and Asp56β located at the ends of CDR2β are highly conserved residues
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Figure 40: Catch-phase exhibit a second state of RA14-NLV-HLA2 interaction. (A-B)
Molecular structure for the two states. The transition from force-free to forced-induced
state involves the changing of the docking orientation and the peptide flexibility. In the
presence of force, the TCR not only forms new interaction with the peptide-MHC; but also
promotes the formation of new H-bonds between the peptide and the MHC. NLV epitope
forms two additional anchor points with residues located inside the MHC binding groove,
Asp77H and Trp147H. These residues anchored the NLV epitope in the new conformer.
Strikingly these residues are highly conserved across HLAs. This suggests that MHCs have
evolutionarily conserved these two residues to lock and modulate the peptide conformations
when the TCR is scanning.
across TCR β chains and form H-bonds with the HLA2. Pro4P, Met5P and Thr8P from NLV
peptide are hot spots since mutating them rendered the epitope ineffective in activating the
T cells.
In protein structure is observed that the RA14 and NLV-HLA2 engage in a conventional
diagonal docking orientation which allows all CDRs to participate in HLA2 binding while
mostly the CDR1s and CDR3s loops participate in peptide recognition [21]. This orienta-
tion specifically allows CDR1α and CDR3α loops to be position closer to the N-terminal
half of the peptide and the α1-MHC helix, while CDR1β and CDR3β loops are close to
the C-terminal end of the peptide and the α2-MHC helix. In addition only CDR3α forms
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H-bonds with the NLV-HLA2, whereas CDR1β and CDR3β forms H-bonds with the NLV-
HLA2. Residue Thr8P forms one and three H-bonds with Glu30CDR1β and Thr97CDR3β, re-
spectively, while residue Met5P forms an H-bond with Asn96CDR3β. Residue Gln72H forms
one H-bonds with Asn96CDR3α and the conserved residues Tyr48β and Asp56β. Residue
Lys146H and ALA149H forms H-bonds with Glu30CDR1β and Tyr101CDR3β, respectively.
Fig 41 and 42 show the stability of those H-bonds reported in the crystal structure [21]
for the RA14-HLA2 and RA14-NLV, respectively. During free MD simulations, only 2
H-bonds are long-lived stable interactions, while two others are unstable and reforming
intermittently. The others are extremely weak and completely unstable. This is consistent
with the lower 3D binding affinity (KD = 27.7±2.3 µM) reported for the RA14-NLV-HLA2































































Figure 41: Stability of H-bonds between TCR and

































Figure 42: Stability of H-
bonds between TCR and pep-
tide from the crystal structure.
4.3.9 The forced-induced H-bonds formed at the catch-bond phase
In protein crystallography, the structures only provide a quantity (# of H-bonds) and they
are unable to assess their quality: strong vs weak or stable vs unstable. Thus, simulation
is required to provide complementary dynamic information. A similar analogy is made in
most biophysical experiments, for instance, micropipette adhesion frequency experiment
provides only the quantity of single bonds as 2D binding affinities, where Biomembrane
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force probe assess their quality by reporting their bond lifetime. In structural immunology,
the underlying assumption is that the docking orientation formed between the TCR and the
pMHC is fixed for immune recognition and their footprint does not change after binding.
This inherently implies that the binding contacts such as H-bonds are mostly stable and not
changing over time. However in free dynamic, these interactions are continuously changing
and some are strong while others are weak and not completely stable since they do not form
a continuous interaction, but sometimes intermittent. An H-bond is considered intermittent
if it breaks and then it subsequently reforms after a period of time. This is different from
the stable and strong H-bond that continuously remains attached over a long period of time.
In the previous sections, it is shown how, in the presence of force, the TCR initially
interacts and then varies its molecular footprint on the pMHC to form a stable forced-induce
state that is functional producing catch bonds. Fig 43 and Fig 44 show the stability of the
forced-induced H-bonds created when the RA14 rotates and forms a catch bond with the
NLV peptide ligand, for the TCR-MHC and peptide-MHC, respectively. Importantly these
interactions are not observed in the crystal structure or free MD simulations. Importantly
the H-bonds are generated when the complex changes its docking angle and simultaneously
the epitope is switched to the new second state; thus a catch bond is formed. A total
of 5 long-lived and stable H-bonds are created during pulling simulations and they are
continuous and strong under the umbrella of the catch phase. The others are unstable and
reforming intermittently. The H-bonds are visually displayed in Fig 45.
4.3.10 The RA14-NLV-HLA2 exhibits a second state at catch bond phase
In the presence of force, the TCR not only forms new interaction with the peptide ligand;
but also promotes the formation of two H-bonds between the peptide and the MHC. Fig 44
shows that the NLV epitope forms two additional H-bond anchor points with residues,
Asp77H and Trp147H, located inside the MHC binding groove. They are visually dis-

































































Figure 43: Stability of forced induced H-bonds be-
























Figure 44: Stability of forced
induced H-bonds between
MHC and the epitope at the
second conformation.
the crystal; however, in SMD it becomes very stable. These residues anchored the NLV
epitope in the new conformer by reducing its mobility and decreasing its flexibility right
after peptide has switched to the second state (“on”). Strikingly these residues are not only
essential for anchoring but they are also highly conserved across HLA2s. There are about
nine conserved residues located at each end of the peptide binding groove of MHCs and
they are Tyr7, Tyr59, Asp77, Tyr84, Thr143, Lys146, Trp147, Tyr159, and Tyr171 [154].
This suggests that MHCs have remained unchanged and evolutionarily conserved these
two residues to lock and modulate the peptide conformations when the TCR is scanning
the binding cleft and thus maximizing the peptide read out. The simulation is assigning an
important functional role for these conserved anchor points.
4.3.11 The RA14 uses a molecular to lever read out a featureless viral peptide ligand
Initially, residue Met5P is surrounded by a small molecular cage formed at the interface of
TCR α and β chains as depicted in Fig. 40. The interaction of Met5P with TCR is mostly
of a hydrophobic nature since it does not form any stable H-bond in free nor steered MD
simulations. This is opposed as it is reported forming an H-bond with Asn96CDR3β. In
Free MD simulations, the Met5P side chain is position inside the molecular cage; however,
in the presence of force, Met5P is dislodged from the molecular cage and it is forced to
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Figure 45: The “in silico” catch bond exhibits a second state of RA14-NLV-HLA2 inter-
action. The two conformations are shown in full molecular detail, the new forced-induced
H-bonds are omitted in the second state for easy visualization. The first state is similar
to the one observed in the crystal structure. The forced-induced H-bonds between the
TCR and MHC participate indirectly in the mechanism of RA14 using a molecular lever.
They provide essential support to maintain together the complex when the TCR rotates and
changes the docking orientation when the pulling force is growing. They hold together the
RA14 and the pMHC otherwise they will dissociate.
relocate its hydrophobic side chain inside the MHC binding groove. This is because the
TCR rotating around the binding axis kicks out Met5P side chain outside the molecular
cage and creates a lever. The molecular lever is formed by the TCR pushing down (from
one end) the tip of the Met5P side chain (Cε) inside the binding groove as it is rotating.
The “out-of-cage” movement of Met5P not only pushed down and buried its side chain
but also: (1) lifts the Cα of Met5P (the load) from the other end; (2) levers up the peptide
hydrophobic core (Pro4P, Met5P, Val6P); (3) and exposes this core to the molecular cage.
This movement also dynamically locked the epitope in this forced-induced conformation
by creating simultaneously another anchor point, Thr8P. Inserting the side chain of Met5P
also brings together Thr8P to MHC α1 domains where the conserved residue, ASP77H, is
located. This promotes the formation of an H-bond between Thr8P and ASP77H. This
defined the transition to the forced-induced conformation since the peptide is no longer
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allowed to move and it is locked at this state by losing its mobility and flexibility.
Thr8P (the fulcrum) has two important functions: one is to interact with the MHC to
form an anchor point for the lever and stand the pressure extorted by RA14 when it is
rotating and lifting the hydrophobic core out of the binding groove; second reduce the
flexibility of the epitope by locking it in this second conformation. This is also opposed as
it is reported that Thr8P forms multiple H-bonds with RA14 and not with MHC. Note that
pushing down Met5P side chain facilitates the insertion of its side chain into the binding
groove since Met is hydrophobic in nature.
The sequential events of the molecular lever are quantified in the Fig. 47. For this
propose, three distances are defined as: d1 is the distance from the tip of the side chain of
Met5P (Cε) to the plane formed by the MHC binding groove; d2 represents the distance from
the Cα of Met5P to the Cα of a hydrophobic residue (Phe98α) located inside the molecular
cage; d3 is the distance between the anchored point (Thre8P) and the conserved residue
Asp77H. The distances are visually depicted as purple arrows and the interacting residues
are highlighted in Fig. 46. The curves in Fig. 47 are composed of free (0 to 100 ns) and
steered MD simulation (100 to 280 ns). This is done to study the behavior of the molecular
lever in the presence and absence of force. The black arrow depicts the moment forces is
applied to the complex and the blue vertical lines enclose the catch-bond region. Initially,
there is a delay of 60 ns to start forming the catch bond as shown Fig. 15; this is because
constant-velocity pulling is used and thus the force is proportional to the time as f =
K(vt − xo). Force starts from zero and requires about 60 ns to reach about ≈ 50 pN.
In the absence of force, the Met5P side chain is always inside the molecular cage and its
tip (Cε) is far away from the plane of the binding MHC; however, as force is applied RA14
rotates and places Met5P side chain outside the molecular cage. Met5P is buried inside the
binding groove and distance, d1, decreases about 6Å in the catch region, Fig. 47 (A). The
tip is then closer to the groove plane. As the catch phase is finished the Met5P side chain
returns to its original position since RA14 is not pushing it down and RA14 is dissociating
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from the pMHC.
Simultaneously distance, d2 (Fig. 47 B), decreases once the tip is dislodged and buried
by the TCR. RA14 uses the molecular lever to lift the peptide hydrophobic core (P4 and
P6) out of the binding groove; thus the core is rapidly sucked into the molecular cage to
avoid contact with water molecules. This also increases the probability of the epitope to
be exposed and maximizes the read out by RA14. This is shown as the distance from the
Met5P Cα to inside the molecular cage decreases only in the presence of force.
Finally, the TCR pushing the lever positions together Thre8P and Asp77H and creates
an anchor point (H-bond) so that the pMHC is stable and does not release the peptide. This
interaction provides stability for the optimal engagement between RA14 and pMHC as the
peptide is being pulled by TCR. This is shown as distance, d3, (Fig. 47 C), sequentially
decreases and reaches an average of 2.6Å in the catch phase; such distance classifies the
H-bond as “strong”. The H-bond is formed between side chain atoms, Thr8P-OG1 and
Asp77H-OD2. Fig. 47 (D) shows that the H-bond is strong and stable only in the catch
region.
The forced-induced H-bonds formed between RA14 and NLV peptide ligand plotted
in Fig. 43 and Fig. 44 are visually shown in Fig. 45. Those H-bonds participate indirectly
in forming the mechanism of the molecular lever since they provide essential support to
maintain together the complex when the TCR is being pulled. They are stickum points and
without them, the TCR will dissociate when rotating.
All simulations performed using constant-velocity pulling at normal and medium ramp-
ing rate show the transition to the forced-induced state for the NLV complex. This state
is longer-lived inside the catch bond. Higher ramping rates render the complex unable to
transition to the second state; thus its dissociation from the pMHC with a footprint similar
to the crystal structure. For simulations performed using constant-force pulling, the com-
plex shifts to the new state only for forces inside the catch bond region. Outside the catch
bond phase, they present only one state that is similar to the crystal structure.
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Figure 46: Illustration of the TCR using a molecular lever to form an “in silico” catch
bond. d1 represents the distance from the tip of Met5P side chain to the plane formed
by the MHC binding groove; d2 is the distance from the backbone of Met5P to the Cα
of hydrophobic residue located inside the molecular cage; d3 is the distance between the
anchored point (Thre8P) and Asp77H. The distances are depicted as purple arrows and the
interacting residues are displayed.
4.3.12 Understanding the evolution of viral escape mutants
Mutating Met5P to Ile5P is unlikely to produce any significant effect since their side chains
have similar chemical properties; however, this is not entirely true. Functional studies
report that NLV peptide ligand is detected, while mutant M5I experiences a different faith.
M5IP peptide ligand is an escaped mutation that is not easily recognized by NLV-specific
TCRs and it also has a decreased binding affinity. T8V peptide ligand is not detected in
SPR experiments and its 2D binding affinity is higher than M5I but still lower than NLV
epitope.
If Thr8P is substituted as in the mutant T8V, the epitope will be either easily removed


























































Figure 47: Quantification of the sequential events of the molecular lever. d1 is the distance
from the tip of the side chain of Met5P to the plane formed by the MHC binding groove;
d2 is the distance from the backbone of Met5P to the Cα of hydrophobic residue located in
the molecular cage; d3 is the distance between the anchored point (Thre8P) and Asp77H.
Both Free and steered MD simulations are shown together to study their time-changing
behaviors in the absence and the presence of force. The black arrow indicates the moment
force is applied starting from 0 pN to the complex. There is a delay of 60 ns before the force
reaches about 50 pN and becomes significant to propagate through the complex and induce
changes in the docking angle and RMSD of the epitope. The catch phase is enclosed and
label. Importantly the mutants, T8V complex fails to secure the second state, while M5I
complex has the same state in the presence of force.
not lock the epitope in the second conformation for a longer period of time. This is because
Valine is unable to form H-bonds with its side chain. For smaller forces, the pMHC would
be able to hold the epitope with the another conserved residue Trp147H and an H-bond
formed with the backbone of Thr8. This interaction is present in both NLV and T8V peptide
ligands in force-free conditions and it becomes strong in the presence of force. At higher
forces beyond the critical force, both contacts are required, Asp77H and Trp147H, to resist
the increasing load.
If M5P is replaced as in the mutant M5I, Thr8P could still form an H-bond with MHC;
however, this replacement disrupts the out-of-pocket movement since the ILE is always
located inside the molecular cages whether or not the TCR rotates. Thus the rotating lever
is lost and not anchor point is formed. As the pulling force grows, it will be easy to remove
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the epitope from the binding groove. This would render eventually the pMHC unstable and
unfolding is possible. In our simulations, the MHC unfolds mostly for the mutant peptide
ligands and this suggests that it may not be an artifact from the modeling but actually a
functional escape pathway for the virus. M5I is a naturally occurring infrequent mutation
in human CMV seropositive patients [145]. Apparently, this mutation does not disrupt
the MHC class I presentation but it impairs its stability in the presence of force. This is
an intelligent mutation strategy from the virus since in the absence of force, the complex,
pMHC, is probably long-lived and stable; however, it becomes very unstable and unfolds
only when it is scanned by the TCR as it applies force. Thus M5I peptide ligand avoids
down regulating the MHC class I presentation and being targeted by the Natural Killer Cell.
The structural and molecular basis is supported by BFP experiments where NLV epi-
topes form a strong catch bond, while T8V forms a very weak catch bond. M5I does not
form catch bonds and its force profile is similar to an ideal bond. This is consistent with
the mutation impacting mostly peptide-MHC Binding stabilization but not pMHC presen-
tation [152, 153]. As soon as the complex is pulled, it dissociates the peptide from the
groove and unfolds the MHC; thus the lifetime reported in the BFP experiment is mostly
the time required to unload the epitope from the MHC binding groove; this is independent
of force since the mutant severally impacts the stability of the complex.
2D diagram plots are presented and they provide detail information about the interaction
among TCR, peptide, MHC in the absence and presence of force. Fig 48 and Fig 49 show
the interactions mediated by hydrogen bonds and by hydrophobic contacts for the force-
free and forced-induced states, respectively. Hydrogen bonds are indicated by dashed lines
between the atoms involved, while hydrophobic contacts are represented by an arc with
spokes radiating towards the ligand atoms they contact. The contacted atoms are shown
with spokes radiating back.
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Figure 48: 2D Diagram plot of the first state: The interaction between the RA14 and NLV-
HLA2 in force-free conditions. Hydrogen bonds are indicated by dashed lines between
the atoms involved, while hydrophobic contacts are represented by an arc with spokes
radiating towards the ligand atoms they contact. The contacted atoms are shown with
spokes radiating back.
Figure 49: 2D Diagram plot of the second state: The interaction between the RA14 and
NLV-HLA2 at the catch-bond phase. Hydrogen bonds are indicated by dashed lines be-
tween the atoms involved, while hydrophobic contacts are represented by an arc with
spokes radiating towards the ligand atoms they contact. The contacted atoms are shown
with spokes radiating back.
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Figure 50: Free MD simulation: The average number of H-bonds at the binding interface
between the TCR and NLV-HLA2 for different donors.
Figure 51: TCR genes shown in the table according to IMGT nomenclature. The data























Figure 52: “In silico” catch bond for different donors. Time evolution of the number of H-
bonds between TCR and NLV-pMHC in the presence of force. Catch-bond is represented
by an increased in the number of the H-bonds. It is used constant-velocity pulling. Donor
42 displays a small catch bond while donor 209 has basically a similar profile with RA14
(donor 9.1). Donor 9.2 displays also a small catch bond.
4.3.13 Structural differences of NLV-specific TCRs from different donors forming
“in silico” catch bonds when ligated to NLV-MHC
Finally, the simulations are initially compared with experiments conducted in Donor 9.
Two new donors are included to address the possibility of donor-to-donor variations. The
two donors are 42 and 209 and they are collected and provided by the Grakoui lab at Emory
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Figure 53: Structural differences of TCRs from different donors at resting phase. Interac-
tion of immunodominant CMV-TCR to NLV peptide in the absence of force for different
donors.
University, School of Medicine. The three donors are CMV seropositive and their NLV-
specific TCRs have indistinguishable 2D affinities as they are in the same log order of
magnitude. They are sequenced in the lab of Dr. David Prize at Cardiff University School
of Medicine and it is shown that Donor 9 has two T-cell populations, one expressing RA14
(called donor 9.1) and a variation (called donor 9.2). Donor 42 and 209 mostly present
one immunodominant T-cell population. Interesting the new donors possess TCRs with
similar CD3α and CD3β; however they present variation in key residues. The sequence and
populations are shown in Fig 51. Since their crystal structures are not currently available,
they are generated performing “in silico” mutations on the RA14-NLV-HLA2. The new
“in silico” complexes and their responses are compared with their respective experimental
profiles. The structures of the new donors are minimized and equilibrated for about 200 ns
and it is observed that their RMSD reaches a stable value (data not shown). For the SMD
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Figure 54: Structural differences of TCRs from different donors at catch phase. Molecular
interaction of immunodominant CMV-TCR to NLV peptide in the presence of force for
different donors.
simulations, all donor were pulled at high force for 5 to 10 ns to further drive them into low
energy states and reequilibrated for 50 ns. Those configurations are pulled at high constant
velocity and Their responses are consistent with the experiments: Donor 42 displays a small
catch bond while donor 209 has basically a similar profile with RA14 (Donor 9.1). Donor
9.2 displays also a small catch bond. The results are shown in Fig 52 and their molecular
details at the catch phase are shown in Fig 54.
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CHAPTER V
THE PRINCIPLES FOR MOLECULAR RECOGNITION OF
ANTIGENS AND ACTIVATION OF CD3 SIGNALING DOMAINS
BY THE T-CELL RECEPTOR
5.1 Abstract
The overall goal of this chapter is understanding the principles for recognition of antigens
and then the activation of CD3 signaling domains by the TCR. The first part is focused
to investigate how the information encoded in the peptide is decoded mechanically by the
TCR and what is the structural role of catch bonds. It is established the general principles
for TCR molecular recognition of antigens by studying the response of five biologically
different TCRs in the presence of force. It is demonstrated that 1) Catch bonds are required
to effectively recognize epitopes; 2)TCR musts rotates around the binding axes to form “in
silico” catch bonds and induce functional conformational states of the peptide. The second
part of this chapter is to study how TCRs uses mechanical forces to determine whether or
not the presented antigen is a threat. The focus is to identify how information read from
the TCR distal-membrane binding site is propagated to the CD3 signaling domains. It is
proposed the peptide-decoding process and intracellular signaling are connected by con-
formational changes traveling across the TCR and it is described the unique features of this
mechanism. The model shows that the TCRs are deformable proteins that can experience
large conformational changes and they use mechanical forces to modulate their conforma-
tions. The ability of TCRs to deform without releasing the peptide ligands is the key to
understand this complex mechanism. Finally, it is unveiled that TCRs uses their Cβ FG
loop as a molecular mechanism to propagate information and connect the CD3 signaling
domains. This is accomplished by changing the conformational states of Cβ FG loop.
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5.2 Background
There are continually strong demands in understanding the principles for molecular recog-
nition of antigens and activation of CD3 signaling domains by the T-Cell receptor because
of their broad implications in immunology and the benefits in cancer immunotherapy. Ow-
ing to the progress of nanobiotechnology, scientists have investigated the functional and
mechanical properties of the TCR at the level of single molecules and a plethora of infor-
mation was collected; however, the studies appear to be disconnected or even contradicting
one from another.
The first part is focused on establishing the principles for molecular recognition of anti-
gens by the T-Cell Receptor. Previously it is shown that RA14 must rotate around the
binding site in order to produce an “in silico” catch bond and this is associated with the
TCR functionally switching to a “forced-induced state”. Interesting, RA14 ligated with
NLV-HLA2 also forms experimentally a catch bond. This poses the following question for
antigen recognition of TCRs interacting with peptide ligands: 1) Are rotating and changing
conformations (for the peptide and the complex) intrinsic properties of TCRs? Or is it a
particular property for RA14?; 2) Are catch bonds required to effectively recognize epi-
topes? To address this question, the response of five different TCRs are investigated in the
presence of force using similar pulling protocols as the previous chapter. Importantly, the
chosen TCRs are completely different biologically from one another and their functionality
has been recorded experimentally. This part systematically investigates and tests the rules
for molecular recognition.
Antigen processing and presentation by MHC molecules was extensively studied; how-
ever, how TCR recognizes peptides and then activates the signaling machinery is not under-
stood. This question has puzzled immunologist for decades. Understanding if there exists a
preconceived traveling pathway, that is genetically encoded in the TCR genes, to propagate
information read from the TCR distal-membrane binding site to the CD3 signaling do-
mains is considered the holy grail of molecular immunology. Multiple competing models
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have been proposed with no clear answer; many of them contradict each other, despite all
models being supported by experimental evidence. Is it possible for a molecule to have ap-
parently multiple mechanisms to accomplish the same task? The second part describes the
molecular mechanism of how this process is accomplished. It is proposed that the decoding
process and intracellular signaling are connected by conformational changes in the TCR,
and a unifying model is presented and its unique features are described to solve this puzzle.
The model is consistent with all experimental observations up to date. The TCR interac-
tions with either or both of the pMHC and CD3 are hardwired on their structural dynamics
and not in their static structure. The TCRs are not rigid entities, as currently thought, but
they are deformable proteins and mechanical forces modulate their local and global con-
formations. Yes, TCRs could potentially experience large conformational changes that are
functional. The ability of TCRs to deform without releasing the pMHCs and to transform a
linear force into functional conformational changes are the key to understand this complex
mechanism. Finally, it is unveiled the molecular mechanism used by the TCR to open and
close its Cβ FG loop. This functional mechanism highlights the important role of the Cβ
FG loop in activating the CD3 signaling machinery.
It is suggested that TCRs mediate sequentially recognition and activation by connecting
their dimeric αβ chains with CD3 εγ, CD3 εδ, and CD3 ζζ subunits using an “unknown
mechanism”. The Cβ FG loop in TCRs is regarded as very important in this process since
its removal severely affects T cell activation and development. For instance, Cβ FG-loop
deleted T cells manifest reduced proliferation and cytokine production abilities upon T cell
stimulation and dramatically impaired negative selection. Therefore, it has been long asked
how recognition of peptide ligands by TCRs evoke activity on T cells since TCR antigen-
specific binding site is located at least 40 Å away from the Cβ FG loop and the overhead
of CD3 subunits. There must exist a structural mechanism that propagates information,
presented at the TCR binding site, to the CD3 complex. This traveling pathway, if exists,
is still a mystery.
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In general, scientists have attempted to understand the TCR interactions by character-
izing their thermodynamic properties, affinity measurements, protein crystallization, and
single-molecule force spectroscopy, with no much success. The problem with not captur-
ing the deformable states of TCRs on those experiments, especially in crystallography, is
that determining their 3D structure is a delicate and complex task where multiple techniques
are required to produce proteins with increased crystallization propensity such as molecular
cloning, recombinant protein expression, and mutagenesis. In addition, the structure of pro-
teins dynamically switches between different functional states and it is altered/modulated
by their ligand under very specific conditions. Those conditions are not easily achieved in
protein crystallization and prevent scientists to capture them in their physiological condi-
tion. Thus they obtain structures that do not usually represent the functional state of the
protein but rather an ensemble of many states. On the other hand, MD simulation is a
powerful technique to explore and observe conformational changes in proteins. MD sim-
ulations can access rare states by employing sampling methods to cross the barrier and
increase the probability for a protein to transition to a different state.
It is also believed that the specific binding orientation and interaction of the TCR
complementary-determining regions (CDRs) with the peptide loaded onto MHC molecule
are the basis of immune recognition. It is still debatable whether the CDR amino acid con-
tacts have co-evolved and thus are germline encoded to govern the TCR-MHC restriction or
the MHC bias is externally imposed on the TCR during thymic selection by co-receptors.
Structural analysis of TCR-pMHC crystals supports a model of physical specificity be-
tween the germline CDR regions and MHC. Other suggest that co-receptors mediating the
thymic selection are responsible for the MHC bias since TCRs can robustly engage non-
MHC ligands when given the chance; thus TCR repertoire is not innately specific for MHC
but instead is subject to externally imposed influences. This proposed a different role for co-
receptors in which they directly influence TCR recognition of pMHC. Nevertheless, what
governs TCR specificity and sensitivity are not understood and they may be also related
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to the ability of TCRs to form catch bonds. For instance, it is difficult to assess if a given
epitope is able to activate the T cells by reading the affinities. This is the case especially
when its binding affinities are not at the end of the spectrum for T cells, very high (1µM) or
very low (100µM). A better predictor to measure the strength of TCR-pMHC interaction is
the bond lifetime measured under forces. If a TCR forms a catch bond, it will activate the
T cell. Conversely, if a T cell forms a slip bond it may produce a reduced activity. In this
case, catch bonds can be useful for assessing functionality. However, the mechanisms of
how TCRs employ catch bonds for molecular recognition of antigens and activation of CD3
signaling domains is not established. Thus this chapter dissects the role of catch bonds in
recognition of antigen and activation of signaling machinery by the TCR.
In molecular immunology, there are still many unanswered questions concerning the
structural dynamics of TCRs such: Does a naive TCR have a similar structure to a mem-
ory TCR? How does the structural landscape of the pMHC binding site define the TCR
repertoire and subsequently its effector function? How a public TCR respond differentiate
from a private TCR? In addition, it is still under debate what quantity best defines a func-
tional binding between TCR and pMHC and what role it has in the T-cell response. The
TCR-pMHC are also likely to form parallel bonds instead of serial at the binding interface;
however, the effect of bonds in parallel on the T-cell responses are still not fully studied;
How close do bonds have to be before they can be lumped together or treated separately?
There is no doubt that structure defines function and influences the TCR biology as it
was found that the structural accessibility of a pMHC binding surface dramatically influ-
ences not only the antigen-specific T-cell response but also biases the expressing profiles
of TCR that are selected from a diverse, naive repertoire during infection, transplantation,
autoimmunity, or hypersensitivity. These support the view that TCR functional response is
mechanically-regulated for immune recognition and activation. Here simulations are used
to molecularly manipulate the TCR conformational changes with position and force reso-
lutions on the order of Å and pN, respectively and understand its functional conformational
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Table 1: Summary of TCRs used in this chapter with their respective recorded experi-
mental data. The TCRs are completely different biologically. Simulation time refers to all
combined simulation performed per TCR in this study. Most simulations are carried out
using RA14 and 1E6. C7, C25, and 2C are used for comparison. M5I∗ forms an ideal bond
experimentally. Ligands∗∗ can be considered very weak agonist or antagonist. † represents
unpublished experiments conducted in the Zhu lab. Not determined or not detected are
abbreviated as n.d.
TCR RA14 1E6 C7 C25 2C
Species Homo Sapiens Homo Sapiens Homo Sapiens Homo Sapiens Transgenic mice
Type Viral Autoimmune Viral Viral Alloreactive
Specific for/




RQFA, RQFI NLV NLV SIYR
Crystal
structure Yes Yes Yes Yes Yes
Affinity Medium High High High High






MVW∗∗, YLG∗∗ n.d. n.d. Many
Crystal
structure No Yes n.d. n.d. Yes
Affinity n.d. Very low n.d. n.d. Medium
Bond type Catch and slip† Slip† n.d. n.d. Slip
Reference [21] [97, 98] [85] [85] [155, 156]
Simulation
Time (µs) 12.0 20.0 1.0 1.0 1.0
changes. This methodology is novel because it is a bottom-up approach that builds from a
molecular perspective and it provides insight into the dynamics of TCR and how its con-
formations modify its specificity and activity. These ideas have not been entirely explored
in experiments due to an inability to characterize high molecular vibrations.
5.3 Results and Discussion
In this section, the general rules for molecular recognition of antigens and activation of
CD3 signaling domains by the TCR are outlined. The observations obtained in the pre-
vious chapter are verified if they are generally applicable to most TCRs forming “catch
bonds”. In this chapter, it is used MD, steered MD, targeted MD simulations (proposed
as an artificial-ligand protocol), “in silico” mutations, and computationally deleting TCR
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loops to systematically understand the dynamics and conformational change in TCRs.
For a few decades of intensive study of the TCR biology, the factors that enable produc-
tive signaling upon a TCR binding to a pMHC still remain elusive and to fully understand
this critical process requires the systematic study of TCR conformational changes as a
mechanosensor and how they interact (bind) with CD3 signaling domains. To solve this
puzzle, it is important to understand that under physiological conditions, protein structures
are not static but they do change dynamically and access an ensemble of conformations
that have significantly narrower distribution compared to random colloids. This is different
from the traditional view that proteins have a native state or unique structure genetically
encoded by their amino acid sequence; but rather the native state– observed in the crystal–
is an ensemble of microstates. The microstates share the same overall folding and 3D struc-
ture but differ in their molecular details such as different lengths in bond and angles that
could significantly impact their local loop conformations, domain packing, or even entire
domain orientations. The ability of proteins to deform their native state is important to
properly and biologically function. The “jigglings and wigglings” of atoms in a protein
enable the access of structural conformers that potentially could have different functional
states. The “jigglings and wigglings” are not only related locally but they are long-range
vibrations that involve interdependence and correlated motion of atoms throughout the en-
tire protein. Disrupting the long-range vibration and breaking the interdependence may
render the protein functionally obsolete or provide a pathway for “remote” control to either
enhance or inhibit the physiological function.
It is shown that the RA14– an NLV-specific TCR– must rotate around its binding axes
in order to form new H-bonds and produce an “in silico” catch bond; the rotation is also
associated with the epitope changing to a “forced-induced state”. These are observed either
the complex was pulled at “constant velocity” or “constant-force”. This suggests that,
for molecular recognition and activation, rotating around the binding axis and generate
new states for the entire complex is an intrinsic property for all TCR ligated to cognate
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pMHC. To address this question, the response of RA14 [21] and 4 new different TCRs:
C25 [85], C7 [85], 2C [155], and 1E6 [97, 98], are individually investigated in the presence
of force using similar pulling protocols. Similarly to RA14, C7 and C25 are human TCRs
specific for HCMV viral infections and they recognize the NLV epitope. RA14 and C25 are
public TCRs used to study clonal diversity. NLV-specific TCRs are notorious for being very
diverse and immunodominant after infection, shaping the TCR repertoire and producing
public T cell responses. 2C is an alloreactive TCR in transgenic mice capable of binding
self and foreign peptide. It recognizes the superagonist peptide, SIYR, loaded into H-
2Kb and it is responsible for causing a peptide-induced fatal syndrome (PIFS) mediated by
CD8+ T cells in naïve 2C transgenic mice. 1E6 is an autoimmune TCR specific for human
type I diabetes that recognizes the preproinsulin peptide (ALW) and it is responsible for
for the killing of human beta cells. 1E6 TCR is also able to recognize more than a million
different peptides and here it is included to study multi-ligand discrimination by a single
TCR. Importantly these TCRs are completely different from each other biologically and
their functionality has been documented experimentally and they are summarized in table 1.
5.3.1 C7, C25, 2C, and 1E6 TCRs are capable of forming “in silico” catch bonds
In this section, the biophysical property of C7, C25, 2C, and 1E6 TCRs are studied. These
TCRs have been verified experimentally to either form catch bonds and inducing early
T cell activation (RA14, 1E6, 2C), or to have higher 3D affinities (C7, C25) compared
to most TCRs and are closed to the higher end of the affinity spectrum. 1E6 TCR also
is capable of forming experimentally slip and catch bonds with weak and strong ligands,
respectively. See table 1 for a complete summary. Fig. 55 illustrates the time evolution of
the total number of H-bonds between the TCR interacting with a pMHC for C25, C7, and
2C. The TCR-pMHC complexes are undergoing a “constant-velocity pulling”. In human
C25 and C7 TCRs and mouse 2C TCR, the total number of H-bonds increases at the TCR-
pMHC binding interface as an applied force at the proteins’ C-terminal, is simultaneously
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growing; and thus forming an in silico catch bond. Then it transitions to slip bond since the
applied force becomes big enough to overpower the H-bonds at the binding interface. The
figure. 55 also shows the average number of H-bonds in free MD simulations for the C25,
C7, 2C and 1E6 TCRs; This information is used later to compared with SMD simulations.
A longstanding question in TCR signaling is how structurally similar ligands that have
similar (2D or 3D) affinities, can have different biological functionality and activity. The
crystal structures of 1E6 TCR bound to a panel of ligands ranging from antagonist to strong
agonist are used to study how the rules for molecular recognition and activation are affected
by the ligand potency. 1E6 TCR is interacting with HLA-A*0201 loaded with a preproin-
sulin peptide (ALW) and 7 altered peptides–MVW, YLG, AQW, RQF(A), RQF(I), RQW,
and YQF. The epitopes differ only by a single amino-acid substitution. The experimental
benchmark is that recognition of ALW peptide by 1E6 autoreactive TCR induces the killing
of human islet beta cells in type 1 diabetes. MVW and YLG have a lower 2D affinity
compared to ALW and require substantially higher peptide concentration than physiolog-
ical conditions to induce T cell killing. RQF(A), RQF(I), RQW, and YQF epitopes have
a higher 2D affinity and induce T cell activation and killing from low to normal peptide
concentration.
Fig. 56 shows the total number of H-bonds vs time at the TCR-pMHC binding interface
for the peptide ligands. Note that the applied force is proportional to the time, f = k(vt −
xo). ALW, MVW, and YLG epitopes display an in silico slip bond where the average
number of H-bond decreases as the force increases with the peaks at their H-bond profile
decreasing in that order, respectively. RQF(A), RQF(I), RQW, and YQF have a catch
bond and their prominence (height and duration) is proportional to the experimental peptide
potency. AQW is roughly showing a very small catch bond or ideal bond– where the
number of H-bonds is independent of force. AQW is considered here the phase-transition
epitope between switching the complex from slip to catch bonds or vice versa. The phase
transition also separates functionality, epitopes forming strong catch bonds have higher
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affinities and are effective inducing the killing of cells, while the ones having slip bonds































































































1E6−TCR Free MD Simulations
Figure 55: “In silico” catch bonds of C7, C25, 2C interacting with cognate peptide ligands.
The number of H-bonds between TCR and pMHC is plotted over time for C7 (A), C25 (B),
2C (C). The TCRs are interacting with their respective agonist epitopes. The “in silico”
catch bond is represented by a total increase in the number of the H-bonds at the binding
interface. (D) and (E) represent the total number of H-bonds at the binding interface in the
absence of force (free MD simulation), for the C7, C25, and 2C (D) and 1E6 interacting
with a panel of peptide ligands ranging from antagonist (MVW, YLG), weak agonist (ALW,
AQW) and strong agonist (RQW, RQFI, RQFA, YQF).
In summary, before entering the catch-bond phase, at zero and small forces, the TCR-
pMHC complex stochastically fluctuates around the initial native structure. In the catch-
bond phase, the TCR-pMHC moves to other intermediate states (with higher energy) and it
starts diffusing slowly along the axis not parallel to the pulling direction. This result in high
mechanical stability that allows the complex to cross any high energy barrier. Increasing
the ramping rates makes the stochastic fluctuations of the TCR-pMHC along the pulling
axis to be irrelevant and the dissociation pathway becomes deterministic. This is because






































































Figure 56: Time evolution of the number of H-bonds between 1E6 TCR interacting with
a panel of peptide ligands ranging from antagonist (MVW, YLG), weak agonist (ALW,
AQW) and strong agonist (RQW, RQFI, RQFA, YQF). Clearly the strong agonist form
an “In silico” catch bonds. The weak agonists display a slip or ideal bond. Ideal bond is
when the lifetime is independent of force. The catch bond potency, height, and duration are
proportional to the experimental peptide potency.
5.3.2 Inside the catch-bond phase, TCRs start rotating with a polarity around the
binding axes defined by the right-hand rule.
Previously it was shown that RA14 TCR changes its docking orientation by gyrating around
the binding axes to form a catch bond. C7 and C25 TCRs dynamically gyrate around the
binding axes to form a in silico catch bond and thus experience a transitional change in the
docking orientation. For instance, C25 increases while C7 decreases their docking angle.
There is a subtle swing in the angle of C25 without breaking any H-bond. It is because the
C25 interaction with the pMHC is centrally focused where most of the contacts are located
around Met5P. This provides a small freedom of rotation while still forming H-bonds.
Nevertheless, the C25 TCR is always moving to and staying in the active conformation. For
both TCRs, the angles change about 20o. 2C TCR also has this common feature of rotating
and increasing the number of H-bonds at the binding interface. Although 2C TCR displays
a relatively small change in the docking angle (≈ 7o), it is statistically significant based on
their normal distribution of both states and the p-value < 10−16 reported by a Welch two
105
sample t-test (data not shown). This is consistent with 2C having a higher affinity to the
super agonist peptide. Unfortunately only 2C TCR forms a stable docking angle; however,
C7, C25, and 2C are dynamically trying to gyrate counter-clockwise around the binding
axes, see Fig. 57.
For the 1E6 TCR, MVW and YLG epitopes display an in silico slip bond. They do
not attain a well-defined docking angle; they are changing over time; and they dissociate
fast before the complex reaches any stable state; thus, a docking angle cannot be clearly
identified. Dissociation occurs first probably because they have a very low affinity, see
Fig. 58(A, B).
ALW has a weak affinity but it is high compared to MVW and YLG. It initially de-
creases its angle in a stepwise manner and reaches a stable state and stays in this state for
most of the simulation. Finally, it then attempts to return to its initial value before dissocia-
tion occurs. AQW has only one stable state in the whole simulation; however, at the end, it
abruptly increases its docking angle and then shortly deattaches from the complex. AQW
is the phase transition peptide, see Fig. 58(C, D).
RQF(A), RQF(I), RQW, YQF show clearly well-defined transitional states for the dock-
ing angle where the change is bigger (≈ 30o) and significant compared to the other peptides.
RQW apparently is dynamically trying to increase its docking orientation to a higher value,
displaying cyclic changes in its angle. The states are also longer-lived. The complex gyrate
counter-clockwise around the binding axes around the catch bond phase, see Fig. 58(E, F,
G, H).
Interesting, the large transition in the angle corresponds to changes in the # of H-bonds
at the binding interface for the peptide ligands. all TCR-pMHC complexes are free to
rotate in any direction around the binding axis in free MD. However, when the complex is
inside the catch bond phase for agonist, or around dissociation for weak ligands, all TCRs
apparently start rotating around the binding axis with a defined “polarity”. The direction
is defined by positioning the thumb of the right-hand along the TCR’s largest principal
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axis and pointing to its membrane-distal binding site; then rotation is defined by curling
the other fingers. This is a counter-clockwise rotation around the TCR main axis. This
is apparently an intrinsic property of the TCRs since all simulations display this behavior.
Changing the docking orientation in step and attaining stable angles is not observed on
those TCRs with the exception of 2C. 2C behaves in a similar fashion as described for




































Figure 57: The docking orientation around the binding site for the C7, C25, and 2C TCRs
interacting with their respective agonist pMHC in the presence of force. Only 2C forms
a stable docking angle; C7 and C25 are dynamically trying to gyrate counter-clockwise






























































































Figure 58: The docking orientation around the binding site for 1E6 TCR interacting with
a panel of ligands classified as antagonists (MVW, YLG), weak agonists (ALW, AQW)
and strong agonists (RQW, RQFI, RQFA, YQF) in the presence of force. MVW and YLG
complexes do not attain a well-defined docking angle; the agonist complex displays mul-
tiple longer-lived stays. Apparently weak- and strong-agonist complexes gyrate counter-
clockwise around the binding axes either around or after passing the catch bond phase or
critical force.
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Potentially the TCR dynamically rotating could be biologically functional and a pos-
sible explanation is that potent epitopes amalgamate the TCR with pMHC and allow the
propagation of force by converting the linear load to angular torque, twisting the TCR in a
specific polarity and producing conformational changes. This is supported by the fact that
the TCR’s structure is very asymmetric with respect to a fragment antigen-binding (Fab);
the TCR Cα and Cβ domains are not attached similarly as the ones in the Fab. They are
connected asymmetrically exposing residues in the interface of the β-sheet of the Cβ that
are buried in the Fab. The asymmetry also impacts the buried surface area between Vβ and
Cβ domains which are higher than the Fabs and probably they are stabilized by the Cβ FG
loop. Note that Fab has almost identical 3D structure compared to the TCR.
5.3.3 TCRs rotating around the binding axis induce functional conformational states
in the peptide
In the previous chapter, it is observed that in order to form a catch bond, not only RA14
needs to rotate and change its docking angle but also the peptide obtains a stable con-
formational state. This is clearly observed in the RMSD of the epitopes interacting with
human C25 and C7, 1E6 TCRs, and mouse 2C TCR. Fig. 59 and 60 shows that the pep-
tides forming catch bonds have at least two states and the transition from the initial inactive
(off) to active (on) states occurs in a stepwise fashion. The forced-induced conformation
is long-lived, well-defined, and stable; it is apparently optimal for forming new H-bonds
at the binding interface; and the peptide remains in the “on” state inasmuch as the com-
plex is forming a catch bond. Importantly the number of long-lived states increases with
the potency of the epitope. This suggests that: First, multiple-state epitopes permit an easy
scanning by the TCR and enhance their engagement and these epitopes move in the antigen-
binding groove and increase the probability of interacting with the TCR CDRs. Second,
not only mobility is necessary for a successful engagement, but also the TCR CDR3 loops
have to be mobile and vibrate at the same frequency of the peptide. Third, after a successful
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engagement, force modulate the flexibility of the epitope, docking the TCR-pMHC com-
plex into a stable angle, and the epitope becomes rigid at catch bond phase or critical force.
This increases the adhesion of the complex.
Conversely epitopes forming slip bonds (MVW, YLG, ALW, T8V, M5I) have either one
state or they initially try to achieve a second state; however, they are unstable and unable
to sustain this conformation for a longer period of time. Thus, it unsuccessfully returns
back to its original state and continuously moves randomly until it dissociates from the
TCR. The phase transition peptide, AQW, has multiple states that initially display smaller
fluctuations and its conformation finally reaches a long-lived state. It is possible to consider
those states as a single one since they have a small deviation in their RMSD; this suggests
that their structural difference is probably insignificant (also p-value > 0.05).
As a summary potent peptides are mobile and malleable; thus their conformation can
be modulated when the TCR is reading out the peptide ligands. Mobility and malleability
are high at the initial binding; however, they are reduced when the epitope is progressing
to the active state and it is docked into a rigid conformation. This would only occur if it










































Figure 59: The RMSD of each peptide for C7, C25, and 2C TCR interacting with their
agonist pMHC in the presence of force. The TCRs modulate the peptide conformation; it
is shown by multiple states in the RMSD.
5.3.4 TCRs forming catch bonds experience the opening and closing of their Cβ FG
loop
Pulling the TCR ligated with pMHC from the C-terminus “allosterically” regulate the con-
formations of the Cβ FG loop while the pMHC C-terminal is constrained in this process.






















































































































Figure 60: The RMSD of 1E6 interacting with a panel of peptides in the presence of
force. Epitopes forming catch bonds have at least two states and the transition from the
initial inactive (off) to active (on) states occurs in a stepwise fashion. For potent epitopes
Mobility and malleability are high at the initial binding; however, they are reduced when
the epitope is docked into a rigid state if it formed dynamically a good match for the TCR.
loop is a string comprised from Leu219β to Pro232β that is extending from the body of the
β chain. The Cβ FG loop is a solvent-exposed, highly-charged 14-residue insertion at the
β-chain constant domain and situated alongside the chain. In humans, the Cβ FG loop has
a distinctive charge distribution: 2 glutamate, 2 aspartate, 1 arginine, and 1 lysine residues,
while mice, it has: 3 glutamate, 1 aspartate, and 2 lysine residues. In both cases, the FG
loops are negatively charged and protruding from the elbow region of the TCR β chain.
Residues Leu219, Asp223, Trp225, Lys231, and Pro232 are highly conserved in human
and mouse while the reminding ones are relatively shared among multiple species. Fig. 4
shows the overall location of the Cβ FG loop (A), its atomic details(B) and the common
residues shared among species. What is intriguing from the structure of human TCRs, is
that the Cβ FG loop is well-structured having its charged residues spatially arranged so that
all negative are facing away while positively charged are facing inward the center of the
loop; they are also separated by charged and cluster at each FG loop end. Lys229β interacts
with the backbone of Asp223β, while Trp225β and Pro232β form strong hydrophobic inter-
actions with β chain. This forms and provides a rigid frame for the Cβ FG loop as observed
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in the crystal structure and here it is termed as the “neutral” conformer (Fig. 71 A). The
neutral state is also very stable and rigid in free MD simulations (data not shown).
5.3.5 The forced-induced states of the Cβ FG loop at the catch phase
In the presence of force, the Cβ FG loop undergoes conformational changes indicated by
first deforming and becoming flexible, then emigrating away from the Vβ-Cβ interface.
The Cβ FG loop then comes to a “down” or “open” conformation (Fig. 61 B) after moving
downward from the elbow region at this point. Subsequently, it returns back to the “neutral”
state to further advance and become very close to the Vβ domain. This is termed the “up” or
“closed” conformer (Fig. 61 C). All conformational states of the Cβ FG loop are displayed
on Fig. 61. Close and open states are quantified by measuring the RMSD using the neutral
conformation as a reference. RMSD measures the average displacement of the atoms of
the Cβ FG loop after optimal superposition. An RMSD of ≈ 3Å and ≈ 5Å correspond to
a closed and open Cβ FG loop, respectively. Importantly the presence of force fosters the
transition between conformations of the Cβ FG loop.
Fig. 62 and Fig. 62 show correlation between the opening of the Cβ FG Loop and the
occurrence of the catch-bond at constant-velocity and constant-force pulling, respectively,
for the RA14 ligated with agonist NLV-HLA2. The Cβ FG loop always remains in the
closed conformation in Free MD simulations or when the pulling force is small. There
exists a positive correlation between the opening of the Cβ FG Loop and the rise of a
computational catch-bond– represented by an increase in the number of H-bonds between
the TCR and the pMHC. In both simulations are observed that the Cβ FG Loop transitions
only to the open state; it also experiences three cyclic transitions between “neutral” to
“open” conformation inside the catch-bond phase; finally the complex dissociates before
the Cβ FG Loop reaches the closed state. Apparently, the opening is a reversible process
since the Cβ FG Loop returns to the neutral conformer once the TCR is detached from the
peptide ligand.
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Figure 61: Illustration of the Cβ FG loop states in the presence of force. The Cβ FG loop is
colored in green. The MHC is loaded with an agonist RQFI peptide. (A) shows the neutral
state, this is common at the beginning of SMD simulation where force is little. (B) show
an “open” or “down” FG loop, the simulation is at the “in silico” catch-bond phase, where
force is moderate and the number of H-bonds is at the peak. The FG loop is “closed” or
“up”around or right before dissociation from pMHC only for potent epitopes as shown in
(C). This state is only achieved by strong agonist peptides.
5.3.6 Quantification of the states of the Cβ FG loop of C7, C25, 2C, and 1E6 TCRs
forming “in silico” catch bonds
All complexes in Fig. 64 undergo constant-velocity pulling and force starts from 0 pN.
C7 and C25 TCR initially opens the Cβ FG loop as indicated by an increase in the RSMD,
Fig. 64 (A, B). C25 shows cyclic transitions between open and neutral conformation. There
are a total of five cycles, three is long-lived while two are short-lived. C7 has only two
long-lived open states. Although C7 experiences smaller deformation at the end of the
simulation, both TCRs converge to the closed conformer and settle to this state; C25 expe-
riences the largest deformation as compared to C7. Nevertheless, before dissociation and
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Figure 62: Correlation between the
opening of the Cβ FG Loop and the oc-
currence of the catch-bond. (A) shows
the total number of H-bonds between the
TCR and pMHC in the presence of force.
(B) shows the RSMD of the Cβ FG loop.
The increase in the RMSD from 1.8 to
3.5Å correspond to the “opening” of the



































Figure 63: Correlation between the
opening of the Cβ FG Loop and the oc-
currence of the catch-bond. (A) shows
the total number of H-bonds between the
TCR and pMHC in the presence of force.
(B) shows the RSMD of the Cβ FG loop.
The increase in the RMSD from 1.8 to
3.5Å correspond to the “opening” of the
Cβ FG loop. The complex underwent a
constant-force pulling.
simulation.
2C TCR also experiences deformation in the Cβ FG loop and initially opens it; how-
ever, after this initial transition, it starts moving to the closed conformation as shown by
the monotonically increase in the RMSD (Fig. 64 C). In the simulation, the Cβ FG loop
only experiences larger deformations that lead to its closing; however, it is not clear what
prevented its complete opening and its cyclic transitions. It is observed that Lys11β residue
initially forms a strong H-bond with Asp223β and at the closed conformation, the Cβ FG
Loop forms multiple H-bonds (≈ 3 to 4) with residues located in the first strand at the Vβ
domain, before 2C dissociates from the complex. The H-bonds form strong interactions
as they are arranged into a β sheet in the closed state. See Fig. 65 and read the caption
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for details. Note that the 2C is a transgenic mouse TCR that shares only key residues with
human TCRs; thus they are not easily compared.
In Fig. 64(D, E, F), the 1E6 TCR is interacting with a panel of peptide ligands, and it
is observed that all ligands from weak (D) to strong (E and F) agonists are able to induce
the opening of the Cβ FG Loop as indicated by the increase in their RMSD ( ≈3Å). Weak
agonists do not display cyclic transitions between states. They only switch one time from
neutral to open; however, it is a long-lived state, (Fig. 64 D). All strong agonists wave the
TCR Cβ FG Loop (neutral to open) from two to five times (Fig. 64 E, F). In addition, at the
end of the simulation, all strong agonist switched to closed conformer before exiting the
catch-bond phase and dissociating from the peptide ligand. This is quantified by the large
increase in the RMSD. The strongest agonist (YQF and RQFA) undergo larger deformation
than others, RQW and RQFI complexes. Apparently, they are proportional to the peptide
potency. Antagonist YLG is also able to open the Cβ FG Loop; however, it is a very short-
lived state since it occurs when it is dissociating from the pMHC. Antagonist MVW does
not induce any substantial deformation of the loop.
In summary, for potent peptide ligands, there is a positive correlation between the defor-
mation of the Cβ FG Loop and the appearance of a catch-bond. Force fosters the transition
between states of the Cβ FG loop only when the number of H-bonds increases at the bind-
ing interface of TCR-pMHC. The transition between neutral to open only occurs inside the
catch-bond region. First, the open state happens and it is then followed by the closed state.
The closed conformer usually appears at the end of the simulation, after passing the critical
force and when the complex is exiting the catch phase. Potent peptide ligands also gener-
ate more cyclic transitions to finally achieve the closing of the FG loop, and it experiences

































































































Figure 64: Time evolution of the RMSD of the Cβ FG loop of C7(A), C25(B), 2C(C) TCRs
interacting with their agonist epitopes in the presence of force. (D), (E), and (F) display
the RMSD of the Cβ FG loop of 1E6 TCR interacting with a panel of ligands classified as
antagonists (MVW, YLG), weak agonists (ALW, AQW) and strong agonists (RQW, RQFI,
RQFA, YQF). All epitopes with the exception of MVW and YLG are capable inducing the
opening of the Cβ FG loop, represented by changing their RMSD to ≈3Å. The deformation
and duration of the state depended on the epitope potency. Only TCR interacting with po-
tent epitopes transition the state of their Cβ FG loop to the closed conformer; 1E6 complex
with RQW, RQFI, RQFA, YQF and C25 and 2C complexed with their respective agonist

















2C TCR Cβ FG loop
Figure 65: Forced-induced H-bonds between the Cβ FG loop and the Vβ domain for the
2C TCR. They initially form a strong H-bond between Lys11β and Asp223β, not present in
the crystal structure. When the FG loop switches to the closed conformation, the H-bond
is replaced by 4 other H-bonds: Lys 224 forms 2 H-bonds with Asn10 and Val12; Asn10
forms one with Asp223; and Arg9 forms one with Glu222. (A) Show the total number of
H-bonds between the Cβ FG loop and the Vβ domain over simulation time. (B) and (C)
depict those interactions in open and closed conformation.
5.3.7 Quantification of the states of RA14 Cβ FG loop forming an “in silico” catch
bond
In the chapter 4, it is studied the force response of RA14 complexed with, antagonist (M5I),
weak agonist(T8V) and agonist (NLV) peptide ligands under different conditions. The ini-
tial configuration (IC) is varied using different ramping rate with constant-velocity pulling
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on those ligands. The ramping rates are defined as normal, medium, and high. A total of
8.9 µs of simulation is generated. The focus here is to evaluate the conformational changes
induced by the presence of force in the Cβ FG loop in these simulations. Fig. 66 shows
the SMD simulations using constant-velocity pulling for RA14 interacting with its peptide
ligands, and they are ordered in columns and colored as NLV (red), T8V (green), and M5I
(blue) complexes. The varying parameter is indicated on the label of the Figures, for in-
stance: SMD1 and SMD3 represent the simulation using the IC1 and IC2; KV represents
the simulation changing the ramping rate from normal to high.
In Fig. 66, NLV complexes (red curves) show that the Cβ FG loop undergoes defor-
mation and cyclic transitioning from neutral to open for all IC pulled independently at the
normal ramping rate (Fig. 66 A, D, G). They oscillate between neutral and open from three
to five times and these states are long-lived. For T8V complexes (green curves) pulled at
normal ramping rate (Fig. 66 B, D, H) are observed that although the Cβ FG loop experi-
ences deformations, it does not completely transition to the open conformer; whenever it
is increasing the RMSD, it returns to the base level. The deformation is also periodically
occurring. For M5I complexes (blue curves) show that the Cβ FG loop is opened once
(Fig. 66 C, F, I); however, this happens at the expenses of unfolding the MHC α3 domain.
At the same time, it was also unable to switch to open and also unfolding happens in the
simulations. Nevertheless, deformations are also observed for the M5I complexes.
In summary, the dependence of the state of the Cβ FG loop on the ramping rate is dis-
played in Fig. 66 (J, K, L, M, N, O). It is shown that increasing the ramping rate attenuates
the catch-bond by decreases its total number of H-bond and its duration. This is trans-
lated into a rapid dissociation of the complex and less force is being propagated to induce
considerable deformation of the Cβ FG loop. For instance, the NLV complex is still experi-
encing small cyclic deformations at the medium ramping rate, Fig. 66 (J); this is drastically
reduced at higher pulling as seen in Fig. 66 (M). Similarly for T8V and M5I complexes
shown in Fig. 66 (K, N, L, O), respectively; increasing the ramping rate renders the peptide
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ligands unable to induce any detectable deformation in the Cβ FG loop. It also appears that
all peptide ligands ranging from weak to strong agonist may initially induce the deforma-
tion of the FG loop and open it to a certain degree when pulled at a normal ramping rate;
however, antagonist or weak agonist is not capable of inducing the closed state. It is clear
that the high ramping rate renders the peptide ligands unable to produce conformational
changes in the FG loop. This is because force starts building up rapidly at the interface
and it does not allow the complex to rearrange and sustain the force, then any transition
(or state) is diminished and only the neutral state is most dominant. This similar to making



























































































































































































































Figure 66: Time evolution of the RMSD of the Cβ FG loop of RA14 TCR interacting
with peptide agonist NLV (A), mutant weak agonist T8V (B), and antagonist M5I (C) in
the presence of force using different simulating parameters. Three different IC and three
varying ramping rates (normal, medium and high) are employed. The peptide ligands are
ordered in columns and have a color coding of red for NLV, green for T8V, and blue for
M5I. The changing parameter is indicated on the label of the Figures.
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It is also varied the SMD protocol by pulling the RA14-NLV-HLA2 using constant-
force. Of note, this part is conducted only in the NLV complex because simulating the
mutants is computationally demanding. Six constant forces are employed varying from 0
(free MD) to 200 pN. At zero force (free MD, data not shown), deformation is not observed
in the Cβ FG loop at the nanosecond scale. As force is increased to 25 pN, three short-lived
open states are observed; importantly they appear to be unstable and the states return back
to the neutral configuration at this level of force, Fig. 67 (A). As force is increased to 50 pN
(Fig. 67 B), at the beginning of the simulation, there starts appearing two distinguishable
short-lived deformations of the Cβ FG loop and it finally settles to the open conformation
for about 40 ns. Subsequently, it undergoes substantial deformations (at 160 ns) that lead
to a rapid transitioning from open to the closed state; this final state is long-lived and stable
and last for about 40 ns. At this point, the RA14 attempts unsuccessfully to open Cβ FG
loop (at 200 ns) and is forced to experience large irreversible deformations to finally close
the Cβ FG loop. Dissociation is not observed at this level of force and time scale. As
force is increased to 90 pN (Fig. 67 C), the transitions between states become cyclic as the
Cβ FG loop oscillates between neutral and open conformer four times; the cycles are also
long-lived and stable. Finally, at this force, it achieves large deformations that induces the
closing of the Cβ FG loop and the TCR dissociation from the peptide ligand is observed.
The closed conformer appears to be stable. At a force of 100 pN (Fig. 67 D), the complex
only displays three long-lived and stable cyclic transition from open to neutral. At this
force, the complex is unable to reach the closed conformation before TCR dissociation
occurs. The open conformation is a reversible process; after the TCR dissociates from the
pMHC, the Cβ FG loop returns to neutral conformation as seen in Fig. 68. At 150 pN
(Fig. 67 E), the complex displays only one transition from neutral to open and afterward
it dissociates. For forces ≥ 200 pN, (Fig. 67 F), there is no noticeable deformation of the
Cβ FG loop; dissociation is achieved rapidly in these cases. Note that 50 pN is the critical
force in the “in silico” catch bond (Fig. 19 B) and 90 and 100 pN are close and considered
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optimal forces in terms of increasing the total number of H-bonds at the binding interface.
In summary, force modulates the states of the Cβ FG loop and it is observed that: 1)
It decreases the complex dissociation time. 2)It increases the number of cyclic transition
between reversible states. 3) After the threshold force is passed, the number of cycles
is reduced. 3) The closed conformation is observed around to the critical force and it is
reached at the end of the simulation; it appears to be a one-time transition. 4) Transitioning
to the open conformer is reversible while closing the Cβ FG loop is an irreversible process.





























































































Figure 67: Time evolution of the RMSD of the Cβ FG loop of RA14 TCR interacting with
agonist NLV peptide ligand using six constant forces of 25, 50, 90, 100, 150, 200 pN.
It is observed that the state of the Cβ FG loop is easily modulated by many parameters
such as changing the ramping rate, increasing the force, mutating the epitope, replacing by
potent epitope, or even using a different species TCR Cβ FG loop. However, it generates
new scientific question: 1)Why does opening appear first and closing usually occurs later
when the complex is exiting the catch-bond phase? 2) Why does the open-to-neutral transi-
tion present periodic cycles? and is the closing a one-time event? 3) Why are the transitions
(from open to neutral) reversible processes while closing is irreversible for potent ligands?
Do forced-induced states of the Cβ FG loop relates to the specificity or sensitivity? Appar-
ently, the human Cβ FG loop is more mobile, and thus more sensitive than mouse TCRs.
This results in the fact that the humans have more T cells (one order-of-magnitude or so).
The next section is focused on addressing these questions.
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Figure 68: Representation of the reversible states of the Cβ FG loop at different simulation
times in the presence of force. The FG loop is colored in green. The MHC is loaded with
a RQFI peptide. (A) shows a FG loop in the neutral state when the simulation is beginning
and force is little. (B) show an open FG loop; the simulation is at the middle and force is
already built-up; the number of H-bonds is also at the peak. The FG loop returns back to
the neutral state after the TCR dissociates from pMHC as shown in (C).
5.3.8 Rotating around the binding axis and waving the FG loop is an intrinsic prop-
erty of TCRs
Normal mode analysis (NMA) is used to observed large-scale motions in the TCR-pMHC
complex, based solely on the structure without including molecular details of the residues
that form the complex. There is a question of whether the observed conformational changes
are typical functional modes of TCRs interacting with pMHCs (intrinsic property). HM-
MER is used for searching the databases for sequence homologs (Fig. 66 A, B). Based
on the HMMER search, BLAST is used to identify and collect protein species down to
a pairwise sequence identity of 70% (Fig. 66 C). There are about 275 structures and the
list of unique species is displayed in Table 2. Interesting RA14 share its sequence identity
broadly with multiple species while 1E6 is more restricted. RA14 is a public CMV-specific
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Table 2: List of unique species identified using the searching database HMMER for se-
quence homologs. RA14 share its sequence identity broadly with multiple species while
1E6 is more restricted. RA14 is a public CMV-specific TCR while 1E6 is an autoimmune
specific TCR for type 1 diabetes.
RA14 1E6 Identity(%)
[1] Homo sapiens [1] Homo sapiens
[2] Mus musculus [2] Mus musculus
[3] Rattus norvegicus [3] Manduca sexta ≥ 70%
[4] Oryctolagus cuniculus [4] Escherichia coli
[5] Bos taurus
[6] Macaca mulatta
[7] Gallus gallus <70%
[8] Cricetulus migratorius
[9] Lama Glama
1167 400 Total hits
TCR while 1E6 is an autoimmune TCR. The protein query is performed based on TCR β
chain sequences. Blast is used to search the PDB database and to identify related struc-
tures. The query is constrained to mammal proteins. NMA is performed in the identified
structures under study and it shows that these complexes have a remarkable similarity in
their profile’s fluctuations. The analysis reveals that all structures have as significant an-
gular displacements around the binding axis and linear displacements for the Cβ FG loop.
For instance, modes 7 and 8 of the NMA correspond to rotating around the binding axis
while mode 9 to 14 correspond to large displacements in the Cβ FG loop. Apparently, these
2 modes are essential and functionally important for the TCR-pMHC complexes since all
studied structures acquire those modes. Remarkably the TCR α chain does not display any
conformational change or large displacement while the TCR β chain is flexible in most of
its loops. Notably MHC α1, α2, and the β2 microglobulin are very stable having little-to-no
deformation; however, α3 domain becomes flexible and its modes (12 to higher) resemble
a potential unfolding of this domain from its C-terminal.
121
(A)























































0 Eukaryota unclassified sequences







































































































































































































Figure 69: Summary of protein query produced by the HMMER and BLAST search: (A)
and (B) show the number of hits obtained when searching the database with HMMER.
The two upper figures in (A) and (B) show the normalized score and bitscore, respectively.
The remaining two lower figures show the distribution of significant hits according to the
bitscores and taxonomic kingdom, respectively. The first bar plot corresponds to the hits
above the cutoff, while the second bar plot corresponds to the hits below this cutoff. The
majority of the top scoring hits is from Eukaryote (red) while the others correspond to other
species that are considered insignificant. (C) Blast is used to search the database for top
scoring structures. The NMA is employed only with the top scoring hits (black).
5.3.8.1 The partial least-squares functional mode analysis
The partial least-squares (PLS) functional mode analysis [157] is used to identify and de-
termine systematically hidden relation between coordinates and functional conformational
changes. The algorithm not only searches for the best relation in the trajectory simula-
tion between the atom coordinates that correlates best with the functional order parameter,
αo, but also, find the one that contributes the most to the fluctuation in αo. The algorithm
can be also employed to established relations among functional parameters in well-defined
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conformational states.
The number of H-bonds, the docking angle, and the RMSD of FG loop are examined
as the functional order parameter. All atoms of the protein are used. The 80% of all trajec-
tories are used as a model training and the remaining 20% for cross-validation. Remark-
ably all simulations display that there is a strong relationship between rotating around the
binding axis and inducing conformational changes in the FG loop when these are chosen as
order parameter; however, using the RMSD of FG loop provides the most notorious confor-
mations. Figure 70 shows visually the two dependent states for RA14 and their respective





































Figure 70: PLS-based functional mode analysis for RA14-NLV-HLA2 forming a “in sil-
ico” catch-bond. (A) The functional order parameter is calculated from a 200 ns steered
MD. The training and cross-validation sets agree very well and show that rotation of the
TCR induces opening of the CβFG loop. (B) Image of the conformational changes of the
TCR-pMHC complex, aligned with respect to the TCR.
5.3.9 The deformation of the FG loop is proportional to the peptide potency.
The FG loop is internally well-structured and closely packed to the β chain by a mini-
hydrophobic core. This apparently integrates the Vβ and Cβ domains and forms a rigid
structural entity. Thus it has no substantial deformation in the absence of force. However,
in the presence of force, the FG loop becomes disorder and emigrates away from TCR β
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chain. This is measured by the increase in its RSMD as shown in previous sections. The
area under the curve delineated by the RMSD of the FG loop is calculated for all epitopes
in the absence and presence of force and their ratio is plotted in Fig. 71. High constant-
velocity pulling is used for the calculation. This represents the percentage increase in the
area in the presence of force when compared to the force-free simulation. The FG loop
becomes disorder and experiences larger conformational changes (deformation) when pre-
sented with agonist epitope (NLV), while its change is smaller when a weak agonist (T8V)
and antagonist(M5I) are presented in the presence of force. This is consistent with our
functional studies; agonist NLV produces significant interferon γ (IFNγ) while mutants
T8V and M5I produce lower levels of IFNγ even at higher peptide concentrations. A simi-
lar analysis is performed for the panel of ligands (from weak to strong agonist) complexed
with the 1E6 TCR, and the results are shown in Fig. 71 (B). Strong ligands, (RQW, RQFI,
RQFA, YQF), induces the deformation of the FG loop compared to the antagonist (MVW)
or weak agonist (YLG, ALW, AQW) and their deformation is proportional to the epitope
potency. This correlation is very important since the FG loop is believed to play a criti-
cal role in activating T cells. This is also consistent with recent experiments showing that
T cells develop adhesion forces with pMHC in a manner that correlates with the peptide
potency to induce the production of T cell calcium and interleukin-2 [158].
(A) (B)
Figure 71: The percentage increase in the area of the Cβ FG loop of RA14 and 1E6 inter-
acting with a panel of ligands in the presence of force as compared to force-free simulation.
(A) The NLV complex shows an increased of 45% in the area. There is no such increase
in mutant T8V and M5I. (B) All strong agonist (RQW, RQFI, RQFA, YQF) induce large
deformation of the FG loop.
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5.3.10 The mechanism of opening and closing of the Cβ FG loop
It is shown so far that the Cβ FG loop is deformable in the presence of force and it is re-
ported here that it displays two new forced-induced conformers when it is compared to all
available crystal structures up to date. This is the first time that such conformation is ob-
served and it has not been reported in experiments or simulations. The two forced-induced
states are defined in the previous section as the “open” or “down” and the “closed” or
“up” conformations; they are visually depicted in Fig. 68.
In free MD simulations, the Cβ FG loop does not experience deformations; thus, it is in
a neutral state and this is basically similar to the one observed in the crystal structures. Im-
portantly, the states are not randomly appearing or transitioning from one to another when
force is applied to the complex, but their transition (between states) occurs sequentially.
In the presence of force The TCR initially opens its Cβ FG loop and stay in this state and
cyclically transition from open to neutral and later it completely moves from neutral to the
closed state.
5.3.10.1 The dependence of the states of the Cβ FG loop on the peptide potency
Similarly, all epitopes (from weak to agonist) initially induce the deformation and open of
the Cβ FG loop in the presence of force to a certain degree as it is shown in the previous
section. The difference among peptides is that weak ones produce less deformation than
stronger ones. However, peptides that are capable to stand some level of force without
dissociating the complex, opens the FG loop. Interestingly only agonist epitopes are able
to transition the Cβ FG loop to a closed state. This is observed in: RA14 interacting with
the NLV-HLA2 but not for T8V- or M5I-HLA2; 1E6 interacting with RQW-, YQF-, RQFA-
, and RQFI-HLA2 but not with YLG and ALW peptide ligands. MVW and YLG peptide
ligands are not able to open the Cβ FG loop; they slightly deform it and then dissociate
from the complex.
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5.3.10.2 The dependence of the states of the Cβ FG loop on the ramping rate
Interesting varying the ramping rate also impacts the states of the Cβ FG loop. Normal
pulling rates sequentially open and then close the Cβ FG loop only for potent ligands.
Weaker peptide ligands may induce some deformation and at most the opening. Pulling a
low ramping rate also abolish the closing state for all ligands and decrease the deformation
of the Cβ FG loop. At this rate, only potent ligands induce the opening of the Cβ FG loop.
There is no significant difference among weaker ligands. This is observed in all ligands
complexed with 1E6 and RA14 TCR, where dissociation occurs first and the opening is
not seen for weaker ligands. This is shown in Fig. 72, where the 1E6 complexed with a
panel of peptide ligands from antagonist to the strong agonist are pulled at slow constant
velocity. No difference is observed in the H-bonds profiles of the ligands; indicating that
it also diminished the transition between states. At the other end of the pulling spectrum,
at high-ramping rates, it also abolishes the open and closed state for the ligands; potent
ligands display more deformation of the Cβ FG loop and in some cases, an opening can
be observed. Finally, another important feature when changing the pulling is that a nor-
mal ramping rate increases the dissociation time when compared to low or higher pulling
rate. For instance at low or high pulling rate all complex dissociate before or around 50ns,
respectively; however, at normal pulling, they dissociate around 200 ns and some potent
ligand even go further. In addition either at low or high ramping rate, the “in silico” catch
bonds are transformed into either an ideal or slip bond for all ligands. No significant differ-
ence is established using a Welch two sample t-test; it reports p-values < 10−9 with a 95%
confidence interval for the samples.
Pulling at constant force also impact the state of the Cβ FG loop. RA14-NLV-HLA2
complex is used and its NLV peptide ligand is considered agonist. At smaller forces, there
is no significant deformation of the Cβ FG loop. As force increases, the opening of the
Cβ FG loop starts appearing. At the forces around the catch bond, both open and neutral
states are observed multiple times. As forces pass this region, mostly the closed state start
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dominating. It is observed that the transition from neutral to open states and vice versa
are a reversible process; however, once the closed state is achieved the TCR experience
permanent and irreversible deformations in the Cβ FG loop. Closed state is only observed
for potent ligands. No significant difference is established using a Welch two sample t-test;


























Figure 72: Time evolution of the number of H-bonds between 1E6 TCR interacting with
a panel of peptide ligands ranging from antagonist (MVW, YLG), weak agonist (ALW,
AQW) and strong agonist (RQW, RQFI, RQFA, YQF) at slow constant-velocity pulling.
There is no clear difference in the H-bond profiles between the strong agonist that previ-
ously formed an “in silico” catch bonds at the normal ramping rate. All epitopes apparently
decrease the number of total of H-bonds at the binding interface as force is increased and
they appear to form a “slip” or “ideal” bond. Nevertheless, in the simulations, the potent
epitopes induce more deformation of the Cβ FG loop.
5.3.11 The moment of inertia of the TCR shows that linear force is translated into
rotational torque that twists the TCR domains
To this point, it is clear that the FG loop has three states, “open”, “neutral”, and “closed”
and force modulates its state and transitions as explained in the previous section. It is also
involved the TCR rotating around the binding axis and reducing the flexibility of epitope.
The moment of inertia (MI) is calculated to understand how linear forces are propagated to
induce rotation and twisting of TCR, that could potentially induce deformations including
the opening and closing of the Cβ FG loop. MI dictates the required torque for changing
the angular moment about an axis and it depends on the mass distribution. For TCRs, it is
visually inspected that its largest principal axis is perpendicular and penetrates the surface
of MHC binding groove as seen in Fig. 73 (A). It also goes through the CDRs loops;
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Figure 73: The moment of inertia of the RA14 TCR. (A) P1, P2, P3 are the principal
axes of rotation of the TCR. When the TCR rotates around this axis, its angular momentum
vector L becomes parallel to the angular velocity vector ω. It is important for molecular
recognition that P3 is perpendicular to the binding interface, intersects the peptide ligand,
and passes parallel to the interface formed between the TCR αβ chain. (B) The docking
orientation between the RA14 interacting with NLV in the presence of force. (C) The mo-
ment of inertia (MI) of the TCR around the principal axis P1, P2, P3; they are normalized
assuming that the TCR is a rectangular box. The TCR size in each dimension is approxi-
mately, dP1=5.1 nm, dP2=5.8 nm, and dP3=7.7 nm; it has a total mass of, mTCR = 49.3 kDa.
It is observed that P2 increases while P3 decreases its value inside the catch-bond phase.
P2 corresponds to the axis where the FG loop opens and closes, while P3 corresponds to
the axis that stretches or compresses the TCR. P1 slowly decreases and reaches an asymp-
totic value. Dramatic changes in the MI are indications that the overall cross sectional area
along the major axis is impacted in the presence of force. The largest cross section is situ-
ated in the cross-sectional plane between the Vα-Vβ and Cα-Cβ domains; and they behave
as an inter-domain rotational hinge. This hinge converts linear force into angular torque
that easily twists the TCR from one end while is held from its membrane-distal binding
site by the peptide ligand. (D) Vectors depicted in yellow and green are defined to measure
the angular rotation of the Cα-Cβ respect to Vα-Vβ complex. The vectors are situated and
passed the center of mass of each Ig-like domains. The TCR is shown in front and top view.
thus a role of changing the MI dynamically while the TCR rotates around to the binding
interface is expected in the presence of force. The MI of the TCR in the presence of force
is calculated and shown unitless in Fig. 73 (C). The values, P1, P2, P3, are normalized
assuming the TCR is a rectangular box with dimension in the axis of dP1=5.1 nm, dP2=5.8
nm, and dP1=7.7 nm, and a total mass of, mTCR = 49.3 kDa. Then the TCR theoretical
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P2 increases while P3 simultaneously decreases its value inside the catch-bond phase.
P2 correspond to the axis where the FG loop opens and closes while P3 correspond to the
axis that stretches the TCR. Interesting, changes in P2 is compensated with variations in P3.
P1 slowly decreases to reach an asymptotic value. Such dramatic changes in the MI is an
indication that the overall cross sectional area along the major axis decreases (or increases)
while it is compensated in the other axis in the presence of force. The largest cross-section
is situated parallel to the P1-P2 plane and it splits the TCR at the middle into halves. This
structurally divides the Vα-Vβ and Cα-Cβ in two independent domains and they behave as
an inter-domain rotational hinge. In other words, a linear force is converted into angular
torque by separating these domains and, thus rotating the hinge at the middle section; the
TCR is held from one end while it is pulled by its membrane-distal binding. This is shown
in Fig. 73 (D) and Fig. 74.
5.3.12 Stretching the TCR rotates the inter-domain hinge and induces conforma-
tional changes of the Cβ FG loop
In this section, controlled computational experiments are performed to understand how
rotations of the inter-hinge domains impact or induce the opening and closing mechanism
of the FG loop. Fig. 73 (D) shows the vectors defined to measure the angular rotation
between the Cα-Cβ respect Vα-Vβ complex in front and top view, and they are situated
in the center of mass of each TCR Ig-like domains. The rotation is visually depicted in
Fig. 74. It is assumed that Cα-Cβ and Vα-Vβ complex independently move or rotate as a
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Figure 74: The TCR inter-domain rotational hinge. The Vα-Vβ and Cα-Cβ are structurally
divided into two independent domains and they behave as an inter-domain rotational hinge.
Pulling linearly the inter-hinge domains is translated into creating a torque that twists the
TCR around the binding axis in a counter-clockwise manner. Linear forces also separate
the TCR domains at the middle section. (A) The force-free state shows that the 310 helix
(green) is spatially away from the Cβ FG loop (yellow). (B) The 310 helix is above and
close to the Cβ FG loop when force induces the rotation of the inter-domain hinge. The
cyan arrow depicts the direction of rotation that brings together the 310 helix and the Cβ FG
loop.
whole unit. This is not a bad assumption since most structures of Ig-like domains are well-
defined and stable. However, the exception is the Cα. This is an unusual domain that is not
totally rigid. Here atoms strategically located in a β-strand of Cα are chosen. Those atoms
are rigid even under load. See section 2.1 for properties of Ig-like domains.
5.3.12.1 The artificial-ligand protocol
The observation that potent ligands produce clearly the two forced-induced conformers
further simplified our model. For the following simulation, an artificially potent ligand is
proposed that does not allow dissociation. Before the complex was pulled from its ends
and force was propagated to the binding site; this induces conformational changes in the
epitope and glues the TCR with the MHC by producing and an “in silico” catch bond. The
focus here is to study the TCR as a nanomachine; thus the artificial ligand will produce an
infinite number of H-bonds and amalgamate the TCR to the binding interface, like a catch
bond does. The process is accomplished by removing the pMHC and replacing it by two
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dummy atoms connected to the center of mass of the TCR Vβ and Vα domains. The dummy
atoms function as a potent peptide ligand and their role is to attach the complex tightly and
prolong the dissociation time and induce conformational changes in the presence of force as
observed in previous simulations. This accomplishes three goals: 1) It reduces the system
size and requires less computer power; 2) It removes the noise from the TCR interacting
with the peptide ligand; 3) It move the complex to the catch-bond phase in a fast and
controlled manner and the TCR stays at this state as long as the simulation runs. Note that
this protocol is a variation of targeted molecular dynamics (TMD). TMD is used to induce
conformational changes from an initial structure to an already known target conformation.
5.3.13 The role of the 310 helix in changing the states of the Cβ FG loop
Another important feature to consider is that all TCRs have in the β chain a small and
unique 310 helix that connects the Vβ with Cβ domains; this connector is also positioned
near the vicinity of the Cβ FG loop. The 310 helix is very stable as it is held together by
salt bridges formed between the Lys119β NH group and the Asp116β and Glu115β CO
group. Fig. 75 (A) shows the molecular details of the 310 helix and it is colored in green.
Importantly the 310 is observed to simultaneously unfolds only when the FG loop transition
to the closed state in all potent ligands in the simulations. The unfolding process is visually
depicted in Fig. 61 (C) and Fig. 75 (C). The unfolding occurs simultaneously when the
FG loop is closed. In the neutral configuration, this connector is folded and formed a
secondary structure of a 310 helix (Fig. 61 A and Fig. 75 A), and the helix is commonly
shared among structures of all TCRs known up to date. In the open conformation, this
connector is displaying some level of linear stretching, Figure 61(B) Fig. 75 (B), while it is
completely unfolded in the closed conformation, Figure 61(C) and Fig. 75 (C).
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Figure 75: Molecular details of the 310 helix and Cβ FG loop. The 310 helix and Cβ FG
loop are colored in green and yellow, respectively. (A) shows an FG loop in the neutral
state; (B) show an open FG loop where force is built-up; (C) shows a closed FG loop. The
interacting residues are drawn and labeled.
5.3.14 Hinge rotation and the open state occur simultaneously when linear force is
translated into rotational torque that twists the TCR domains
Simulations are performed to validate if the artificial-ligand (AP) pulling produces the
forced-induced conformers of the Cβ FG loop. RA14 and 1E6 TCRs pulled at normal ramp-
ing rate using the AL pulling, 3 simulations are performed per TCR. It is observed that AL
induces sequentially the open and closed states and the results are shown in Fig. 76. RA14
and 1E6 interacting with the AL peptide ligand are pulled using constant-velocity with a
normal ramping rate. The pulling force is applied at 50 ns and starts growing from 0 pN
(Shown in Figures). Before 50 ns all complexes display the neutral conformer. Open and
closed states of the Cβ FG loop are labeled and shown in black arrows. After a delay of
50 and 130 ns for RA14 and 1E6 TCRs, respectively, both complexes start experiencing
conformational changes (deformations) as depicted: in the increase of the RMSD of their
Cβ FG loop (Fig. 76 A, D) and the 310-helix connector (Fig. 76 B, E) and the rotation of the
TCR inter-domain hinge (Fig. 76 C, F).
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5.3.15 The unfolding of the 310-helix connector allows the closing of the Cβ FG loop
As force is applied, RA14 TCR starts slowly experiencing a linear increase in the RMSD
corresponding to the deformation of its Cβ FG loop and eventually leads to an open state,
while it simultaneously rotates its inter-domain hinge angle. Pulling linearly the inter-hinge
domains is translated into creating a torque that twists the TCR around the binding axis in
a counter-clockwise manner (Fig. 74). The RMSD of their Cβ FG loop experience four
discrete deformation steps during the opening state; then it transitions to the neutral con-
former as indicated by a suddenly decreased in the RMSD. Finally, it moves abruptly to
the closed state and experiences irreversible deformations as the 310-helix connector com-
pletely unfolds. The transition between neutral to open states is mark by a linear increase
in the inter-domain hinge.
As force is applied, RA14 TCR starts slowly experiencing a linear increase in the
RMSD (Fig. 76 A), corresponding to the deformation of its Cβ FG loop that eventually
leads to its opening, while it simultaneously rotates the inter-domain hinge angle (Fig. 76
B). Pulling linearly the inter-hinge domains is translated into creating a torque that twists
the TCR around the binding axis in a counter-clockwise manner. The RMSD of their Cβ FG
loop experience four small discrete deformation steps during the opening state; then it tran-
sitions to the neutral conformer as indicated by a sudden decreased in the RMSD. Finally,
it moves abruptly to the closed state and experiences irreversible deformations and at the
same time the 310-helix connector completely unfolds (Fig. 76 C). The transition between
“neutral” to “open states” is marked by a linear increase in the inter-domain hinge while
the transition from “open” to “close” is identified by an abruptly jump in the hinge angle
(Fig. 76 B). The 310-helix only experiences major changes when the Cβ FG loop moves
from open to closed since it is abruptly unfolding at this state.
For 1E6 TCR, the Cβ FG loop starts experiencing deformations later in the simulation
that put it into a closed state in an stay there in a very short time (∼20ns in Fig. 76 D). This is





























































































































Figure 76: Characterization of the Opening and Closing states of the Cβ FG loop in terms
of its deformation (A, D), extension of the 310-helix connector (B, E), and changes of the
inter-domain rotational hinge (C, F) for RA14 and 1E6 TCRs, respectively, using constant-
velocity with a normal ramping rate. The pulling force is applied from 0 pN at 50 ns.
Before applying the force, RA14 and 1E6 TCRs display the neutral conformer. Open and
closed states of the Cβ FG loop are labeled and shown in black arrows.
rapidly transitions to the open state by showing a decrease in the RMSD. Note that moving
from closed to open state, it has to pass first through the neutral state and this is shown in
the shortly-lived steepest valley at 200ns (and 190ns for RA14, Fig. 76 A). Finally, the load
is huge that the Cβ FG loop is forced to closed. Interesting the transitions between states are
produced by the rotations of the inter-domain hinge angle. The unfolding process consists
of two steps as shown in the RMSD of the 310-helix connector; however, the hinge angle
is roughly constant in each unfolding step. It is shown that reaching the unfolding of the
310-helix connector is an irreversible process and after this step, only closed conformation
is observed.
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5.3.16 The hinge rotation brings together the 310 helix and Cβ FG loop and creates a
huge electrostatic repulsion
Here the question is what opens and closes the Cβ FG loop? The FG loop is highly charged
having 4 negatively and 2 positively charged residues and it is able to form at most 8 salt-
bridges. Salt-bridges are considered strong interaction since they are generated when two
ionized residues form a hydrogen bond and an electrostatic interaction. For RA14 and 1E6
TCRs, their salt bridges become coordinated only when the Cβ FG loop is undertaking an
open or closed conformation as it is seen in Fig. 76 and 77. The Lys229 strongly interact
with the negatively charged cluster to open the Cβ FG loop, Fig. 77 (A and C). The electro-
static force coordinating the strong slat-bridge is mainly between Lys229 and Glu219 and
Asp 221. Importantly all species have the negatively charged cluster in a similar location
and those three residues are highly conserved among them. The rotation of the inter-domain
hinge brings together those residues in order to open the Cβ FG loop and simultaneously
the angle increases while their distance decreases, Fig. 76 and 77. Arg227 has similar be-
havior; however it mostly interact with either Asp221 or Glu222, Fig. 77 (B and D). Note
if the Arg227 is missing as in other species, it will impact in the duration of the open state;
nevertheless, a shorter and less-pronounced opening should be still observed. In the closed
conformation, the electrostatic interactions are pulled apart, Fig. 77. The molecular details
of the interacting residues of the Cβ FG loop and their location are shown in Fig. 75.
In summary, the rotation of the hinge causes the opening and closing of the Cβ FG loop.
In both TCRs, the transition from neutral to open is observed to be gradual and continuous
while moving from open to close occurs abruptly and there is a jump in the value of the
hinge angle and the RMSD of 310-helix connector and the Cβ FG loop. Once the second
unfolding occurs, it appears that the closed state becomes a punctuated equilibrium. The
open state is a steady state at any specific level of force; if removed, it returns to the neutral
state, or, if increased, it closes the Cβ FG loop. Changing from open to close is presented in


















































































Figure 77: Salt-bridges formed by charged residues located in the Cβ FG loop. The Cβ
FG loop has 4 negatively and 2 positively charged residues. The salt bridge becomes co-
ordinated only when the Cβ FG loop is undertaking an open or closed conformation. The
Lys229 strongly interact with the negatively charged cluster to open the Cβ FG loop. Open
and closed states of the Cβ FG loop are labeled and shown in black arrows.
conformer is unstable and short-lived in the presence of force. The inter-domain hinge
rotation is responsible for the formation of open and closed states. Note that the jump in
the RMSD of 310-helix connector (unfolding) corresponds to the subtle separation of the
Vα-Vβ from Cα-Cβ interface. The transition from open to closed is fast and appears to
be like releasing a compressed spring. Once the compressing force is removed the spring
extends.
5.3.17 Performing single or double mutations on the Cβ FG loop abolishes the open
state
The next step is to test the model and determine if the opening or closing of the Cβ FG
loop can be manipulated by enhancing one phase while abolishing the other. Based on
the previous understanding, it is predicted that pulling a high ramping rate the complex
or performing a single or double in silico mutations on the Cβ FG loop would abolish the
open conformation. In addition, a closer inspection in the RA14 and 1E6 hinge angles,
Fig. 76(D and E), reveal that when force is applied initially and it is in the neutral state,
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the angles experience subtle swings (ups and downs) until enough force is built to start
migrating continuously to the open, or drastically to the close conformation. Thus, com-
putationally deleting the Cβ FG loop would render the inter-domain hinge rotation smooth
























































































































Figure 78: States of the Cβ FG loop at high constant-velocity and constant-force pulling
for RA14 TCR. The open state is diminished and becomes unstable. High pulling moves the
Cβ FG loop from the neutral to the closed conformer. The 310-helix connector is unfolded
in this process and the hinge inter-domain angle displays an abruptly increased when the
loop is closed.
Fig. 78 show indeed that pulling either at high constant-velocity or constant-force com-
pletely abolished the open state as it becomes unstable and short-lived. High ramping rates
transition the loop almost directly from the neutral state to closed conformer; a similar re-
sponse is observed at high constant-force pulling. Fig. 78 (A, D) show mostly loner-lived
closed conformers, while the open ones become shorter-lived. At medium-to-high constant
forces, the Cβ FG loop mostly transitions from neutral to closed and vice versa before the
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310-helix connector is unfolded, Fig. 78 (E). The hinge inter-domain angle also displays the
abruptly increased when there is a transition from neutral to closed.
Fig. 79 show that performing a single and double in silico mutation on 1E6 TCR de-
creases and abolishes the open conformer. The single mutation disrupts the salt bridge and
breaks the symmetry; thus the electrostatic interactions between the charges lose its coor-
dination and become attractively weak, and the deformation is minimal in both the Cβ FG
loop and 310-helix connector, Fig. 79 (A, B). Instead of opening, there is a transition phase
where the TCR attempts to deform the Cβ FG loop; however, it fails to open it. The dou-
ble mutation completely destroys the ability to move from neutral to the open conformer,
Fig. 79 (D, E). Importantly the inter-domain rotational hinge is not affected by either muta-
tion; instead, it continuously increases as it is allowed to move without any resistance nor
repulsive electrostatic force. This is observed even before there is any sign of deforming
in the loop, Fig. 79 (C, F). Unfolding of 310-helix is only observed once the Cβ FG loop
moves to the closed conformer, Fig. 79 (B, E).
5.3.18 Deleting the Cβ FG loop allows the hinge angle to rotate and unfolds the 310
helix
Fig. 80 (A, D) show that deleting the Cβ FG loop computationally would permit the inter-
domain hinge angle freedom to rotate around the binding axis. In addition 310-helix is easily
extended in the presence of normal to huge load. The unfolding process of the 310-helix,
previously involves its abrupt extension, but now it is replaced by a linear increase with
little to no resistance, Fig. 80 (B, E). Note that before it was required 150 ns and 20 ns to
induce any conformational changes in the 310-helix at medium and high constant-velocity
pulling; however it now requires 60 ns and 5 ns at medium and high, respectively. The
waiting time has dramatically reduced with the removal of the Cβ FG loop. This means that
the removal allows an easy transition and separation of the Vα-Vβ from the Cα-Cβ and their
interface becomes weakly attached. Apparently, Cβ FG loop provides a complementary






































































































































Figure 79: Single and double in silico mutations on 1E6 TCR. The single mutation dis-
rupts the salt bridge and the electrostatic interactions are lost and their attractions become
weak; the deformation is minimal in both the Cβ FG loop and 310-helix connector. A
double mutation abolishes completely the transition from neutral to open conformer. The
inter-domain hinge is barely affected by either mutation; it increases and moves without
any constraint or resistance. Unfolding of the 310-helix is only observed when the Cβ FG
loop is closed.
plotted the distance between Vβ and Cβ for a wild type and FG-loop deleted TCR. RA14 is
used for comparing the two cases and both complexes are pulled at high ramping rates. It
is observed that after 80 ns the FG-loop deleted RA14 TCR is already separated 15Åwhile
the wild type is only displaced 5Å. This clearly shows the removal impacts the stability of
the complex under load. A computationally FG-loop deleted TCR is depicted in the Fig. 80




























































































Figure 80: Characterization of conformational changes of Cβ FG-loop deleted TCR for
the RA14. FG-loop deleted TCRs allow the inter-domain hinge angle to rotate around
the binding axis. 310-helix is easily extended once a small level of force is reached. The
unfolding process of the 310-helix shows a linear increase in the RMSD. (F) shows an easily
extended FG-loop deleted TCR.
5.3.19 Deformations that eventually open the Cβ FG loop can be observed in long-
time MD simulations.
It is also predicted that long-time MD simulations may capture deformations of the Cβ FG
loop that eventually cause the open of the loop. It is observed in the simulation that the
domains, Vα-Vβ and Cα-Cβ, are not completely constrained, they are rotating respect to
one another, and the rotation is mainly occurring the binding axis ( the angular rotation
is in the range of ± 15o. When the domains rotate in opposing directions as to increases
the rotational angle, the change in the hinge angle is expected to induce deformations that
potentially open of the Cβ FG loop if the domains are moving at high velocity. In this
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scenario, Cβ FG loop should transition from neutral to open conformer and the duration
should be proportional to the angular velocity. On the other hand, the closing of the Cβ
FG loop would require forces since it apparently has a bigger energy barrier since it also






























































Figure 81: Characterization of the opening and closing states of the Cβ FG loop in terms
of its deformation (A), changes of the inter-domain rotational hinge (B), and the extension
of the 310-helix connector (C, D) for RA14 , using microsecond MD simulations. The open
states of the Cβ FG loop are labeled and shown in black arrows.
Note that those would be rare events in free MD simulations. In order to access those
rare conformers and cross the energy barrier between the states, an external force is applied
to complex to reduce barriers and move the TCR across those configurations using steered
MD simulation. The SMD simulations force the transition from an equilibrium conforma-
tion (neutral) to a rare event (steady state, open or closed). For instance, if the system is
provided with enough time, the closed conformer or even the folding and unfolding process
should be observed without the application of external forces.
Fig. 82 shows the potential conformational changes of TCRs when external forces are
applied to the complex. The conformations occur sequentially and are characterized as the
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Figure 82: Conformational changes of TCRs upon recognition of peptide ligands. They
fall into the following categories: the rotation of the inter-domain hinge, the opening and
closing of the Cβ FG loop, the unfolding of the 310-helix connector, the separation of TCR
domains, and the unfolding of the TCR membrane-proximal stalk. The conformations
impact the TCR structures and remodel the CD3 binding interface for activating the TCR
and recognition of peptide ligands.
rotation of the inter-domain hinge, the opening and closing of the Cβ FG loop, the unfolding
of the 310-helix connector, the separation of TCR domains (Vα-Vβ from Cα-Cβ), and the
unfolding of the TCR membrane-proximal stalk. The conformations not only impact the
TCR structures but also remodel the CD3 binding interface for activating the TCR and
recognition of peptide ligands.
5.3.20 The mechanism of how the opening and closing of the Cβ FG loop induce
T-cell activation by connecting with the CD3 signaling domains
Finally, the model is tested and verified using the super powerful Anton2 machine–a
special-purpose, massively-parallel supercomputer for performing microsecond MD simu-
lations of proteins. The results support the model: 1) the inter-domain hinge is allowed to
rotate and swing around 10o with an angular velocity of ≈ π/9 µs−1. 2) The deformation of
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the Cβ FG loop is observed and it is similar to the forced-induced one. 3) There is a sym-
metric up and down phase in the measured angle whenever hinge rotates. 3) The closed
conformation is unstable in the absence of force. 4) Once the closed state is achieved,
the complex experience globally irreversible deformation. 5) It is found that conserved
residues in the TCR α chain stabilize the closed conformation. 6) The TCR could experi-
ence large conformational changes that are potentially functional. In this part, the RA14
alone and complexed with pMHC is used, and the 1E6 (alone) in the different conformation




























































































Figure 83: Salt-bridges formed by charged residues located in the Cβ FG loop at the
microsecond scale. The Cβ FG loop has 4 negatively and 2 positively charged residues.
The salt bridge becomes coordinated only when the Cβ FG loop is undertaking an open
conformation. The Lys229 strongly interact with the negatively charged cluster to open the
Cβ FG loop. Open states of the Cβ FG loop is labeled and shown in black arrows.
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5.3.21 What are the resting and activated states of the TCR?
The TCR-CD3 complex recognizes antigens and transmits signals into the T cell to initiate
the adaptive immune response. By using computer simulations, in this section, a structural
model is provided to unify conformational changes reported experimentally and it is pro-
posed a connecting pathway between TCR and the CD3 subunits; and the molecular basis
of TCR-CD3 interactions is examined.
Figure 84: Molecular assembly of the TCR interacting with the CD3 signaling subunits
at the resting state. CD3εδ and CD3εγ could be located “below” TCRα and TCRβ, re-
spectively, or they could be adjacent to the constant domain of the TCR. The model is
created using the crystal structure of RA14 (PDB code 3GSN), CD3εγ is made (PDB code
1SY6), and CD3εδ (PDB code 1XIW). The resting state is initially constructed by using the
contacting residues between the TCR and the CD3 signaling subunits from reference [51].
The main conformational changes in this model for activating the TCR are: the rotation
of the inter-domain hinge; the opening and closing of the Cβ FG loop; the unfolding of the
310-helix connector; the separation of TCR domains (Vα-Vβ from Cα-Cβ); and the unfolding
of the TCR membrane-proximal stalk, see Fig. 82 and Fig. 85. This model is consistent
with all experimental observations reported up to now and it is explained in the following
paragraph.
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In the resting state of this model, the TCR is not required to be bound to the CD3
signaling subunits at the resting state. The CD3 subunits could be diffusing in the plasma
membrane or they could be around the TCR when it encounters the peptide ligand. CD3εδ
and CD3εγ could be located “below” TCRα and TCRβ, respectively, or they could be
adjacent to the constant domain of the TCR; thus, they do not have a specific binding site
at the resting state (Fig. 84).
Upon the TCR ligation to the peptide ligand, a mechanical force is generated that pulls
the TCR-pMHC complex. The pulling force induces the rotation of the TCR around the
binding site and allows an easy scanning and attachment of the CD3 subunits to the TCR
constant region. The rotation allows the interaction of the Cα AB and DE loop with the
CD3εδ and the Cβ CC’ loop with both CD3εγ and CD3εδ and this movement firmly ac-
commodates and places the CD3ε domains below the small cavity formed by the TCR
constant domains.
The transition between the neutral and open state of the Cβ FG loop facilitates the con-
tacting of the upper surface of the CD3εγ. At this point, the TCR behave as a “bulldozer”
and the Cβ FG loop is the “dozer blade” that search for the CD3 subunits that are placed
below. It is important that the Cβ FG is waved multiple times when the TCR is rotating;
if not already in close contact with the signaling subunits; it would increase the probabil-
ity of encountering and attaching to the CD3 subunits. Importantly the hinge rotation and
the transition from neutral to open state occur simultaneously. This proposes that the CD3
subunits are reorientated and docked dynamically to the TCR upon antigen binding.
Once they are in good contact, and if force is propagating, it would eventually pull
the CD3 subunits out of the plasma membrane. This is accomplished by unfolding the
TCR connecting peptides and transmit a mechanical force across the membrane that finally
dislodges the CD3 cytoplasmic tails from the plasma membrane and exposes their ITAM
motifs for phosphorylation and activation. When the connecting peptides are extended,
the Cβ helix-3 and helix 4-F strand and Cα F and C strands are also exposed and moved
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aways from the plasma membrane and they are allowed to firmly interacts with the CD3εγ
and CD3εδ, respectively. Then, the closing of the Cβ FG loop occurs when the 310-helix
connector unfolds. At this step, Vα-Vβ is slightly separated from Cα-Cβ and the TCR is
switched to the active state and the buried residues of the TCR α/β-interface are observed
to undergo a systematic reorganization that produces significant conformational changes in
these residues (Fig. 85).
Note that the hinge rotation brings together 310-helix connector and Cβ FG loop and
it creates a huge electrostatic repulsion that opens the FG loop. Unfolding releases the
electrostatic repulsion and put into contact opposed charged residues that pull up the Cβ
FG loop and brings it to a closed state.
Figure 85: Molecular assembly of the TCR interacting with the CD3 signaling subunits
at the activated state. The TCR behave as a “bulldozer” and the Cβ FG loop is the “dozer
blade” that levels the CD3 subunits up. The Cβ FG is waved multiple times when the
TCR is rotating so it attaches the CD3 subunits. Once they are in contact, and if force is
continuing propagating, it would pull the CD3 subunits out of the plasma membrane. The
model is created using the crystal structure of RA14 (PDB code 3GSN), CD3εγ is made
(PDB code 1SY6), and CD3εδ (PDB code 1XIW).
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CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS
This thesis addresses various aspects of TCR mechanobiology by integrating computer
simulation, biology, and engineering principles and the results are compared with exper-
iments performed in the Zhu lab. The main goal of this thesis is directed to understand
the molecular mechanisms of the TCR-pMHC-CD3 interactions and their underlying bi-
ological processes. The proposed methodology is studying this complex system by using
the principles of statistical physics, which ensures that the models are theoretical sounded
and it provides testable predictions that can be verified in experiments. The key benefit of
this approach is that it enables the manipulation of complex systems at the molecular level
and in a more logical way. This is the first step moving forward to the ultimate goal of
immuno-engineering –a rational drug design, as it provides insights into the mechanisms
of TCR function and generates new ideas for fighting infections, cancer, and autoimmune
diseases using the body own’s immune system.
This thesis proposes a mechanism to connect structurally the ligand binding, the catch
bond, and the triggering of TCRs interacting with their peptide ligands and the CD3 sig-
naling subunits. For instance, it describes a general mechanism used by TCR to recognize
pMHC in the context of viral infections and how this information is propagated to the CD3
signaling domains. For understanding how T cells accomplish their function of transfer-
ring information from outside to inside the cells is very important to study the dynamics of
their receptors and how they connect and interact with their ligands. Proteins are not static
structures under physiological conditions as they dynamically change across multiple con-
formations. This is different from the current view of immune receptors that are believed
to have unique docking interactions.
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Aim 1 describes the mechanism how featureless viral peptide ligands are read by TCRs
and explores many parameters that can be used to compare directly simulations with exper-
iments. It is demonstrated that catch bonds formed experimentally between a TCR and a
pMHC can be predicted by using simulations for the first time. The best predictor of catch
bonds is the total number of H-bonds of TCR-pMHC interactions. This supports the idea
that tensile force is a principal axis in regulating TCR function and induces the formation
of “in silico” catch bonds. It is described the molecular characteristics and requirements
for a TCR to form catch bonds in the context of antigen recognition and how mutant pep-
tides convert it to slip bonds. It is then explained the mechanism of how the TCR changing
its initial docking orientation modulates the peptide conformation inside the MHC binding
groove. This highlights that the TCR docking angle is fundamental for immune recognition
of antigenic peptides. At the catch-bond phase, TCRs start rotating with a defined polarity
around the binding axis and the peptide has an on and off state for interacting with the TCR
and forming catch bonds. It is proposed a molecular lever mechanism for recognition of vi-
ral epitopes. This aim could be also used to understand the mechanism of generating public
vs private TCRs since most immunodominant viral epitopes resemble the NLV peptide (in
terms of sidechain exposure) and elicit highly diverse T cell responses. A visual summary
is presented in Fig 86 (A).
Aim 2 describes molecular mechanism of information is read and propagated to the
CD3 signaling domains by the TCR. The first part is focused to investigate the structural
role of catch bonds and how the information encoded in the peptide is decoded mechani-
cally by the TCR. It is demonstrated that catch bonds are required to recognize epitopes and
they are formed by the TCR rotating around the binding axes and inducing conformational
changes in the peptide. The second part is focused to study how TCRs uses mechanical
forces to determine whether or not the presented antigen is a threat. It is demonstrated that
the peptide-decoding process and intracellular signaling are connected by conformational
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changes traveling across the TCR. The molecular model shows that mechanical forces mod-
ulate the TCR states and that the TCRs are deformable proteins that can experience large
conformational changes. It is shown that the TCR behaves as a “bulldozer” and the Cβ FG
loop is the “dozer blade” that levels the CD3 subunits up. The Cβ FG is waved multiple
times when the TCR is rotating so it attaches the CD3 subunits. Once they are in contact,
and if force is continuing propagating, it would pull the CD3 subunits out of the plasma
membrane as the TCR is undergoing large deformations. This subjects that proposed the
ability of TCRs to deform without releasing the pMHC is fundamental to switch the TCR
from the resting to activated states. A visual summary is presented in Fig 86 (B).
Overall, this thesis has laid the groundwork using computational methodologies to
study how TCRs read viral and autoimmune peptide ligands and how they activate the
signaling domains. However, this project can be expanded to study other TCRs as a unique
framework is outlined to directly compare simulations with experiments. One intriguing
and physiological relevant field is HIV-specific TCRs (infections) or cross-reactive TCRs
for organ transplants. These would provide a better understanding into the molecular basis
of the immune response leading to the loss of recognition of viral proteins or the strong
attack of healthy cells, respectively. In addition, in Aim 2, the proposed mechanism of the
opening and closing of the FG loop and the activated state of the TCR can be verified ex-
perimentally by doing site-directed mutagenesis since the molecular details are completely
provided. This can be a project to determine if it is a functional mechanism or just an
evolutionary relic.
Many problems in biology, in general, are just beginning to be thought in this frame-
work, where molecular models with statistical-mechanical approaches are used to under-
stand how proteins work. The major downside of this approach is that it is very computa-
tionally expensive and requires HPC supercomputer. It is time to simulate the TCR-pMHC
complexed with co-receptors, the CD3 signaling domains including the cytoplasmic tails,
and the plasma membrane. This new system would represent more physiologically the
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TCR environment and it can be used to verify the proposed pathway of signal transduction
between the ligand binding to the cytoplasmic tails.
The difficulty is that TCR simulations are still contained to the time scale and it would
require at least hundreds of microseconds to observe conformational changes. A coarse-
grain model can be built and used to track large propagations of structural changes through
multiple domains. Importantly this should be performed in parallel with all-atom simula-
tions to identify important interactions and assess their relevance in conformational changes
and in the binding. The combination of these two types of simulations is a rising technique
in MD simulations to study the structural changes in proteins.
Figure 86: A visual summary of the results from Aim 1 and Aim 2. (A) The peptide
potency increases the quality of the “in silico” catch bond while high ramping rates or
pulling forces decrease it. The quality is defined as the duration and height of the catch
bond. (B) Strong ligands open and close the Cβ FG loop and induce large deformations in
the TCR while weak ligands open the Cβ FG loop and deform minimally the TCR. Very
weak ligands do not deform the Cβ FG loop and the TCR. Potent ligands produce catch
bonds while weak ones convert them to slip or ideal bonds.
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CHAPTER VII
LIST OF EXPECTED PUBLICATIONS
7.1 Aim 1:
Describe the molecular mechanism of how TCRs recognize featureless viral pMHC land-
scapes and how epitopes mutations decrease immune recognition in the context of human
infection.
• “Forced reorientation of CMV-specific TCR induces catch-bond formation with pMHC
via a molecular lever mechanism”; Paul Cardenas*, Prithi Jothikumar*, et. al.
(Manuscript in preparation) *First co-author
7.2 Aim 2:
Describe a previously unknown mechanism of how recognition of peptides by TCRs prop-
agates to the CD3 signaling domains to induce T-cell activation.
• “Conformational changes in the TCR Cβ FG loop: The mechanism of connecting
ligand binding, catch bonds, and triggering of TCRs”; Paul Cardenas and Cheng
Zhu (Manuscript in preparation)
7.3 Other: Simulations of the PD-1 complexed with PD-1 ligands
• “Structural mechanism of PD-1 catch-bonds and PD-Ligands”; (Manuscript in prepa-
ration)
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